BE2016C059I2 - - Google Patents

Download PDF

Info

Publication number: BE2016C059I2
Authority: BE; Belgium

Application number

BE2016C059C

Other languages

Dutch (nl)

Original Assignee

Novozymes Biopharma Dk As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-04-12

Filing date

2016-11-04

Publication date

2020-08-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27394014&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2016C059(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-11-04 Application filed by Novozymes Biopharma Dk As filed Critical Novozymes Biopharma Dk As

2020-08-20 Publication of BE2016C059I2 publication Critical patent/BE2016C059I2/nl

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Endocrinology (AREA)
Toxicology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Virology (AREA)
Epidemiology (AREA)
Oncology (AREA)
Neurology (AREA)
Physical Education & Sports Medicine (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
Dermatology (AREA)
Neurosurgery (AREA)
Communicable Diseases (AREA)
General Engineering & Computer Science (AREA)
Rheumatology (AREA)
Hematology (AREA)

BE2016C059C 2000-04-12 2016-11-04 BE2016C059I2 (fr)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
US22935800P	2000-04-12	2000-04-12
US19938400P	2000-04-25	2000-04-25
US25693100P	2000-12-21	2000-12-21
EP06076852A EP1832599A3 (fr)	2000-04-12	2001-04-12	Proteines de fusion d'albumine
EP08075909A EP2067488A1 (fr)	2000-04-12	2001-04-12	Protéines de fusion d'albumine
EP01934875A EP1278767A4 (fr)	2000-04-12	2001-04-12	Proteines fusionnees a l'albumine

Publications (1)

Publication Number	Publication Date
BE2016C059I2 true BE2016C059I2 (fr)	2020-08-20

Family

ID=27394014

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BE2016C059C BE2016C059I2 (fr)	2000-04-12	2016-11-04

Country Status (10)

Country	Link
US (23)	US6926898B2 (fr)
EP (21)	EP2213743A1 (fr)
JP (9)	JP2004506407A (fr)
AU (7)	AU2001259066A1 (fr)
BE (1)	BE2016C059I2 (fr)
CA (8)	CA2405557C (fr)
DK (2)	DK2236152T3 (fr)
ES (2)	ES2529300T3 (fr)
FR (1)	FR16C0043I2 (fr)
WO (7)	WO2001079442A2 (fr)

Families Citing this family (676)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2686899B1 (fr)	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6057287A (en)	1994-01-11	2000-05-02	Dyax Corp.	Kallikrein-binding "Kunitz domain" proteins and analogues thereof
GB9526733D0 (en) *	1995-12-30	1996-02-28	Delta Biotechnology Ltd	Fusion proteins
WO2001034769A2 (fr) *	1999-11-05	2001-05-17	Human Genome Sciences, Inc.	24 proteines humaines secretees
US20020137890A1 (en)	1997-03-31	2002-09-26	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP0892047A3 (fr) *	1997-07-09	2000-03-08	Hoechst Marion Roussel Deutschland GmbH	Semaphorine L humaine et murine
US20030022293A1 (en) *	1997-09-18	2003-01-30	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20050181482A1 (en) *	2004-02-12	2005-08-18	Meade Harry M.	Method for the production of an erythropoietin analog-human IgG fusion proteins in transgenic mammal milk
DE69933216T2 (de) *	1998-06-15	2007-09-20	GTC Biotherapeutics, Inc., Framingham	Erythropoietin-analog-menschliches serum-albumin fusionsprotein
US20040199099A1 (en) *	1998-07-10	2004-10-07	Matson James R	Hemofiltration systems, methods and devices used to treat inflammatory mediator related disease
US20030190740A1 (en)	1998-10-13	2003-10-09	The University Of Georgia Research Foundation, Inc	Stabilized bioactive peptides and methods of identification, synthesis, and use
US6818611B1 (en)	1998-10-13	2004-11-16	University Of Georgia Research Foundation, Inc.	Stabilized bioactive peptides and methods of identification, synthesis and use
ATE320486T1 (de) *	1999-05-05	2006-04-15	Phylogica Ltd	Isolierung von biologischen modulatoren aus bibiotheken mit biologisch vielfältigen genfragmenten
US6946129B1 (en)	1999-06-08	2005-09-20	Seattle Genetics, Inc.	Recombinant anti-CD40 antibody and uses thereof
US7632803B2 (en)	1999-10-01	2009-12-15	Dmi Life Sciences, Inc.	Metal-binding compounds and uses therefor
US7592304B2 (en)	1999-10-01	2009-09-22	Dmi Life Sciences, Inc.	Metal-binding compounds and uses therefor
JP2003528587A (ja) *	1999-10-29	2003-09-30	ヒューマンジノームサイエンシーズ，インコーポレイテッド	２７個のヒト分泌タンパク質
AU1449001A (en) *	1999-11-05	2001-06-06	Human Genome Sciences, Inc.	28 human secreted proteins
CA2389724A1 (fr) *	1999-11-12	2001-05-17	Human Genome Sciences, Inc.	28 proteines humaines secretees
DK1234031T3 (en)	1999-11-30	2017-07-03	Mayo Foundation	B7-H1, AN UNKNOWN IMMUNE REGULATORY MOLECULE
EP1240337B1 (fr)	1999-12-24	2006-08-23	Genentech, Inc.	Methodes et compositions permettant de prolonger les demi-vies d'elimination de composes bioactifs
US7534417B2 (en)	2000-02-24	2009-05-19	Agensys, Inc.	103P2D6: tissue specific protein highly expressed in various cancers
US7291122B2 (en) *	2000-03-24	2007-11-06	Immunocept, L.L.C.	Hemofiltration methods for treatment of diseases in a mammal
US20050100991A1 (en) *	2001-04-12	2005-05-12	Human Genome Sciences, Inc.	Albumin fusion proteins
US6946134B1 (en)	2000-04-12	2005-09-20	Human Genome Sciences, Inc.	Albumin fusion proteins
EP2213743A1 (fr)	2000-04-12	2010-08-04	Human Genome Sciences, Inc.	Protéines de fusion d'albumine
US7030219B2 (en)	2000-04-28	2006-04-18	Johns Hopkins University	B7-DC, Dendritic cell co-stimulatory molecules
EP1285066A1 (fr) *	2000-05-12	2003-02-26	MERCK PATENT GmbH	Proteine de boite f
US6787040B2 (en) *	2000-05-16	2004-09-07	Immunocept, L.L.C.	Method and system for colloid exchange therapy
AU2001274923A1 (en) *	2000-05-23	2001-12-03	Lexicon Genetics Incorporated	Novel human thrombospondin-like proteins and polynucleotides encoding the same
US6965018B2 (en)	2000-06-06	2005-11-15	Bristol-Myers Squibb Company	Antibodies directed to B7-related polypeptide, BSL-2
EP1283886A2 (fr) *	2000-06-08	2003-02-19	Incyte Genomics, Inc.	Proteines de signalisation intracellulaires
MXPA02012717A (es) *	2000-06-21	2003-09-22	Amgen Inc	Polipeptidos estromaticos-1 del colon, epiteliales, secretados, acidos nucleicos que los codifican y sus usos.
AU2001229507A1 (en) *	2000-08-18	2002-03-04	Human Genome Sciences, Inc.	21 human secreted proteins
CA2419306A1 (fr) *	2000-08-18	2002-02-28	Human Genome Sciences, Inc.	23 proteines humaines secretees
CA2418680A1 (fr) *	2000-08-18	2002-02-28	Human Genome Sciences, Inc.	11 proteines humaines secretees
CA2420902A1 (fr) *	2000-08-28	2002-03-07	Craig A. Rosen	18 proteines humaines secretees
CA2420192A1 (fr) *	2000-09-20	2002-03-28	Human Genome Sciences, Inc.	21 proteines humaines secretees
CA2421147A1 (fr) *	2000-09-29	2002-04-11	Human Genome Sciences, Inc.	24 proteines humaines secretees
WO2002031111A2 (fr) *	2000-10-12	2002-04-18	Hyseq, Inc.	Acides nucleiques et polypeptides
US6949371B2 (en)	2000-10-20	2005-09-27	Applera Corporation	Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
US6531297B2 (en) *	2000-10-20	2003-03-11	Applera Corporation	Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
FR2815964A1 (fr) *	2000-10-30	2002-05-03	Inst Nat Sante Rech Med	Proteine recepteur de la renine et/ou de la prorenine, acide nucleique codant pour ce recepteur et leur applications
US6855493B2 (en)	2000-11-28	2005-02-15	Medimmune, Inc.	Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
WO2002046228A2 (fr) *	2000-12-05	2002-06-13	Wisconsin Alumni Research Foundation	Recepteur de la toxine du b. anthracis
IL155812A0 (en)	2000-12-07	2003-12-23	Lilly Co Eli	Glp-1 fusion proteins
US20030148920A1 (en) *	2000-12-27	2003-08-07	Steven Rosen	Sulfatases and methods of use thereof
JP4344519B2 (ja) *	2000-12-28	2009-10-14	旭化成ファーマ株式会社	ＮＦ−κＢ活性化遺伝子
EP1368468A4 (fr) *	2001-02-23	2005-02-16	Human Genome Sciences Inc	83 proteines humaines secretes
WO2002072138A1 (fr) *	2001-03-08	2002-09-19	Hyseq, Inc.	Methodes et materiels se rapportant a des polypeptides et a des polynucleotides apparentes a la fibuline
WO2002083921A2 (fr)	2001-04-10	2002-10-24	Agensys, Inc.	Acides nucleiques et proteines correspondantes utiles pour la detection et le traitement de divers cancers
US7507413B2 (en)	2001-04-12	2009-03-24	Human Genome Sciences, Inc.	Albumin fusion proteins
US20060084794A1 (en) *	2001-04-12	2006-04-20	Human Genome Sciences, Inc.	Albumin fusion proteins
US20050244931A1 (en) *	2001-04-12	2005-11-03	Human Genome Sciences, Inc.	Albumin fusion proteins
US7164007B2 (en)	2001-06-20	2007-01-16	Genentech, Inc.	Anti-PR020044 antibodies
AU2002328853A1 (en) *	2001-07-06	2003-01-21	Geneprot, Inc.	Carcinoma-related peptides
US7176278B2 (en)	2001-08-30	2007-02-13	Biorexis Technology, Inc.	Modified transferrin fusion proteins
US8129504B2 (en)	2001-08-30	2012-03-06	Biorexis Technology, Inc.	Oral delivery of modified transferrin fusion proteins
AU2002332041A1 (en) *	2001-10-05	2003-04-22	Human Genome Sciences, Inc.	Albumin fusion proteins
DE10251673A1 (de)	2001-11-09	2003-07-10	Hoffmann La Roche	Alström-Syndrom-Gen, Genvarianten, codiertes Protein und Verfahren zur Diagnose des Alström-Syndroms
KR100406760B1 (ko) *	2001-11-16	2003-11-21	신코엠 주식회사	반도체 메모리 장치
EP1458756B1 (fr)	2001-12-17	2009-01-28	Laboratoires Serono SA	Mutants de chimiokines agissant en tant qu'antagonistes de chimiokines
US20040082761A1 (en) *	2001-12-18	2004-04-29	Duggan Brendan M.	Cell adhesion proteins
AU2002364586A1 (en) *	2001-12-21	2003-07-30	Delta Biotechnology Limited	Albumin fusion proteins
WO2005003296A2 (fr)	2003-01-22	2005-01-13	Human Genome Sciences, Inc.	Proteines hybrides d'albumine
KR101271635B1 (ko) *	2001-12-21	2013-06-12	휴먼 게놈 사이언시즈, 인코포레이티드	알부민 융합 단백질
WO2003059934A2 (fr)	2001-12-21	2003-07-24	Human Genome Sciences, Inc.	Proteines de fusion d'albumine
US20060253913A1 (en) *	2001-12-21	2006-11-09	Yue-Jin Huang	Production of hSA-linked butyrylcholinesterases in transgenic mammals
US20080194481A1 (en) *	2001-12-21	2008-08-14	Human Genome Sciences, Inc.	Albumin Fusion Proteins
US7081446B2 (en) *	2002-01-31	2006-07-25	The Trustees Of Columbia University In The City Of New York	Long-acting follicle stimulating hormone analogues and uses thereof
US20050222023A1 (en) *	2002-02-07	2005-10-06	Hans-Peter Hauser	Albumin-fused kunitz domain peptides
US20060241027A1 (en) *	2002-02-07	2006-10-26	Hans-Peter Hauser	Hiv inhibiting proteins
WO2003066824A2 (fr) *	2002-02-07	2003-08-14	Aventis Behring Gmbh	Peptides du domaine kunitz fusionnes a l'albumine
DE10205520A1 (de) *	2002-02-08	2003-08-14	Aventis Behring Gmbh	Inhibitorischer, monoklonaler Antikörper gegen die den Blutgerinnungsfaktor VII aktivierende Protease
BR0307871A (pt) *	2002-02-21	2005-04-12	Wyeth Corp	Proteìnas contendo domìnio de folistatina
EP1483580A4 (fr) *	2002-03-05	2006-10-11	Merck & Co Inc	Marqueur biologique indiquant l'efficacite des medicaments coupe-faim
US20030191056A1 (en) *	2002-04-04	2003-10-09	Kenneth Walker	Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
AU2003231731A1 (en) *	2002-04-15	2003-11-03	American National Red Cross	Method for detecting ligands and targets in a mixture
US20070015230A1 (en) *	2002-04-15	2007-01-18	Hammond David J	Identification and characterization of analytes from whole blood
WO2003089608A2 (fr)	2002-04-18	2003-10-30	The General Hospital Corporation	Famille de genes drg11 (dragon)
US7141381B2 (en)	2002-04-25	2006-11-28	Bristol-Myers Squibb Company	Human leucine-rich repeat-containing proteins specifically expressed in the nervous system
GB0210464D0 (en)	2002-05-08	2002-06-12	Svanborg Catharina	Therapeutic treatment
ES2348230T3 (es)	2002-06-07	2010-12-01	Dyax Corp.	Prevención y reducción de la isquemia.
US7153829B2 (en)	2002-06-07	2006-12-26	Dyax Corp.	Kallikrein-inhibitor therapies
DK1531850T3 (da) *	2002-06-07	2012-06-04	Zymogenetics Inc	Anvendelse af 1L-21 og monoklonalt antistof til behandling af solide cancere
US7425618B2 (en)	2002-06-14	2008-09-16	Medimmune, Inc.	Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en)	2002-06-14	2006-11-07	Medimmune, Inc.	Stabilized liquid anti-RSV antibody formulations
US8029803B2 (en)	2002-06-20	2011-10-04	Paladin Labs, Inc.	Chimeric antigens for eliciting an immune response
CN1241946C (zh) *	2002-07-01	2006-02-15	美国福源集团	对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白
CN101172091B (zh) *	2007-09-25	2011-04-27	北京美福源生物医药科技有限公司	含人血清白蛋白与皮肤细胞生长因子的融合蛋白护肤产品制备工艺和用途
AU2003245090A1 (en) *	2002-07-03	2004-01-23	Nexgen Biotechnologies, Inc.	Method for preparing fusion polypeptide comprising epidermal growth factor and human serum albumin in plants
WO2004004649A2 (fr) *	2002-07-08	2004-01-15	Genentech, Inc.	Compositions et procedes destines au traitement de maladies liees au systeme immunitaire
WO2004009626A1 (fr) *	2002-07-22	2004-01-29	Yamanouchi Pharmaceutical Co., Ltd.	Nouveau gene associe a l'arthrite rhumatoide
GB0217033D0 (en)	2002-07-23	2002-08-28	Delta Biotechnology Ltd	Gene and polypeptide sequences
CA2496002A1 (fr) *	2002-08-07	2004-02-19	Delta Biotechnology Ltd.	Facteur neurotrophique ciliaire hybride avec l'albumine
AU2003255276A1 (en) *	2002-08-13	2004-02-25	Arbios Systems, Inc.	Selective plasma exchange therapy
EP2386310B1 (fr)	2002-08-28	2018-11-07	Dyax Corp.	Procédés de conservation d'organes et de tissus
JP4601426B2 (ja) *	2002-09-06	2010-12-22	アレクシオンファーマシューティカルズ，インコーポレイテッド	補体成分ｃ５に対する抗体を使用する喘息の処置の方法
US20050271660A1 (en)	2002-09-06	2005-12-08	Alexion Pharmaceuticals, Inc.	Nebulization of monoclonal antibodies for treating pulmonary diseases
US9415102B2 (en)	2002-09-06	2016-08-16	Alexion Pharmaceuticals, Inc.	High concentration formulations of anti-C5 antibodies
KR20050071498A (ko) *	2002-09-18	2005-07-07	상트르 오스피딸리에 드 루니버시떼 드 몬트리알	성장 호르몬 방출 호르몬 유사체
US7432351B1 (en)	2002-10-04	2008-10-07	Mayo Foundation For Medical Education And Research	B7-H1 variants
DE10254601A1 (de)	2002-11-22	2004-06-03	Ganymed Pharmaceuticals Ag	Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
AU2003292273A1 (en) *	2002-12-20	2004-07-14	Karolinska Institutet Innovations Ab	Asthma susceptibility locus
EP1577322A4 (fr) *	2002-12-26	2006-01-25	Takeda Pharmaceutical	Nouvelles proteines et leur utilisation
CA2515708A1 (fr) *	2003-02-11	2004-08-26	Transkaryotic Therapies, Inc.	Diagnostic et traitement de la deficience en sulfatase multiple et d'autres deficiences en sulfatase
EP1606305A4 (fr) *	2003-03-12	2009-06-24	Vasgene Therapeutics Inc	Composes d'acide nucleique pouvant inhiber l'angiogenese et la croissance tumorale
US7381410B2 (en) *	2003-03-12	2008-06-03	Vasgene Therapeutics, Inc.	Polypeptide compounds for inhibiting angiogenesis and tumor growth
WO2004082640A2 (fr) *	2003-03-19	2004-09-30	New Century Pharmaceuticals, Inc.	Fragments ou polymeres d'albumine a temps de residence vasculaire modulable utilisables pour la mise au point de therapies d'administration et de vaccins
KR20060017585A (ko) *	2003-04-04	2006-02-24	유니베르시떼 드 로잔느	암 치료용 펩타바디
AU2004229501B2 (en)	2003-04-11	2011-08-18	Medimmune, Llc	Recombinant IL-9 antibodies and uses thereof
WO2004094589A2 (fr) *	2003-04-18	2004-11-04	Incyte Corporation	Proteines secretees
US20050079546A1 (en) *	2003-05-01	2005-04-14	Dasa Lipovsek	Serum albumin scaffold-based proteins and uses thereof
US6987270B2 (en)	2003-05-07	2006-01-17	General Electric Company	Method to account for event losses due to positron range in positron emission tomography and assay of positron-emitting isotopes
US7517655B2 (en) *	2003-06-30	2009-04-14	Nihon University	Protein capable of deposition onto extracellular matrix
US7393534B2 (en)	2003-07-15	2008-07-01	Barros Research Institute	Compositions and methods for immunotherapy of cancer and infectious diseases
US8007805B2 (en) *	2003-08-08	2011-08-30	Paladin Labs, Inc.	Chimeric antigens for breaking host tolerance to foreign antigens
GB0320877D0 (en) *	2003-09-05	2003-10-08	Celltech R&D Ltd	A protein involved in carcinoma
ATE447412T1 (de)	2003-11-04	2009-11-15	Novartis Vaccines & Diagnostic	Antagonist-anti-cd40-monoklonale antikörper und anwendungsverfahren
ES2380022T3 (es) *	2003-12-03	2012-05-07	Monika KRÖZ	Proteínas de fusión a interleucina-11
CN100379762C (zh) *	2003-12-08	2008-04-09	中国人民解放军军事医学科学院生物工程研究所	人血清白蛋白与白细胞介素2的融合蛋白及其编码基因
US9050378B2 (en)	2003-12-10	2015-06-09	Board Of Regents, The University Of Texas System	N2S2 chelate-targeting ligand conjugates
US7371381B2 (en)	2003-12-12	2008-05-13	Amgen Inc.	Anti-galanin antibodies and uses thereof
GB0329681D0 (en)	2003-12-23	2004-01-28	Delta Biotechnology Ltd	Gene expression technique
GB0329722D0 (en)	2003-12-23	2004-01-28	Delta Biotechnology Ltd	Modified plasmid and use thereof
US9057061B2 (en)	2003-12-23	2015-06-16	Novozymes Biopharma Dk A/S	Gene expression technique
WO2006067511A1 (fr)	2004-12-23	2006-06-29	Novozymes Delta Limited	Technique d'expression genetique
EP1712619A4 (fr) *	2003-12-24	2008-01-02	Takeda Pharmaceutical	Substance destinee a la prevention et au traitement du cancer
HUE027902T2 (en)	2004-02-09	2016-11-28	Human Genome Sciences Inc Corp Service Company	Albumin fusion proteins
SE0400489D0 (sv) *	2004-02-27	2004-02-27	Biovitrum Ab	Therapeutic proteins
EP1721008B1 (fr) *	2004-03-03	2010-02-24	EVOTEC Neurosciences GmbH	Utilisation diagnostique et therapeutique du gene et de la proteine mal2 pour les maladies neurodegenerescentes
AU2005227192A1 (en) *	2004-03-11	2005-10-06	Kythera Biopharmaceuticals, Inc.	Compositions and methods for preventing and treating skin and hair conditions
US20050201959A1 (en) *	2004-03-11	2005-09-15	Vvii Newco 2003, Inc.	Methods and compositions for altering skin coloration
DK1730196T3 (da)	2004-03-12	2011-03-28	Vasgene Therapeutics Inc	EphB4-bindende antistoffer til inhibering af antiogenese og tumorvækst
US9592277B2 (en) *	2004-04-14	2017-03-14	Avirid, Inc.	Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases
HRP20060362A2 (en) *	2004-04-23	2007-03-31	Conjuchem Biotechnologies Inc.	Method for the purification of albumin conjugates
KR100599454B1 (ko) *	2004-04-27	2006-07-12	재단법인서울대학교산학협력재단	종양 억제자로 작용하는 ａｉｍ3의 신규 용도
DE102004024617A1 (de)	2004-05-18	2005-12-29	Ganymed Pharmaceuticals Ag	Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP1756554A4 (fr) *	2004-06-03	2009-04-29	Vermillion Inc	Biomarqueurs pour l'arteriopathie peripherique (ap)
CA2578709C (fr) *	2004-06-17	2010-06-15	Virun, Inc.	Compositions comprenant une proteine adherant aux muqueuses et principe actif pour la delivrance d'agents dans des muqueuses
EP1773375A1 (fr)	2004-07-14	2007-04-18	University of Utah Research Foundation	Compositions et utilisations liees a des netrines
CN101018874A (zh) *	2004-08-13	2007-08-15	千年药品公司	用于鉴定、评估、预防和治疗前列腺癌的基因、组合物、试剂盒和方法
EP1793850A4 (fr)	2004-09-21	2010-06-30	Medimmune Inc	Anticorps dirigé contre le virus respiratoire syncytial et procédés de production de vaccins associés
CA2581423A1 (fr) *	2004-09-23	2006-03-30	Vasgene Therapeutics, Inc.	Composes de polypeptides pour l'inhibition de l'angiogenese et de croissance tumorale
US7235530B2 (en)	2004-09-27	2007-06-26	Dyax Corporation	Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US20060078541A1 (en) *	2004-10-01	2006-04-13	Giles Brian C	Method and formula for stem cells' stimulation, targeting release, trafficking and homing
DK1810026T3 (en)	2004-10-06	2018-07-16	Mayo Found Medical Education & Res	B7-H1 AND PD-1 FOR TREATMENT OF RENAL CELL CARCINOM
WO2006042197A2 (fr) *	2004-10-11	2006-04-20	The Board Of Trustees Of The Leland Standford Junior University	Utilisation de del-1 dans une regeneration de cheveux, d'os et de cartilage
JP5036546B2 (ja)	2004-10-25	2012-09-26	イミューンシステムキーリミテッド	胸腺特異的タンパク質
KR100583350B1 (ko) *	2004-11-03	2006-06-05	(주)넥스젠	Ｆａｓ-1 도메인을 함유하는 융합 단백질을 이용한상피세포재생인자의 생산 방법
DE602005009856D1 (de) *	2004-11-09	2008-10-30	Ares Trading Sa	Verfahren zur reinigung von fsh
US20090196850A1 (en)	2005-01-06	2009-08-06	Novo Nordisk A/S	Anti-Kir Combination Treatments and Methods
US20060178301A1 (en) *	2005-02-04	2006-08-10	Mathias Jurs	Albumin-fused ciliary neurotrophic factor
HUE025945T2 (en)	2005-02-15	2016-07-28	Univ Duke	Anti-CD19 antibodies and their applications in oncology
US20110230407A1 (en) *	2005-03-14	2011-09-22	Alexander Yuzhakov	Hepatocyte growth factor pathway activators in demyelinating diseases and central nervous system trauma
EP1864138A2 (fr) *	2005-03-23	2007-12-12	Wyeth	Detection d'agents modulateurs de gdf-8
JP2008537777A (ja) *	2005-03-23	2008-09-25	ワイス	Ｇｄｆ−８調節剤に対する免疫応答の検出
CA2604222A1 (fr)	2005-04-18	2006-10-26	Novo Nordisk A/S	Variantes de l'il-21
US7833979B2 (en) *	2005-04-22	2010-11-16	Amgen Inc.	Toxin peptide therapeutic agents
PL1874821T3 (pl)	2005-04-26	2013-09-30	Trion Pharma Gmbh	Kombinacja przeciwciał i glikokortykoidów do leczenia raka
WO2007052154A2 (fr)	2005-04-29	2007-05-10	University Of Medicine And Dentistry Of New Jersey	Peptide court derive d'erythropoietine et ses mimetiques utilises comme modulateurs immuno / inflammatoires
US9345745B2 (en)	2005-04-29	2016-05-24	Bo Wang	Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides
US9585932B2 (en)	2005-04-29	2017-03-07	Peter C. Dowling	Use of EPO-derived peptide fragments for the treatment of neurodegenerative disorders
EP1885755A4 (fr)	2005-05-05	2009-07-29	Univ Duke	Traitements des maladies auto-immunes par anticorps anti-cd19
WO2007149067A2 (fr) *	2005-05-12	2007-12-27	Zymogenetics, Inc.	Procédés d'utilisation de phhla2 pour une stimulation conjointe des lymphocytes t
CA2611861C (fr)	2005-06-08	2017-11-28	The Brigham And Women's Hospital, Inc.	Methodes et compositions pour le traitement d'infections persistantes
WO2007014167A2 (fr) *	2005-07-22	2007-02-01	Five Prime Therapeutics, Inc.	Compositions et procedes pour le traitement de maladies epitheliales avec des facteurs de croissance
US8323666B2 (en) *	2005-08-01	2012-12-04	Allergan, Inc.	Botulinum toxin compositions
PL2573114T3 (pl)	2005-08-10	2016-10-31		Identyfikacja i inżynieria przeciwciał z wariantami regionów FC oraz sposoby ich stosowania
US8008453B2 (en)	2005-08-12	2011-08-30	Amgen Inc.	Modified Fc molecules
WO2007022799A1 (fr) *	2005-08-26	2007-03-01	Ares Trading S.A.	Procede de preparation d'interferon beta glycosyle
US7713715B2 (en) *	2005-09-06	2010-05-11	University Of Tennessee Research Foundation	Method for diagnosing infections
US20090099031A1 (en) *	2005-09-27	2009-04-16	Stemmer Willem P	Genetic package and uses thereof
US7855279B2 (en)	2005-09-27	2010-12-21	Amunix Operating, Inc.	Unstructured recombinant polymers and uses thereof
US7846445B2 (en) *	2005-09-27	2010-12-07	Amunix Operating, Inc.	Methods for production of unstructured recombinant polymers and uses thereof
JP2009509535A (ja) *	2005-09-27	2009-03-12	アムニクス，インコーポレイテッド	タンパク様薬剤およびその使用
US20080274096A1 (en) *	2005-10-03	2008-11-06	Astrazeneca Ab	Fusion Proteins Having a Modulated Half-Life in Plasma
US8168592B2 (en) *	2005-10-21	2012-05-01	Amgen Inc.	CGRP peptide antagonists and conjugates
EP1790664A1 (fr)	2005-11-24	2007-05-30	Ganymed Pharmaceuticals AG	Anticorps monoclonaux contre claudin-18 pour le traitement du cancer
US20090304687A1 (en) *	2005-12-09	2009-12-10	Seattle Genetics , Inc.	Methods of using cd40 binding agents
EP1960419B1 (fr) *	2005-12-09	2016-03-16	Ares Trading S.A.	Procede de purification de la fsh ou d'un mutant de la fsh
US8841255B2 (en)	2005-12-20	2014-09-23	Duke University	Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US20130172274A1 (en)	2005-12-20	2013-07-04	Duke University	Methods and compositions for delivering active agents with enhanced pharmacological properties
CN101384623B (zh) *	2005-12-22	2013-07-24	常山凯捷健生物药物研发（河北）有限公司	白蛋白与治疗剂的预成型偶联物的制备方法
WO2007082144A2 (fr) *	2006-01-05	2007-07-19	Mayo Foundation For Medical Education And Research	Methode permettant de detecter un cancer a l'aide de b7-h1 et de survivine
WO2007082154A2 (fr) *	2006-01-05	2007-07-19	Mayo Foundation For Medical Education And Research	Methode permettant de detecter un cancer a l'aide de b7-h1 et de b7-h4
CA2637600A1 (fr)	2006-01-17	2007-07-26	Health Research, Inc.	Bio-essai de suivi en heteroduplex
EP1816201A1 (fr)	2006-02-06	2007-08-08	CSL Behring GmbH	Facteur de coagulation VIIa modifié ayant une stabilité 'half-life' améliorée
US20070248646A1 (en) *	2006-02-16	2007-10-25	Ali Hafezi-Moghadam	Use of azurocidin inhibitors in prevention and treatment of ocular vascular leakage
EP1999148B8 (fr)	2006-03-06	2014-03-05	Medlmmune, LLC	Anticorps humanisés dirigés contre l'antigène cd22 et leur utilisation à des fins thérapeutiques en oncologie, ainsi que dans le cadre de transplantations et de maladies auto-immunes
CN102887955A (zh)	2006-04-05	2013-01-23	艾博特生物技术有限公司	抗体纯化
DE602007007923D1 (de)	2006-04-11	2010-09-02	Csl Behring Gmbh	Verfahren zur erhöhung der in-vivo-gewinnung therapeutischer polypeptide
WO2007124361A2 (fr) *	2006-04-20	2007-11-01	Mayo Foundation For Medical Education And Research	B7-h1 soluble
WO2007146038A2 (fr)	2006-06-07	2007-12-21	Human Genome Sciences, Inc.	Protéines de fusion d'albumine
US7939632B2 (en)	2006-06-14	2011-05-10	Csl Behring Gmbh	Proteolytically cleavable fusion proteins with high molar specific activity
EP2032607B2 (fr)	2006-06-14	2017-02-22	CSL Behring GmbH	Protéine de fusion pouvant subir un clivage protéolytique et contenant un facteur de coagulation sanguine
AU2013202566C1 (en) *	2006-06-14	2018-07-12	Csl Behring Gmbh	Proteolytically cleavable fusion protein comprising a blood coagulation factor
EP1867660A1 (fr)	2006-06-14	2007-12-19	CSL Behring GmbH	Protéine de fusion qui peut être clivée protéolyticalement et qui contient un facteur de la coagulation sanguine
EP2049560B1 (fr) *	2006-07-13	2013-05-15	Novozymes Biopharma DK A/S	Procédé de fabrication de particules d'un matériau protéique
CN101511868B (zh)	2006-07-24	2013-03-06	比奥雷克西斯制药公司	毒蜥外泌肽融合蛋白
US20090208480A1 (en) *	2006-08-04	2009-08-20	Yue Huang	Long half-life recombinant butyrylcholinesterase
CA2663047A1 (fr) *	2006-09-06	2008-03-13	Phase Bioscience, Inc.	Proteines de fusion de polypeptide de type elastine therapeutique
CN106008699A (zh)	2006-09-08	2016-10-12	Ambrx公司	经修饰的人类血浆多肽或Fc骨架和其用途
US10925977B2 (en)	2006-10-05	2021-02-23	Ceil>Point, LLC	Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
PE20081140A1 (es) *	2006-10-25	2008-09-22	Amgen Inc	Agentes terapeuticos a base de peptidos derivados de toxinas
JP2010507382A (ja)	2006-10-26	2010-03-11	ノヴォノルディスクアクティーゼルスカブ	Ｉｌ−２１変異体
WO2008057459A2 (fr)	2006-11-07	2008-05-15	Merck & Co., Inc.	Antagonistes de pcsk9
MX2009006398A (es)	2006-12-12	2009-06-23	Biorexis Pharmaceutical Corp	Genotecas de proteinas de fusion de transferrina.
CA2673331A1 (fr)	2006-12-19	2008-06-26	Ablynx N.V.	Sequences d'acides amines dirigees contre les gpcr et polypeptides les contenant pour le traitement de maladies et de troubles lies au gpcr
EP2102244A2 (fr)	2006-12-19	2009-09-23	Ablynx N.V.	Séquences d'acides aminés dirigées contre une métalloprotéinase de la famille adam et polypeptides les comprenant à des fins de traitement de maladies et troubles liés à adam
EP1935430A1 (fr) *	2006-12-22	2008-06-25	CSL Behring GmbH	Facteurs de coagulation modifiés avec une demi-vie in vivo prolongée
CA2673459C (fr) *	2006-12-22	2016-09-13	Stefan Schulte	Facteurs de coagulation modifies presentant une demi-vie in vivo prolongee
EP2450368A1 (fr)	2007-01-30	2012-05-09	Epivax, Inc.	Épitopes de lymphocytes t régulateurs, compositions et utilisations de ceux-ci
CA2678001C (fr)	2007-02-12	2017-07-11	Stefan Schulte	Application therapeutique d'inhibiteurs de serine protease de type kazal
WO2008118386A2 (fr)	2007-03-27	2008-10-02	Merck & Co., Inc.	Procédé de détection de pcsk9 sécrétée, autogénérée
AU2008247382B2 (en)	2007-05-07	2014-06-05	Medimmune, Llc	Anti-ICOS antibodies and their use in treatment of oncology, transplantation and autoimmune disease
MX376656B (es)	2007-05-14	2025-03-07	Kyowa Kirin Co Ltd	Metodos para reducir niveles de basófilos.
EP2162540A2 (fr)	2007-05-22	2010-03-17	Amgen Inc.	Compositions et procédés pour produire des protéines de fusion bioactives
EP1997830A1 (fr)	2007-06-01	2008-12-03	AIMM Therapeutics B.V.	Molécules à liaison spécifiques RSV et leur moyen de fabrication
CN101784564B (zh)	2007-07-13	2014-07-02	约翰霍普金斯大学	B7-dc变体
US20100268055A1 (en) *	2007-07-19	2010-10-21	Arizona Board of Regents, a body corporate acting for and on behalf of Arizona State University	Self-Anchoring MEMS Intrafascicular Neural Electrode
JP2010536341A (ja) *	2007-08-15	2010-12-02	アムニクス，インコーポレイテッド	生物学的に活性なポリペプチドの特性を改変するための組成物および方法
MX338397B (es)	2007-08-29	2016-04-15	Sanofi Aventis	Anticuerpos anti - cxcr5 humanizados, derivados de los mismos y su uso.
JP2009055838A (ja) *	2007-08-31	2009-03-19	Nipro Corp	融合タンパク質、該融合タンパク質に関連する遺伝子、ベクター、形質転換体及び抗炎症性医薬組成物
CN101868246A (zh) *	2007-09-21	2010-10-20	加利福尼亚大学董事会	被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性
EP2050764A1 (fr)	2007-10-15	2009-04-22	sanofi-aventis	Nouveau format d'anticorps bispécifique polyvalent
WO2009053360A1 (fr) *	2007-10-22	2009-04-30	Merck Serono S.A.	Procédé de purification d'une protéine contenant fc
US20100249381A1 (en) *	2007-10-22	2010-09-30	David Delvaille	Method for Purifying FC-Fusion Proteins
WO2009070642A1 (fr)	2007-11-28	2009-06-04	Medimmune, Llc	Formulation de protéine
KR101759457B1 (ko)	2007-12-21	2017-07-31	메디뮨 리미티드	인터루킨-4 수용체 알파(ＩＬ-4Ｒα)에 대한 결합 구성원-173
US8092804B2 (en)	2007-12-21	2012-01-10	Medimmune Limited	Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
WO2009097318A1 (fr) *	2008-01-28	2009-08-06	Bristol-Myers Squibb Company	Dosage de liaison par polarisation en fluorescence pour caractériser des ligands de la glucokinase
AR070316A1 (es)	2008-02-07	2010-03-31	Merck & Co Inc	Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
AR070315A1 (es)	2008-02-07	2010-03-31	Merck & Co Inc	Anticuerpos 1b20 antagonistas de pcsk9
WO2009111315A2 (fr) *	2008-02-29	2009-09-11	Mayo Foundation For Medical Education And Research	Méthodes de réduction de l’inflammation granulomateuse
JP5020135B2 (ja) *	2008-03-19	2012-09-05	ソニーモバイルコミュニケーションズ，エービー	携帯端末装置およびコンピュータプログラム
CN102065903B (zh)	2008-04-01	2015-02-18	诺沃-诺迪斯克有限公司	胰岛素清蛋白缀合物
JP2011516520A (ja)	2008-04-07	2011-05-26	アブリンクスエン．ヴェー．	Ｎｏｔｃｈ経路に指向性を有するアミノ酸配列及びその使用
EA201001734A1 (ru)	2008-05-02	2011-10-31	Новартис Аг	Улучшенные связывающие молекулы на основе фибронектина и их применение
AU2013202564B2 (en) *	2008-06-24	2015-09-17	Csl Behring Gmbh	Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life
PL2291523T3 (pl) *	2008-06-24	2015-05-29	Csl Behring Gmbh	Czynnik VIII, czynnik von Willebranda lub ich kompleksy o wydłużonym okresie półtrwania in vivo
CN102131516B (zh)	2008-06-27	2016-03-16	杜克大学	包含弹性蛋白样肽的治疗剂
CN102149379A (zh)	2008-07-10	2011-08-10	安吉翁生物医药有限公司	调节肝细胞生长因子(分散因子)活性的方法和肝细胞生长因子(分散因子)活性的小分子调节剂组合物
WO2010010119A1 (fr)	2008-07-22	2010-01-28	Ablynx Nv	Séquences d’acides aminés dirigées contre des récepteurs de désactiveurs multicibles et polypeptides
PY09026846A (es)	2008-08-05	2015-09-01	Novartis Ag	Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
AU2009288730B2 (en)	2008-08-25	2013-06-20	Amplimmune, Inc.	Compositions of PD-1 antagonists and methods of use
JP2012500855A (ja) *	2008-08-25	2012-01-12	アンプリミューン、インコーポレーテッド	Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法
NZ591488A (en)	2008-09-07	2012-11-30	Glyconex Inc	Anti-extended type i glycosphingolipid antibody, derivatives thereof and use
JP5933975B2 (ja)	2008-11-12	2016-06-15	メディミューン，エルエルシー	抗体製剤
WO2010059315A1 (fr)	2008-11-18	2010-05-27	Merrimack Pharmaceuticals, Inc.	Lieurs de sérum-albumine humaine et conjugués de ceux-ci
MX2011005691A (es)	2008-11-28	2011-07-20	Univ Emory	Metodos para el tratamiento de infecciones y tumores.
EP3255060A1 (fr) *	2008-12-09	2017-12-13	F. Hoffmann-La Roche AG	Anticorps anti-pd-l1 et leur utilisation pour améliorer la fonction des lymphocytes t
WO2010068526A1 (fr)	2008-12-12	2010-06-17	Merck Sharp & Dohme Corp.	Immunodosage de pcsk9
US8637454B2 (en)	2009-01-06	2014-01-28	Dyax Corp.	Treatment of mucositis with kallikrein inhibitors
CN102378635A (zh)	2009-01-16	2012-03-14	特瓦制药工业有限公司	重组人白蛋白-人粒细胞集落刺激因子融合蛋白的新稳定制剂
US8852608B2 (en)	2009-02-02	2014-10-07	Medimmune, Llc	Antibodies against and methods for producing vaccines for respiratory syncytial virus
US8703717B2 (en) *	2009-02-03	2014-04-22	Amunix Operating Inc.	Growth hormone polypeptides and methods of making and using same
ES2610356T3 (es)	2009-02-03	2017-04-27	Amunix Operating Inc.	Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos
US8680050B2 (en) *	2009-02-03	2014-03-25	Amunix Operating Inc.	Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
KR101722961B1 (ko)	2009-02-11	2017-04-04	알부메딕스 에이/에스	알부민 변이체 및 접합체
CA2755336C (fr)	2009-03-20	2015-07-14	Amgen Inc.	Immunoglobulines porteuses et utilisations de celles-ci
DK2427486T3 (en)	2009-05-07	2015-05-26	Novozymes Biopharma Dk As	A process for purifying albumin
EP2258398A1 (fr) *	2009-05-26	2010-12-08	Araclón Biotech, S. L.	Conjugués d'albumine-peptide d'amyloide et leurs utilisations
US11512326B2 (en) *	2009-05-26	2022-11-29	University Of Florida Research Foundation, Incorporated	Small angiotensin peptide expression system in mammalian cells
WO2010144508A1 (fr) *	2009-06-08	2010-12-16	Amunix Operating Inc.	Polypeptides de régulation du glucose et leurs procédés de production et d'utilisation
US9849188B2 (en)	2009-06-08	2017-12-26	Amunix Operating Inc.	Growth hormone polypeptides and methods of making and using same
CA2769822C (fr)	2009-08-13	2019-02-19	The Johns Hopkins University	Methodes de modulation de la fonction immunitaire
WO2011020866A2 (fr)	2009-08-20	2011-02-24	Csl Behring Gmbh	Facteurs de coagulation fusionnés à de l'albumine pour l'administration non intraveineuse dans le cadre de la thérapie et du traitement prophylactique des troubles hémostatiques
US10420862B2 (en)	2009-08-24	2019-09-24	Aresenal AAA, LLC.	In-situ forming foams for treatment of aneurysms
US9044580B2 (en)	2009-08-24	2015-06-02	Arsenal Medical, Inc.	In-situ forming foams with outer layer
CA2771999A1 (fr)	2009-08-24	2011-03-10	Amunix Operating Inc.	Compositions de facteurs de coagulation vii et procedes de preparation et d'utilisation de celles-ci
US9173817B2 (en)	2009-08-24	2015-11-03	Arsenal Medical, Inc.	In situ forming hemostatic foam implants
US12544491B2 (en)	2009-08-24	2026-02-10	Arsenal Medical, Inc.	In situ forming hemostatic foam implants
US20110202016A1 (en) *	2009-08-24	2011-08-18	Arsenal Medical, Inc.	Systems and methods relating to polymer foams
US8451450B2 (en) *	2009-09-14	2013-05-28	Bio-Rad Laboratories, Inc.	Near real time optical phase conjugation
US20110172398A1 (en)	2009-10-02	2011-07-14	Boehringer Ingelheim International Gmbh	Bispecific binding molecules for anti-angiogenesis therapy
UY32917A (es)	2009-10-02	2011-04-29	Boehringer Ingelheim Int	Moléculas de unión a dll-4
US8568726B2 (en)	2009-10-06	2013-10-29	Medimmune Limited	RSV specific binding molecule
JP5898082B2 (ja)	2009-10-07	2016-04-06	マクロジェニクス，インコーポレーテッド	フコシル化程度の変更により改良されたエフェクター機能を示すＦｃ領域含有ポリペプチドおよびその使用法
WO2011051278A1 (fr) *	2009-10-26	2011-05-05	Externautics S.P.A.	Marqueurs de tumeurs du poumon et leurs méthodes d'utilisation
IN2012DN03824A (fr)	2009-10-30	2015-08-28	Merck Sharp & Dohme
WO2011051327A2 (fr)	2009-10-30	2011-05-05	Novartis Ag	Petites protéines à chaîne unique de type anticorps
EP2493921B1 (fr)	2009-10-30	2018-09-26	Albumedix Ltd	Variants d'albumine
CN102596249A (zh)	2009-10-30	2012-07-18	默沙东公司	Ax1和ax189 pcsk9拮抗剂和变体
WO2011051466A1 (fr)	2009-11-02	2011-05-05	Novartis Ag	Molécules de liaison anti-idiotypiques à base de fibronectine et leurs utilisations
CA2817671A1 (fr) *	2009-11-17	2011-05-26	Universite De Montreal	Peptides a structure binaire et leurs utilisations dans des applications de biocapteur
SI2506868T1 (en) *	2009-12-06	2018-04-30	Bioverativ Therapeutics Inc.	HYPER AND HYBRID POLYPETTIDES FACTOR VIII-FC AND METHODS FOR THEIR USE
JP2013512959A (ja)	2009-12-08	2013-04-18	テバファーマシューティカルインダストリーズリミティド	コカイン乱用を治療するためのＢＣｈＥアルブミン融合体
EP3309176B1 (fr)	2009-12-14	2025-10-01	Ablynx N.V.	Anticorps à domaine variable unique contre ox40l, constructions et leur utilisation thérapeutique
CA2784861A1 (fr)	2009-12-21	2011-07-14	Pharmathene, Inc.	Butyrylcholinesterases recombinantes et produits de troncature de ceux-ci
SMT201800552T1 (it)	2010-01-06	2018-11-09	Dyax Corp	Proteine che legano la callicreina plasmatica
AR079944A1 (es)	2010-01-20	2012-02-29	Boehringer Ingelheim Int	Anticuerpo neutralizante de la actividad de un anticoagulante
MX338357B (es)	2010-01-22	2016-04-13	Novo Nordisk Healthcare Ag	Compuestos estables de la hormona de crecimiento.
RS59459B1 (sr)	2010-01-22	2019-11-29	Novo Nordisk Healthcare Ag	Hormoni rasta sa produženom in-vivo efikasnošću
WO2011092233A1 (fr)	2010-01-29	2011-08-04	Novartis Ag	Conjugaison de levures pour produire des combinaisons de liants à base de fibronectine à haute affinité
US9120855B2 (en)	2010-02-10	2015-09-01	Novartis Ag	Biologic compounds directed against death receptor 5
EP2547328B1 (fr) *	2010-02-11	2017-06-07	Ecole Polytechnique Fédérale de Lausanne (EPFL)	Administration et co-administration de ligands de ccr7 en immunothérapie
NZ601117A (en)	2010-03-03	2014-06-27	Boehringer Ingelheim Int	Biparatopic abeta binding polypeptides
EP2371857A1 (fr)	2010-04-01	2011-10-05	CSL Behring GmbH	Inhibiteurs de facteur XII pour traiter la maladie de poumon interstitiel
EP2556087A1 (fr)	2010-04-09	2013-02-13	Novozymes Biopharma DK A/S	Dérivés et variants d'albumine
PH12012502193A1 (en)	2010-05-06	2021-08-09	Novartis Ag	Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
EP2566892B1 (fr)	2010-05-06	2017-12-20	Novartis AG	Compositions et procédés d'utilisation d'anticorps thérapeutiques dirigés contre la protéine 6 liée à la lipoprotéine de basse densité (lrp6)
EP2571901B1 (fr)	2010-05-20	2019-01-02	Ablynx N.V.	Matériaux biologiques associés à her3
PL3552619T3 (pl)	2010-07-09	2025-12-01	Bioverativ Therapeutics Inc.	Polipeptydy czynnika ix i sposoby ich zastosowania
EP3508573A1 (fr)	2010-07-09	2019-07-10	Bioverativ Therapeutics Inc.	Systèmes de traitement de facteur viii et procédés associés
WO2012019061A2 (fr)	2010-08-05	2012-02-09	Stem Centrx, Inc.	Nouveaux effecteurs et leurs procédés d'utilisation
WO2012019168A2 (fr)	2010-08-06	2012-02-09	Moderna Therapeutics, Inc.	Acides nucléiques modifiés et leurs procédés d'utilisation
WO2013121296A1 (fr)	2012-02-15	2013-08-22	Ecole Polytechnique Federale De Lausanne	Agents thérapeutiques se liant aux érythrocytes
EP2603520A4 (fr)	2010-08-10	2014-02-19	Ecole Polytech	Agents thérapeutiques se liant aux érythrocytes
US9517257B2 (en)	2010-08-10	2016-12-13	Ecole Polytechnique Federale De Lausanne (Epfl)	Erythrocyte-binding therapeutics
US9850296B2 (en)	2010-08-10	2017-12-26	Ecole Polytechnique Federale De Lausanne (Epfl)	Erythrocyte-binding therapeutics
AU2011290672B2 (en)	2010-08-20	2015-07-09	Novartis Ag	Antibodies for epidermal growth factor receptor 3 (HER3)
SG10201506782XA (en)	2010-08-27	2015-10-29	Stem Centrx Inc	Notum protein modulators and methods of use
AU2011295715B9 (en)	2010-09-03	2017-02-23	Abbvie Stemcentrx Llc	Novel modulators and methods of use
US20120225081A1 (en)	2010-09-03	2012-09-06	Boehringer Ingelheim International Gmbh	Vegf-binding molecules
MX360946B (es)	2010-09-22	2018-10-29	Amgen Inc Star	Inmunoglobulinas portadoras y usos de las mismas.
PT2621515T (pt)	2010-09-28	2017-07-12	Aegerion Pharmaceuticals Inc	Polipéptido quimérico de leptina de foca-ser humano com solubilidade aumentada
EP2625189B1 (fr)	2010-10-01	2018-06-27	ModernaTX, Inc.	Synthèse d'acides nucléiques et méthodes d'utilisation associées
US8892184B2 (en)	2010-10-18	2014-11-18	Siemens Medical Solutions Usa, Inc.	Systems and methods for reducing interference in a dual modality imaging system
US8853490B2 (en) *	2010-10-26	2014-10-07	Pioneer Hi Bred International Inc	Antifungal proteins and methods of use
US20130225496A1 (en)	2010-11-01	2013-08-29	Novozymes Biopharma Dk A/S	Albumin Variants
ES2758994T3 (es)	2010-11-05	2020-05-07	Zymeworks Inc	Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
AU2011328246B2 (en)	2010-11-08	2016-06-30	Ablynx N.V.	CXCR2 binding polypeptides
US9095606B1 (en)	2010-11-13	2015-08-04	Sirbal Ltd.	Molecular and herbal combinations for treating psoriasis
US9066974B1 (en)	2010-11-13	2015-06-30	Sirbal Ltd.	Molecular and herbal combinations for treating psoriasis
WO2012069466A1 (fr)	2010-11-24	2012-05-31	Novartis Ag	Molécules multi-spécifiques
NZ611428A (en)	2010-12-08	2015-07-31	Stemcentrx Inc	Novel modulators and methods of use
EP2660600B1 (fr)	2010-12-28	2018-08-08	Sumitomo Dainippon Pharma Co., Ltd.	Médicament de diagnostic et procédé de diagnostic pour la maladie d'alzheimer
US20120171195A1 (en)	2011-01-03	2012-07-05	Ravindranath Mepur H	Anti-hla-e antibodies, therapeutic immunomodulatory antibodies to human hla-e heavy chain, useful as ivig mimetics and methods of their use
KR102320178B1 (ko)	2011-01-06	2021-11-02	다케다 파머수티컬 컴패니 리미티드	혈장 칼리크레인 결합 단백질
SA112330278B1 (ar)	2011-02-18	2015-10-09	ستيم سينتركس، انك.	مواد ضابطة جديدة وطرق للاستخدام
CA2828405A1 (fr)	2011-02-28	2012-09-07	Istituto Di Ricovero E Cura A Carattere Scientifico Materno-Infantile Bu Rlo Garofolo - Ospedale Di Alta Specializzazione E Di Rilievo Nazionale	Molecules induisant l'apoptose et leurs utilisations
AU2012222833B2 (en)	2011-03-03	2017-03-16	Zymeworks Inc.	Multivalent heteromultimer scaffold design and constructs
EP2497489A1 (fr)	2011-03-09	2012-09-12	CSL Behring GmbH	Inhibiteur du facteur XII pour le traitement de la pénombre ischémique cérébrale et l'ischémie d'autres organes
US9352016B2 (en)	2011-03-09	2016-05-31	Csl Behring Gmbh	Factor XII inhibitors for the administration with medical procedures comprising contact with artificial surfaces
TWI719112B (zh)	2011-03-16	2021-02-21	賽諾菲公司	雙重ｖ區類抗體蛋白質之用途
PH12013501865A1 (en)	2011-03-16	2014-01-06	Amgen Inc	Potent and selective inhibitors of nav1.3 and nav1.7
US9340584B2 (en)	2011-03-29	2016-05-17	The General Hospital Corporation	Engineered thioredoxin-like fold proteins
PE20140964A1 (es)	2011-03-30	2014-08-17	Boehringer Ingelheim Int	Antidotos anticoagulantes
AU2012236099A1 (en)	2011-03-31	2013-10-03	Moderna Therapeutics, Inc.	Delivery and formulation of engineered nucleic acids
US20130078247A1 (en)	2011-04-01	2013-03-28	Boehringer Ingelheim International Gmbh	Bispecific binding molecules binding to dii4 and ang2
US9527925B2 (en)	2011-04-01	2016-12-27	Boehringer Ingelheim International Gmbh	Bispecific binding molecules binding to VEGF and ANG2
NZ713461A (en)	2011-04-15	2017-02-24	Compugen Ltd	Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
EP2515112B1 (fr) *	2011-04-22	2015-08-12	Sysmex Corporation	Procédé de détection électrochimique d'analytes
US9062106B2 (en)	2011-04-27	2015-06-23	Abbvie Inc.	Methods for controlling the galactosylation profile of recombinantly-expressed proteins
UA117218C2 (uk)	2011-05-05	2018-07-10	Мерк Патент Гмбх	Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
CA2830660A1 (fr)	2011-05-05	2012-11-08	Novozymes Biopharma Dk A/S	Variants de l'albumine
WO2012170742A2 (fr)	2011-06-07	2012-12-13	University Of Hawaii	Traitement et prévention du cancer avec des antagonistes du hmgb1
US9244074B2 (en)	2011-06-07	2016-01-26	University Of Hawaii	Biomarker of asbestos exposure and mesothelioma
US9486507B2 (en)	2011-06-10	2016-11-08	Biogen Ma Inc.	Pro-coagulant compounds and methods of use thereof
WO2012172495A1 (fr)	2011-06-14	2012-12-20	Novartis Ag	Compositions et procédés de ciblage du tem8 par des anticorps
US20160145589A1 (en)	2011-06-24	2016-05-26	Green Cross Corporation	Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
KR102231139B1 (ko) *	2011-06-28	2021-03-24	인히브릭스, 인크.	세르핀 융합 폴리펩타이드 및 이의 이용 방법
RU2014103288A (ru)	2011-07-01	2015-08-10	Байер Интеллектчуал Проперти Гмбх	Слитые полипептиды релаксина и их применение
JP6247210B2 (ja)	2011-07-05	2017-12-13	アルブミディクスアクティーゼルスカブ	アルブミン製剤及び用途
KR20140039257A (ko)	2011-07-08	2014-04-01	바이엘 인텔렉쳐 프로퍼티 게엠베하	릴랙신을 방출하는 융합 단백질 및 이의 용도
CN103957926B (zh)	2011-07-08	2018-07-03	安米林药品有限责任公司	具有增强的作用持续时间和降低的免疫原性的工程改造的多肽
BR112014001274A2 (pt) *	2011-07-18	2017-04-18	Arts Biologics As	composto de hormônio luteinizante, e, composição farmacêutica
IL230564B2 (en)	2011-07-22	2023-09-01	Csl Ltd	Anticoagulant monoclonal antibodies anti–factor xii/fxiia, a method for their preparation, a pharmaceutical compound containing them and medical uses.
US20130058947A1 (en)	2011-09-02	2013-03-07	Stem Centrx, Inc	Novel Modulators and Methods of Use
US9464124B2 (en)	2011-09-12	2016-10-11	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
DE19216461T1 (de)	2011-10-03	2021-10-07	Modernatx, Inc.	Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
US10598653B2 (en)	2011-11-01	2020-03-24	Bionomics Inc.	Methods of blocking cancer stem cell growth
US8993831B2 (en) *	2011-11-01	2015-03-31	Arsenal Medical, Inc.	Foam and delivery system for treatment of postpartum hemorrhage
WO2013067057A1 (fr)	2011-11-01	2013-05-10	Bionomics, Inc.	Anticorps anti-gpr49
CN104053671A (zh)	2011-11-01	2014-09-17	生态学有限公司	治疗癌症的抗体和方法
US9221907B2 (en)	2011-11-01	2015-12-29	Bionomics Inc.	Anti-GPR49 monoclonal antibodies
ES2666856T3 (es)	2011-11-04	2018-05-08	Novartis Ag	Proteína 6 relacionada con lipoproteínas de baja densidad (LRP6) - constructos extensores de la vida media
BR112014010580B1 (pt)	2011-11-04	2021-01-12	Zymeworks, Inc.	constructo de fc heteromultimérico isolado, composição, uso de um constructo de fc heteromultimérico isolado, composição de ácido nucléico e método para expressar o constructo de fc heteromultimérico isolado
EP2780364A2 (fr)	2011-11-18	2014-09-24	Eleven Biotherapeutics, Inc.	Protéines ayant une demi-vie et d'autres propriétés améliorées
EP3590538A1 (fr)	2011-12-05	2020-01-08	Novartis AG	Anticorps dirigés contre le récepteur 3 du facteur de croissance épidermique (her3)
CN104105709A (zh)	2011-12-05	2014-10-15	诺华股份有限公司	抗her3的结构域ii的表皮生长因子受体3(her3)抗体
CA3018046A1 (fr)	2011-12-16	2013-06-20	Moderna Therapeutics, Inc.	Nucleoside, nucleotide, et compositions d'acide nucleique modifies
ES2728278T3 (es)	2011-12-21	2019-10-23	Novartis Ag	Composiciones que comprenden anticuerpos dirigidos al factor P y C5
JP6127063B2 (ja)	2011-12-22	2017-05-10	ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー	中枢神経系の続発性浮腫の治療のためのｃ１インヒビターの使用
US10800847B2 (en)	2012-01-11	2020-10-13	Dr. Mepur Ravindranath	Anti-HLA class-IB antibodies mimic immunoreactivity and immunomodulatory functions of intravenous immunoglobulin (IVIG) useful as therapeutic IVIG mimetics and methods of their use
US20130177574A1 (en)	2012-01-11	2013-07-11	Paul I. Terasaki Foundation Laboratory	ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE
CN104271150A (zh)	2012-01-12	2015-01-07	比奥根艾迪克Ma公司	嵌合因子viii多肽及其用途
EP2623110A1 (fr)	2012-01-31	2013-08-07	CSL Behring GmbH	Inhibiteurs de facteur XII pour le traitement de troubles inflammatoires neurologiques
WO2013120939A1 (fr) *	2012-02-15	2013-08-22	Csl Behring Gmbh	Variants du facteur de von willebrand ayant une affinité de liaison au facteur viii améliorée
EP2822577B1 (fr)	2012-02-15	2019-02-06	Bioverativ Therapeutics Inc.	Protéines de facteur viii de recombinaison
JP6256882B2 (ja)	2012-02-15	2018-01-10	アムニクスオペレーティングインコーポレイテッド	第ｖｉｉｉ因子組成物、ならびに組成物の作製方法および用途
BR112014020826A8 (pt)	2012-02-24	2017-09-19	Stem Centrx Inc	Anticorpo que se liga especificamente a um epítopo, ácido nucleico, vetor ou célula hospedeira, conjugado de fármaco anticorpo, composição farmacêutica compreendendo o referido anticorpo, uso do mesmo, kit e método de preparação do conjugado
PH12021553014A1 (en)	2012-02-27	2022-09-05	Ablynx Nv	Cx3cr1-binding polypeptides
DK2825556T3 (en)	2012-03-16	2018-04-16	Albumedix As	albumin Variants
GB201204868D0 (en) *	2012-03-20	2012-05-02	San Raffaele Centro Fond	Peptides
US9592289B2 (en)	2012-03-26	2017-03-14	Sanofi	Stable IgG4 based binding agent formulations
CA2862516C (fr)	2012-03-27	2023-02-14	Ngm Biopharmaceuticals, Inc.	Compositions et methodes d'utilisation pour le traitement de troubles metaboliques
US9572897B2 (en)	2012-04-02	2017-02-21	Modernatx, Inc.	Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9254311B2 (en)	2012-04-02	2016-02-09	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of proteins
WO2013151665A2 (fr)	2012-04-02	2013-10-10	modeRNA Therapeutics	Polynucléotides modifiés destinés à la production de protéines associées à une maladie humaine
US9283287B2 (en)	2012-04-02	2016-03-15	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of nuclear proteins
US9067990B2 (en)	2013-03-14	2015-06-30	Abbvie, Inc.	Protein purification using displacement chromatography
WO2013158273A1 (fr)	2012-04-20	2013-10-24	Abbvie Inc.	Procédés de modulation de la distribution de variant de lysine c-terminal
WO2013158279A1 (fr)	2012-04-20	2013-10-24	Abbvie Inc.	Procédés de purification de protéines pour réduire des espèces acides
CN110078827A (zh) *	2012-04-27	2019-08-02	西托姆克斯治疗公司	结合表皮生长因子受体的可活化的抗体其使用方法
WO2013166290A1 (fr)	2012-05-04	2013-11-07	Abbvie Biotherapeutics Inc.	Dosage de biomarqueurs de p21
US9328174B2 (en)	2012-05-09	2016-05-03	Novartis Ag	Chemokine receptor binding polypeptides
WO2013167153A1 (fr)	2012-05-09	2013-11-14	Ganymed Pharmaceuticals Ag	Anticorps utiles dans le diagnostic du cancer
AU2013258834B2 (en)	2012-05-10	2017-09-07	Zymeworks Bc Inc.	Heteromultimer constructs of immunoglobulin heavy chains with mutations in the Fc domain
WO2013177386A1 (fr)	2012-05-24	2013-11-28	Abbvie Biotherapeutics Inc.	Biomarqueurs destinés à prédire la réponse à une thérapie par un agoniste du récepteur tweak (tweakr)
WO2013176754A1 (fr)	2012-05-24	2013-11-28	Abbvie Inc.	Nouvelle purification d'anticorps au moyen de chromatographie à interaction hydrophobe
EP2854535A1 (fr)	2012-05-30	2015-04-08	Bayer Cropscience AG	Compositions comprenant un agent de lutte biologique et un insecticide
EP3281526A1 (fr)	2012-05-30	2018-02-14	Bayer CropScience Aktiengesellschaft	Compositions comprenant un agent de contrôle biologique et un fongicide
NZ725994A (en)	2012-05-30	2018-07-27	Bayer Cropscience Ag	Composition comprising a biological control agent and a fungicide selected from inhibitors of the ergosterol biosynthesis
CN107027809A (zh)	2012-05-30	2017-08-11	拜耳作物科学股份公司	包含生物防治剂和选自呼吸链复合物i或ii抑制剂的杀真菌剂的组合物
WO2013178661A1 (fr)	2012-05-30	2013-12-05	Bayer Cropscience Ag	Compositions comprenant un agent de lutte biologique et un insecticide
PT2854552T (pt)	2012-05-30	2019-07-25	Bayer Cropscience Ag	Composição compreendendo um agente de controlo biológico e um fungicida selecionado a partir de inibidores da biossíntese de aminoácidos ou proteínas, inibidores da produção de atp e inibidores da síntese da parede celular
WO2013178658A1 (fr)	2012-05-30	2013-12-05	Bayer Cropscience Ag	Compositions comprenant un agent de lutte biologique et un insecticide
KR20150023475A (ko)	2012-05-30	2015-03-05	바이엘 크롭사이언스 아게	생물학적 방제제, 및 지질막 합성, 멜라닌 생합성, 핵산 합성 또는 신호 전달의 억제제로부터 선택된 살진균제를 포함하는 조성물
AU2013269662B2 (en)	2012-05-30	2016-12-15	Bayer Cropscience Ag	Compositions comprising a biological control agent and an insecticide
HRP20181752T1 (hr)	2012-05-30	2018-12-28	Bayer Cropscience Ag	Pripravak koji sadrži biološko kontrolno sredstvo i fluopikolid
EP2854529B1 (fr)	2012-05-30	2018-01-17	Bayer Cropscience AG	Compositions comprenant un agent de lutte biologique et un insecticide
TR201816257T4 (tr)	2012-05-30	2018-11-21	Bayer Cropscience Ag	Bir biyolojik kontrol ajanı ve trifloksistrobin içeren bileşim.
CA2875247A1 (fr)	2012-06-08	2013-12-12	Biogen Idec Ma Inc.	Facteurs de coagulation chimeriques
WO2013185113A1 (fr)	2012-06-08	2013-12-12	Biogen Idec Ma Inc.	Composés pro-coagulants
KR101380740B1 (ko)	2012-06-29	2014-04-11	쉐어 휴먼 제네텍 세러피스, 인코포레이티드	이듀로네이트-2-설파타제의 정제
US9150841B2 (en)	2012-06-29	2015-10-06	Shire Human Genetic Therapies, Inc.	Cells for producing recombinant iduronate-2-sulfatase
US10656156B2 (en)	2012-07-05	2020-05-19	Mepur Ravindranath	Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E
CN104661674A (zh)	2012-07-11	2015-05-27	阿穆尼克斯运营公司	具有xten和血管性血友病因子蛋白的因子viii复合物、及其用途
WO2014012082A2 (fr)	2012-07-13	2014-01-16	Zymeworks Inc.	Conception d'échafaudages hétéromultimères et produits de recombinaison
WO2014036520A1 (fr)	2012-08-30	2014-03-06	Merrimack Pharmaceuticals, Inc.	Polythérapies comprenant des agents anti-erbb3
HK1211981A1 (en)	2012-09-02	2016-06-03	Abbvie Inc.	Methods to control protein heterogeneity
US9512214B2 (en)	2012-09-02	2016-12-06	Abbvie, Inc.	Methods to control protein heterogeneity
HK1213767A1 (zh)	2012-10-18	2016-07-15	Bioverativ Therapeutics Inc.	使用固定劑量凝血因子的方法
MX2015005363A (es)	2012-11-08	2015-11-06	Novozymes Biopharma Dk As	Variantes de albumina.
JP6499079B2 (ja)	2012-11-13	2019-04-10	バイオエヌテックアーゲーＢｉｏＮＴｅｃｈＡＧ	クローディンを発現するガン疾患を処置するための剤
PL2922554T3 (pl)	2012-11-26	2022-06-20	Modernatx, Inc.	Na zmodyfikowany na końcach
WO2014084859A1 (fr)	2012-11-30	2014-06-05	Novartis Ag	Molécules et procédés pour la modulation d'activités de tmem16a
DK2928921T3 (da)	2012-12-05	2021-04-19	Novartis Ag	Sammensætninger og fremgangsmåder til antistoffer målrettet epo
US20160067347A1 (en)	2012-12-20	2016-03-10	Amgen Inc.	Apj receptor agonists and uses thereof
EP2945703A4 (fr)	2013-01-15	2016-08-31	Teva Pharma	Formulations d'albu-bche, leur préparation et leurs utilisations
KR101503907B1 (ko) *	2013-01-17	2015-03-20	서울대학교산학협력단	흉막폐렴균과 마이코플라즈마 하이오뉴모니아 감염 질환 예방을 위한 재조합 단백질 백신
KR101993714B1 (ko)	2013-01-30	2019-06-28	엔지엠 바이오파마슈티컬스, 아이엔씨.	대사 장애를 치료하는데 이용하기 위한 조성물과 방법
US9161966B2 (en)	2013-01-30	2015-10-20	Ngm Biopharmaceuticals, Inc.	GDF15 mutein polypeptides
TWI635098B (zh)	2013-02-01	2018-09-11	再生元醫藥公司	含嵌合恆定區之抗體
MX2015010259A (es)	2013-02-11	2015-10-29	Bayer Cropscience Lp	Composiciones que comprenden un agente de control biologico basado en la cepa nrrl b-50550 de streptomyces microflavus y otro agente de control biologico.
WO2014127215A1 (fr)	2013-02-15	2014-08-21	Biogen Idec Ma Inc.	Gène du facteur viii optimisé
US20160033523A1 (en)	2013-02-16	2016-02-04	Novozymes Biopharma Dk A/S	Pharmacokinetic animal model
ES2609070T3 (es)	2013-02-28	2017-04-18	Csl Behring Gmbh	Agente terapéutico para el embolismo de líquido amniótico
US9255262B2 (en) *	2013-03-06	2016-02-09	Vision Global Holdings Ltd.	Albumin-binding arginine deminase and the use thereof
USRE48805E1 (en)	2013-03-06	2021-11-02	Vision Global Holdings Ltd.	Method for cancer targeting treatment and detection of arginine using albumin-binding arginine deiminase fusion protein
CN105188750A (zh)	2013-03-08	2015-12-23	德国杰特贝林生物制品有限公司	治疗和预防远端缺血-再灌注损伤
WO2014164703A1 (fr)	2013-03-11	2014-10-09	University Of Florida Research Foundation, Inc.	Délivrance d'une protéine card en tant que thérapie pour inflammation oculaire
HK1207960A1 (en)	2013-03-12	2016-02-19	Abbvie Inc.	Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014165277A2 (fr)	2013-03-12	2014-10-09	Amgen Inc.	Inhibiteurs sélectifs et puissants de nav1.7
EP2968587A2 (fr)	2013-03-13	2016-01-20	Bristol-Myers Squibb Company	Domaines d'échafaudage à base de fibronectine liés à une sérum albumine ou fragment se liant à celle-ci
EP2968391A1 (fr) *	2013-03-13	2016-01-20	Moderna Therapeutics, Inc.	Molécules polynucléotidiques à longue durée de vie
WO2014159579A1 (fr)	2013-03-14	2014-10-02	Abbvie Inc.	Anticorps anti-tnfα ayant mutés et leurs procédés d'utilisation
US9302005B2 (en)	2013-03-14	2016-04-05	Mayo Foundation For Medical Education And Research	Methods and materials for treating cancer
US9017687B1 (en)	2013-10-18	2015-04-28	Abbvie, Inc.	Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9499614B2 (en)	2013-03-14	2016-11-22	Abbvie Inc.	Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
EP3611189A1 (fr)	2013-03-14	2020-02-19	Novartis AG	Anticorps dirigés contre notch 3
WO2014144549A1 (fr)	2013-03-15	2014-09-18	Biogen Idec Ma Inc.	Préparations contenant un polypeptide du facteur ix
US8980864B2 (en)	2013-03-15	2015-03-17	Moderna Therapeutics, Inc.	Compositions and methods of altering cholesterol levels
EP2978451B1 (fr)	2013-03-29	2019-11-27	Alexion Pharmaceuticals, Inc.	Compositions et procédés pour augmenter la demi-vie sérique d'un agent thérapeutique ciblant c5 complémentaire
US11045523B2 (en)	2013-04-05	2021-06-29	Novo Nordisk Healthcare Ag	Formulation of growth hormone albumin-binder conjugate
EP2796145B1 (fr)	2013-04-22	2017-11-01	CSL Ltd.	Un complexe covalent de facteur von willebrand et de faktor viii conjugé par un pont disulfure
UY35620A (es)	2013-06-21	2015-01-30	Novartis Ag	Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
AR096601A1 (es)	2013-06-21	2016-01-20	Novartis Ag	Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
CN113817069A (zh)	2013-06-28	2021-12-21	比奥贝拉蒂治疗公司	具有xten的凝血酶可裂解连接子和其用途
CA2916399C (fr)	2013-06-28	2022-08-02	Marc Nolte	Polytherapie utilisant un inhibiteur du facteur xii et un inhibiteur de c1
CN104342420B (zh) *	2013-07-30	2017-09-15	惠觅宙	一种重组长效人透明质酸酶、其编码基因、生产方法及应用
TW202003554A (zh)	2013-08-14	2020-01-16	美商百歐維拉提夫治療公司	因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
US20160311885A1 (en)	2013-08-14	2016-10-27	Biogen Ma Inc.	Recombinant factor viii proteins
CA2920835A1 (fr)	2013-08-20	2015-02-26	Anutra Medical, Inc.	Systeme de remplissage de seringue et procede associe
SG11201601424PA (en)	2013-08-28	2016-03-30	Stemcentrx Inc	Site-specific antibody conjugation methods and compositions
CN105792836A (zh)	2013-08-28	2016-07-20	施特姆森特克斯股份有限公司	新型sez6调节剂以及应用方法
HUE057005T2 (hu)	2013-09-25	2022-04-28	Bioverativ Therapeutics Inc	Oszlopon történõ vírusinaktiváló eljárások
CN103468662A (zh) *	2013-09-29	2013-12-25	惠觅宙	一种重组人透明质酸酶、其生产纯化方法、制剂及使用方法与应用
WO2015048744A2 (fr)	2013-09-30	2015-04-02	Moderna Therapeutics, Inc.	Polynucléotides codant des polypeptides de modulation immunitaire
ES2714708T3 (es)	2013-10-01	2019-05-29	Mayo Found Medical Education & Res	Procedimientos para el tratamiento de cáncer en pacientes con niveles elevados de Bim
EP3052521A1 (fr)	2013-10-03	2016-08-10	Moderna Therapeutics, Inc.	Polynucléotides codant pour un récepteur de lipoprotéines de faible densité
US9598667B2 (en)	2013-10-04	2017-03-21	Abbvie Inc.	Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
WO2015057403A2 (fr) *	2013-10-17	2015-04-23	Tarix Pharmaceuticals Ltd.	Compositions et méthodes de traitement d'une maladie inflammatoire chronique de l'intestin
US8946395B1 (en)	2013-10-18	2015-02-03	Abbvie Inc.	Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en)	2013-10-18	2015-07-21	Abbvie, Inc.	Low acidic species compositions and methods for producing and using the same
US9181337B2 (en)	2013-10-18	2015-11-10	Abbvie, Inc.	Modulated lysine variant species compositions and methods for producing and using the same
WO2015066279A2 (fr)	2013-10-30	2015-05-07	Cytomx Therapeutics, Inc.	Anticorps activables se liant au récepteur du facteur de croissance épidermique et méthodes d'utilisation de ceux-ci
HRP20192080T1 (hr)	2013-10-31	2020-02-07	Resolve Therapeutics, Llc	Terapeutske fuzije nukleaza-albumine i postupci
KR101977449B1 (ko)	2013-11-01	2019-05-10	유니버시티에트 이 오슬로	알부민 변이체 및 이의 용도
EP3065769A4 (fr)	2013-11-08	2017-05-31	Biogen MA Inc.	Composé de fusion procoagulant
US20150139988A1 (en)	2013-11-15	2015-05-21	Abbvie, Inc.	Glycoengineered binding protein compositions
WO2015089283A1 (fr)	2013-12-11	2015-06-18	Cytomx Therapeutics, Inc.	Anticorps qui se lient à des anticorps activables et leurs procédés d'utilisation
US8980273B1 (en)	2014-07-15	2015-03-17	Kymab Limited	Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8986691B1 (en)	2014-07-15	2015-03-24	Kymab Limited	Method of treating atopic dermatitis or asthma using antibody to IL4RA
WO2015104711A1 (fr)	2014-01-09	2015-07-16	Hadasit Medical Research Services And Development Ltd.	Compositions cellulaires améliorées et procédés pour la thérapie du cancer
AU2015204646B2 (en)	2014-01-10	2020-08-27	Bioverativ Therapeutics Inc.	Factor VIII chimeric proteins and uses thereof
SG11201606761RA (en)	2014-02-21	2016-09-29	Ecole Polytecnique Federale De Lausanne Epfl Epfl Tto	Glycotargeting therapeutics
US10953101B2 (en)	2014-02-21	2021-03-23	École Polytechnique Fédérale De Lausanne (Epfl)	Glycotargeting therapeutics
US10046056B2 (en)	2014-02-21	2018-08-14	École Polytechnique Fédérale De Lausanne (Epfl)	Glycotargeting therapeutics
US10946079B2 (en)	2014-02-21	2021-03-16	Ecole Polytechnique Federale De Lausanne	Glycotargeting therapeutics
AU2015229381B2 (en)	2014-03-11	2019-11-07	University Of Florida Research Foundation, Inc.	Use of AAV-expressed M013 protein as an anti-inflammatory therapeutic
WO2015140591A1 (fr)	2014-03-21	2015-09-24	Nordlandssykehuset Hf	Anticorps anti-cd14 et leurs utilisations
WO2015160618A1 (fr)	2014-04-16	2015-10-22	Bayer Cropscience Lp	Compositions comprenant de la ningnanmycine et un agent de lutte biologique
WO2015164615A1 (fr)	2014-04-24	2015-10-29	University Of Oslo	Anticorps anti-gluten et leurs utilisations
CA2947127A1 (fr)	2014-05-02	2015-11-19	Cerenis Therapeutics Holding Sa	Marqueurs de therapie hdl
US10302653B2 (en)	2014-05-22	2019-05-28	Mayo Foundation For Medical Education And Research	Distinguishing antagonistic and agonistic anti B7-H1 antibodies
CN105198999A (zh) *	2014-05-27	2015-12-30	上海生物制品研究所有限责任公司	一种融合蛋白、其制备方法及其应用
USD774182S1 (en)	2014-06-06	2016-12-13	Anutra Medical, Inc.	Anesthetic delivery device
USD763433S1 (en)	2014-06-06	2016-08-09	Anutra Medical, Inc.	Delivery system cassette
USD750768S1 (en)	2014-06-06	2016-03-01	Anutra Medical, Inc.	Fluid administration syringe
WO2015191781A2 (fr)	2014-06-10	2015-12-17	Amgen Inc.	Polypeptides d'apéline
JP7109160B2 (ja)	2014-06-18	2022-07-29	ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー	神経外傷性障害において第ｘｉｉ因子インヒビターを使用する療法
EP3157947A1 (fr)	2014-06-23	2017-04-26	Novartis AG	Polypeptide de fusion hsa-gdf-15 et son utilisation
RU2017101436A (ru)	2014-06-24	2018-07-24	Ново Нордиск А/С	Mic-1 слитные белки и их применение
US11008561B2 (en)	2014-06-30	2021-05-18	Bioverativ Therapeutics Inc.	Optimized factor IX gene
WO2016014148A1 (fr)	2014-07-23	2016-01-28	Mayo Foundation For Medical Education And Research	Ciblage d'adn-pkcs et de b7-h1 pour traiter le cancer
AU2015296640B2 (en)	2014-07-30	2020-05-21	Ngm Biopharmaceuticals, Inc.	Compositions and methods of use for treating metabolic disorders
WO2016020880A2 (fr)	2014-08-07	2016-02-11	Novartis Ag	Anticorps de l'angiopoïétine-like 4 et procédés d'utilisation correspondants
WO2016020882A2 (fr)	2014-08-07	2016-02-11	Novartis Ag	Anticorps de type angiopoétine 4 (angptl4) et procédés d'utilisation
JP6886917B2 (ja)	2014-08-22	2021-06-16	國立成功大學ＮａｔｉｏｎａｌＣｈｅｎｇＫｕｎｇＵｎｉｖｅｒｓｉｔｙ	ロドストミンバリアント、ロドストミンバリアントをコードするポリヌクレオチド、当該ポリヌクレオチドを含む組換え宿主細胞、及びロドストミンバリアントを含む医薬組成物
MX390380B (es)	2014-09-17	2025-03-20	Basf Corp	Composiciones que comprenden celulas recombinantes de bacillus y otro agente de control biologico.
US9616114B1 (en)	2014-09-18	2017-04-11	David Gordon Bermudes	Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
CU20170038A7 (es)	2014-09-26	2017-10-05	Bayer Pharma AG	Derivados de adrenomedulina estabililzados especialmente útiles en el tratamiento y/o prevención de trastornos cardiovasculares, edematosos y/o inflamatorios
MA41044A (fr)	2014-10-08	2017-08-15	Novartis Ag	Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
BR112017007765B1 (pt)	2014-10-14	2023-10-03	Halozyme, Inc	Composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo
MA40835A (fr)	2014-10-23	2017-08-29	Biogen Ma Inc	Anticorps anti-gpiib/iiia et leurs utilisations
MA40861A (fr)	2014-10-31	2017-09-05	Biogen Ma Inc	Anticorps anti-glycoprotéines iib/iiia
EP3701969A1 (fr)	2014-10-31	2020-09-02	NGM Biopharmaceuticals, Inc.	Compositions et leurs méthodes d'utilisation pour le traitement de troubles métaboliques
US20160130324A1 (en) *	2014-10-31	2016-05-12	Shire Human Genetic Therapies, Inc.	C1 Inhibitor Fusion Proteins and Uses Thereof
GB201420139D0 (en)	2014-11-12	2014-12-24	Ucl Business Plc	Factor IX gene therapy
UY36449A (es)	2014-12-19	2016-07-29	Novartis Ag	Composiciones y métodos para anticuerpos dirigidos a bmp6
EP3590500B1 (fr)	2014-12-23	2025-06-25	Merz Pharma GmbH & Co. KGaA	Récipient pré-rempli de toxine botulinique
WO2016161010A2 (fr) *	2015-03-30	2016-10-06	Regeneron Pharmaceuticals, Inc.	Régions constantes de chaînes lourdes présentant une liaison réduite aux récepteurs fc gamma
JP2016204292A (ja) *	2015-04-21	2016-12-08	国立大学法人熊本大学	Ｂｍｐ７変異体とアルブミンとの融合体、及び該融合体を含む腎疾患治療剤
JP2018518945A (ja) *	2015-04-29	2018-07-19	メディオラヌム・ファルマチェウティチ・ソチエタ・ペル・アツィオーニ	可溶性キメラインターロイキン−１０受容体およびその療法使用
US10676723B2 (en)	2015-05-11	2020-06-09	David Gordon Bermudes	Chimeric protein toxins for expression by therapeutic bacteria
WO2016195723A1 (fr) *	2015-06-03	2016-12-08	Beller Pharmaceuticals LLC	Méthodes de traitement d'états médiés par la substance p
EP3303387A2 (fr)	2015-06-05	2018-04-11	Novartis AG	Anticorps ciblant la protéine morphogénétique osseuse 9 (bmp9) et méthodes associées
JP2018524067A (ja)	2015-06-11	2018-08-30	アットウィルメディカルソルーションズインコーポレイテッド	アンチトロンビン−ヘパリン組成物を利用する医療機器、システムおよび方法
UY36751A (es)	2015-06-26	2017-01-31	Novartis Ag	Anticuerpos de factor xi y métodos de uso
US11020455B2 (en) *	2015-07-30	2021-06-01	Endor Technologies, S.L	Colony stimulating factor for use in pancreatic or colon cancer treatment
US11236159B2 (en)	2015-08-03	2022-02-01	Novartis Ag	Methods of treating FGF21-associated disorders
EA201890423A1 (ru)	2015-08-03	2018-07-31	Биовератив Терапьютикс Инк.	Слитые белки фактора ix, способы их получения и применения
WO2017024198A1 (fr) *	2015-08-06	2017-02-09	The Trustees Of The University Of Pennsylvania	Glp-1 et son utilisation dans des compositions pour traiter des maladies métaboliques
JP7007261B2 (ja)	2015-08-20	2022-01-24	アルブミディクスリミティド	アルブミン変異体及びコンジュゲート
CA3183289A1 (fr)	2015-09-08	2017-03-16	Jcr Pharmaceuticals Co., Ltd.	Nouveau mutant d'albumine serique humaine
EA038332B1 (ru)	2015-09-09	2021-08-10	Новартис Аг	Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
HRP20210650T1 (hr)	2015-09-09	2021-05-28	Novartis Ag	Protutijela koja vežu timusni stromalni limfopoetin (tslp) i postupci uporabe protutijela
CN117659160A (zh) *	2015-09-11	2024-03-08	小利兰·斯坦福大学托管委员会	生物相关正交细胞因子/受体对
AU2016325630B2 (en)	2015-09-23	2022-11-17	Regeneron Pharmaceuticals, Inc.	Optimized anti-CD3 bispecific antibodies and uses thereof
WO2017075045A2 (fr)	2015-10-30	2017-05-04	Mayo Foundation For Medical Education And Research	Anticorps anti-b7-h1
UA122079C2 (uk)	2015-12-04	2020-09-10	Бьорінгер Інгельхайм Інтернаціональ Гмбх	Поліпептид, що специфічно зв'язується з lrp5 і lrp6
EP3387018A1 (fr)	2015-12-11	2018-10-17	Dyax Corp.	Inhibiteurs de la kallicréine plasmatique et utilisations desdits inhibiteurs pour traiter une crise d'angio- dème héréditaire
RU2018126297A (ru)	2015-12-18	2020-01-22	Новартис Аг	Антитела, нацеленные на cd32b, и способы их применения
JP6946304B2 (ja)	2015-12-22	2021-10-06	ノバルティスアーゲー	増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を処置するまたは軽快させる方法
WO2017122130A1 (fr)	2016-01-11	2017-07-20	Novartis Ag	Anticorps monoclonaux humainisés immunostimulants dirigés contre l'interleukine -2 humaine, et leurs protéines de fusion
MA55746A (fr)	2016-01-21	2022-03-02	Novartis Ag	Molécules multispécifiques ciblant cll-1
CA3012695A1 (fr)	2016-02-01	2017-08-10	Bioverativ Therapeutics Inc.	Genes du facteur viii optimises
JP2017165713A (ja)	2016-03-14	2017-09-21	Ｊｃｒファーマ株式会社	血清アルブミン−２０ｋ成長ホルモン融合タンパク質
WO2017161414A1 (fr)	2016-03-22	2017-09-28	Bionomics Limited	Administration d'un anticorps monoclonal anti-lgr5
MY194669A (en)	2016-03-31	2022-12-12	Ngm Biopharmaceuticals Inc	Binding Proteins and Methods of use Thereof
US11174321B2 (en)	2016-04-06	2021-11-16	Csl Limited	Method of treating atherosclerosis
WO2017189724A1 (fr)	2016-04-27	2017-11-02	Novartis Ag	Anticorps dirigés contre le facteur de différenciation de croissance 15 et leurs utilisations
RS61510B1 (sr)	2016-05-18	2021-03-31	Boehringer Ingelheim Int	Anti pd-1 i anti-lag3 antitela za lečenje kancera
KR102433503B1 (ko)	2016-05-24	2022-08-18	노보 노르디스크 에이/에스	Mic-1 화합물 및 이것의 사용
AU2017283787B2 (en)	2016-06-15	2020-09-17	Novartis Ag	Methods for treating disease using inhibitors of bone morphogenetic protein 6 (BMP6)
EP3481416B1 (fr) *	2016-07-08	2020-09-09	CSL Behring Lengnau AG	Administration sous-cutanée de facteur ix à action prolongée chez des humains
WO2018014260A1 (fr)	2016-07-20	2018-01-25	Nanjing Legend Biotech Co., Ltd.	Protéines de liaison antigènes multi-spécifiques et leurs procédés d'utilisation
US20190175683A1 (en)	2016-08-05	2019-06-13	Csl Behring Gmbh	Pharmaceutical formulations of c1 esterase inhibitor
US20190183991A1 (en)	2016-08-23	2019-06-20	Csl Behring Gmbh	Method of preventing acute attacks of hereditary angioedema associated with c1 esterase inhibitor deficiency
WO2018068201A1 (fr)	2016-10-11	2018-04-19	Nanjing Legend Biotech Co., Ltd.	Anticorps à domaine unique et ses variants contre ctla-4
EP3535585A1 (fr)	2016-11-04	2019-09-11	Aarhus Universitet	Identification et traitement de tumeurs caractérisées par une surexpression du récepteur fc néonatal
JP2019535834A (ja) *	2016-11-18	2019-12-12	ユニベルシタデバルセロナ	感染症及び関連炎症プロセスの処置のためのｃｄ６及びイミペネムの併用療法
WO2018096396A1 (fr)	2016-11-22	2018-05-31	University Of Oslo	Variants d'albumine et leurs utilisations
MX2019006444A (es)	2016-12-02	2019-10-30	Bioverativ Therapeutics Inc	Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
JP2019536794A (ja)	2016-12-02	2019-12-19	バイオベラティブセラピューティクスインコーポレイテッド	凝固因子に対する免疫寛容を誘導する方法
US11129906B1 (en)	2016-12-07	2021-09-28	David Gordon Bermudes	Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en)	2016-12-07	2021-11-23	David Gordon Bermudes	Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US20200031895A1 (en)	2016-12-16	2020-01-30	Biogen Ma Inc.	Stabilized proteolytically activated growth differentiation factor 11
EP3360898A1 (fr)	2017-02-14	2018-08-15	Boehringer Ingelheim International GmbH	Molécules bispécifiques présentant une immunoréactivité par rapport à tnf-related apoptosis-inducing ligand receptor 2 et à cadherin 17 pour le traitement du cancer
IL267519B2 (en)	2016-12-23	2025-04-01	Novartis Ag	Factor XI/XIA for use in the prevention, treatment, management, or reduction of the risk of stroke or thromboembolism in a patient with end-stage renal disease
AU2017383232B2 (en)	2016-12-23	2024-09-12	Novartis Ag	Factor XI antibodies and methods of use
KR20230125856A (ko)	2016-12-23	2023-08-29	프레지던트 앤드 펠로우즈 오브 하바드 칼리지	Pcsk9의 유전자 편집
WO2018132768A1 (fr)	2017-01-13	2018-07-19	Sanna Pietro P	Procédés et compositions pour le traitement de l'hyperactivité hpa
EA201991768A1 (ru)	2017-01-31	2020-01-22	Байоверетив Терапьютикс Инк.	Слитые белки на основе фактора ix и способы их получения и пути применения
KR102572663B1 (ko)	2017-02-08	2023-09-01	노파르티스 아게	Fgf21 모방 항체 및 이의 용도
US10767164B2 (en)	2017-03-30	2020-09-08	The Research Foundation For The State University Of New York	Microenvironments for self-assembly of islet organoids from stem cells differentiation
JP2020517657A (ja)	2017-04-20	2020-06-18	ノヴォノルディスクアー／エス	アルブミン融合タンパク質の精製方法
TWI710377B (zh)	2017-05-23	2020-11-21	丹麥商諾佛儂迪克股份有限公司	Ｍｉｃ－１化合物及其用途
MY206158A (en)	2017-05-24	2024-12-02	Novartis Ag	Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
EP3630816B1 (fr)	2017-05-31	2024-03-20	Boehringer Ingelheim International GmbH	Polypeptides antagonistes de la signalisation wnt dans des cellules tumorales
WO2018232176A1 (fr)	2017-06-16	2018-12-20	The University Of Chicago	Compositions et procédés d'induction d'une tolérance immunitaire
WO2018229715A1 (fr)	2017-06-16	2018-12-20	Novartis Ag	Compositions comprenant des anticorps anti-cd32b et procédés d'utilisation correspondants
AU2018294517B2 (en)	2017-06-29	2024-09-26	CSL Behring Lengnau AG	21-day dosing regimen for fusion proteins comprising factor IX and human albumin for prophylactic treatment of hemophilia and methods thereof
LT3661562T (lt)	2017-08-04	2024-10-25	Amgen Inc.	Cys-mab konjugavimo būdas
NZ762100A (en)	2017-08-09	2025-12-19	Bioverativ Therapeutics Inc	Nucleic acid molecules and uses thereof
EP3684811A2 (fr)	2017-08-17	2020-07-29	Massachusetts Institute of Technology	Agents de liaison à spécificité multiple de chimiokines cxc et leurs utilisations
IL273185B2 (en)	2017-09-15	2024-10-01	Cedars Sinai Medical Center	C1 esterase inhibitors for use in improving organ function in organ transplantation subjects
JP7793287B2 (ja) *	2017-10-18	2026-01-05	シーエスエルリミティド	ヒト血清アルブミン変異体およびその使用
WO2019081983A1 (fr)	2017-10-25	2019-05-02	Novartis Ag	Anticorps ciblant cd32b et leurs procédés d'utilisation
AU2018382222B2 (en)	2017-12-15	2025-09-04	Csl Limited	Use of a FXIIa-inhibitor in the treatment of renal fibrosis and/or chronic kidney disease
WO2019129054A1 (fr)	2017-12-27	2019-07-04	信达生物制药(苏州)有限公司	Triacorps, son procédé de préparation et son utilisation
CN117050184A (zh)	2017-12-28	2023-11-14	南京传奇生物科技有限公司	针对tigit的单域抗体和其变体
US11246908B2 (en) *	2018-01-10	2022-02-15	The Johns Hopkins University	Compositions comprising albumin-FMS-like tyrosine kinase 3 ligand fusion proteins and uses thereof
CN111699200B (zh)	2018-01-15	2023-05-26	南京传奇生物科技有限公司	针对pd-1的单域抗体和其变体
AU2019215063B2 (en)	2018-02-01	2025-10-16	Bioverativ Therapeutics, Inc.	Use of lentiviral vectors expressing Factor VIII
ES2953362T3 (es) *	2018-03-13	2023-11-10	Sepsia Therapeutics S L	Péptidos de unión bacteriana para el tratamiento de enfermedades infecciosas y procesos inflamatorios relacionados
IL277049B2 (en)	2018-03-13	2024-02-01	Zymeworks Bc Inc	Conjugates of biparatopic anti-HER2 antibody and drug and methods of use
PE20210313A1 (es)	2018-03-28	2021-02-12	Bristol Myers Squibb Co	Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso
TW202003567A (zh)	2018-03-30	2020-01-16	大陸商南京傳奇生物科技有限公司	針對lag-3之單一結構域抗體及其用途
KR102119197B1 (ko) *	2018-04-23	2020-06-05	주식회사 엘베이스	세포에서의 자가포식작용 억제용 조성물, 및 이를 포함하는 종양성 질환의 예방 또는 치료용, 또는 항암제 내성 억제용 약학적 조성물
EP3790577A4 (fr)	2018-05-09	2022-04-27	The University of Chicago	Compositions et procédés d'induction d'une tolérance immunitaire
WO2019222296A1 (fr)	2018-05-14	2019-11-21	Werewolf Therapeutics, Inc.	Polypeptides d'interleukine 12 activables et procédés d'utilisation associés
AU2019271148B9 (en)	2018-05-14	2025-05-29	Werewolf Therapeutics, Inc.	Activatable interleukin-2 polypeptides and methods of use thereof
PL3793588T3 (pl)	2018-05-18	2025-09-01	Bioverativ Therapeutics Inc.	Sposoby leczenia hemofilii a
EP3569618A1 (fr)	2018-05-19	2019-11-20	Boehringer Ingelheim International GmbH	Antagonisation d'anticorps cd73
TWI869346B (zh)	2018-05-30	2025-01-11	瑞士商諾華公司	Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
KR102870868B1 (ko)	2018-06-01	2025-10-15	노파르티스 아게	Bcma에 대한 결합 분자 및 이의 용도
EP3806889A4 (fr)	2018-06-18	2022-07-13	Anwita Biosciences, Inc.	Protéines de fusion à base de cytokine et leurs utilisations
KR20210027426A (ko)	2018-07-03	2021-03-10	브리스톨-마이어스 스큅 컴퍼니	Fgf21 제제
EP3833766A1 (fr)	2018-08-09	2021-06-16	Bioverativ Therapeutics Inc.	Molécules d'acide nucléique et leurs utilisations pour une thérapie génique non virale
US10842885B2 (en)	2018-08-20	2020-11-24	Ucl Business Ltd	Factor IX encoding nucleotides
GB201813528D0 (en)	2018-08-20	2018-10-03	Ucl Business Plc	Factor IX encoding nucleotides
CA3110513A1 (fr)	2018-08-31	2020-03-05	Regeneron Pharmaceuticals, Inc.	Strategie de dosage permettant d'attenuer le syndrome de liberation de cytokines pour des anticorps bispecifiques cd3/c20
EP3852874A1 (fr) *	2018-09-17	2021-07-28	Kyoto University	Administration d'un agent anti-c5 pour le traitement d'une lésion ou d'une insuffisance hépatique
US20220002370A1 (en)	2018-09-27	2022-01-06	Xilio Development, Inc.	Masked cytokine polypeptides
US12331320B2 (en)	2018-10-10	2025-06-17	The Research Foundation For The State University Of New York	Genome edited cancer cell vaccines
UY38407A (es)	2018-10-15	2020-05-29	Novartis Ag	Anticuerpos estabilizadores de trem2
CA3117961A1 (fr) *	2018-10-29	2020-05-07	Spin Therapeutics, Llc	Compositions et methodes pour les dereglements de l'alpha-1 antitrypsine
WO2020092839A1 (fr)	2018-10-31	2020-05-07	Mayo Foundation For Medical Education And Research	Méthodes et matériaux de traitement du cancer
GB201818477D0 (en)	2018-11-13	2018-12-26	Emstopa Ltd	Tissue plasminogen activator antibodies and method of use thereof
EP3887393A1 (fr)	2018-11-26	2021-10-06	Novartis AG	Polypeptides de fusion de lpl-gpihbp1
JP7644007B2 (ja)	2018-12-06	2025-03-11	バイオベラティブセラピューティクスインコーポレイテッド	第ｉｘ因子を発現するレンチウイルスベクターの使用
US20230051872A1 (en)	2019-03-22	2023-02-16	Reflexion Pharmaceuticals, Inc.	Multivalent D-Peptidic Compounds for Target Proteins
KR20220044612A (ko)	2019-03-22	2022-04-08	리플렉시온 파마슈티컬스, 인크.	Vegf에 대한 d-펩티드성 화합물
US20220169706A1 (en)	2019-03-28	2022-06-02	Danisco Us Inc	Engineered antibodies
EP3927702A4 (fr)	2019-04-11	2022-05-11	Angion Biomedica Corp.	Formes solides de (e)-3-[2-(2-thiényl)vinyl]-1h-pyrazole
EP3969035A4 (fr)	2019-05-14	2023-06-21	Werewolf Therapeutics, Inc.	Groupes caractéristiques de séparation, procédés et utilisation associés
US12037378B2 (en)	2019-05-21	2024-07-16	Novartis Ag	Variant CD58 domains and uses thereof
JP7489407B2 (ja)	2019-05-21	2024-05-23	ノバルティスアーゲー	Ｃｄ１９結合分子及びその使用
JP7784898B2 (ja)	2019-05-24	2025-12-12	サノフイ	全身性硬化症を治療するための方法
EP3986918A1 (fr)	2019-06-18	2022-04-27	Bayer Aktiengesellschaft	Analogues d'adrénomédulline pour stabilisation à long terme et leur utilisation
IL267614A (en)	2019-06-24	2019-09-26	Lotem Michal	Nucleic acids to modulate SLAMF6 isoforms
MX2022002638A (es)	2019-09-06	2022-03-25	Novartis Ag	Proteinas de fusion terapeuticas.
CN114502590A (zh)	2019-09-18	2022-05-13	诺华股份有限公司	Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
TW202124446A (zh)	2019-09-18	2021-07-01	瑞士商諾華公司	與ｅｎｔｐｄ２抗體之組合療法
KR20220097891A (ko)	2019-09-30	2022-07-08	바이오버라티브 테라퓨틱스 인크.	렌티바이러스 벡터 제형
US20240228573A9 (en) *	2019-10-17	2024-07-11	Jcr Pharmaceuticals Co., Ltd.	Method for producing fusion protein of serum albumin and growth hormone
WO2021085518A1 (fr)	2019-10-30	2021-05-06	Ｊｃｒファーマ株式会社	Composition pharmaceutique aqueuse contenant une protéine de fusion d'albumine sérique et d'hormone de croissance
MX2022005666A (es)	2019-11-14	2022-10-07	Werewolf Therapeutics Inc	Polipeptidos de citocina activables y metodos de uso de los mismos.
US20230000774A1 (en)	2019-12-04	2023-01-05	Albumedix Limited	Methods and compositions produced thereby
CN121517534A (zh)	2019-12-13	2026-02-13	辛德凯因股份有限公司	Il-2直向同源物及其使用方法
US20210181200A1 (en) *	2019-12-17	2021-06-17	Women's College Hospital	Ovarian cancer biomarker and methods of using same
CN115379850A (zh)	2019-12-24	2022-11-22	裘美娜治疗公司	再生性多肽及其用途
EP4090427A1 (fr)	2020-01-13	2022-11-23	Takeda Pharmaceutical Company Limited	Inhibiteurs de la kallicréine plasmatique et leurs utilisations pour traiter une crise d'angio-oedème héréditaire pédiatrique
US20230203191A1 (en)	2020-03-30	2023-06-29	Danisco Us Inc	Engineered antibodies
MX2022012683A (es)	2020-04-09	2023-01-11	Verve Therapeutics Inc	Edicion de bases de pcsk9 y metodos de uso de la misma para el tratamiento de enfermedades.
WO2021236658A1 (fr)	2020-05-19	2021-11-25	Boehringer Ingelheim International Gmbh	Molécules de liaison pour le traitement du cancer
CA3182800A1 (fr)	2020-06-14	2021-12-23	Vertex Pharmaceuticals Inc.	Compositions et procedes associes au facteur i du complement
MX2023000156A (es)	2020-06-24	2023-02-16	Bioverativ Therapeutics Inc	Metodos para la eliminacion de factor viii libre de preparaciones de vectores lentivirales modificados para expresar dicha proteina.
EP4232474A1 (fr)	2020-10-21	2023-08-30	Boehringer Ingelheim International GmbH	Molécules de liaison anti-vegf et anti-trkb bispécifiques pour le traitement de maladies oculaires
CA3200309A1 (fr) *	2020-10-30	2022-05-05	Shenzhen Protgen Ltd.	Utilisation d'albumine serique humaine dans le traitement de maladies
CA3199095A1 (fr)	2020-11-06	2022-05-12	Novartis Ag	Molecules de liaison a cd19 et utilisations associees
WO2022115865A2 (fr)	2020-11-25	2022-06-02	Xilio Development, Inc.	Lieurs clivables spécifiques aux tumeurs
WO2022166720A1 (fr) *	2021-02-05	2022-08-11	华南理工大学	Protéine de fusion à base d'albumine sérique, et nano-ensemble, son procédé de préparation et son application
CN117321076A (zh)	2021-02-19	2023-12-29	美国卫生及公众服务部代表	中和SARS-CoV-2的单结构域抗体
JP2024523033A (ja)	2021-06-17	2024-06-25	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	新規の三重特異的結合分子
WO2022271466A1 (fr) *	2021-06-21	2022-12-29	Juvena Therapeutics, Inc.	Polypeptides régénérateurs et leurs utilisations
CN114133458B (zh) *	2021-12-08	2023-11-14	福州大学	一种在人血清白蛋白内部融合多肽的方法
CA3250114A1 (fr) *	2022-01-28	2023-08-03	Sigilon Therapeutics, Inc.	Thérapies pour la mucopolysaccharidose de type 6
IL316174A (en)	2022-04-26	2024-12-01	Novartis Ag	Multiple specific antibodies targeting IL-13 and IL-18
EP4554619A1 (fr)	2022-07-15	2025-05-21	Danisco US Inc.	Procédés de production d'anticorps monoclonaux
IL317689A (en)	2022-07-15	2025-02-01	Boehringer Ingelheim Int	Binding molecules for cancer treatment
EP4605077A1 (fr)	2022-10-18	2025-08-27	Confo Therapeutics N.V.	Séquences d'acides aminés dirigées contre le récepteur de la mélanocortine 4 et polypeptides les comprenant pour le traitement de maladies et de troubles liés à mc4r
WO2024130158A1 (fr)	2022-12-16	2024-06-20	Modernatx, Inc.	Nanoparticules lipidiques et polynucléotides codant l'interleukine-22 à demi-vie sérique étendue pour le traitement d'une maladie métabolique
JP2026503406A (ja) *	2022-12-20	2026-01-29	シーエスエルイノベーションプロプライアタリーリミティド	ＦｃＲｎ拮抗薬及びその使用
EP4389762A1 (fr)	2022-12-23	2024-06-26	Ospedale San Raffaele S.r.l.	Inhibiteurs de l'activité de dux4 et leur utilisation en thérapie.
WO2024178305A1 (fr)	2023-02-24	2024-08-29	Modernatx, Inc.	Compositions de protéines de fusion il-15 codées par arnm et leurs méthodes d'utilisation pour le traitement du cancer
EP4442251A1 (fr)	2023-04-05	2024-10-09	Albumedix Ltd	Formulations et leurs utilisations
WO2025034806A1 (fr)	2023-08-08	2025-02-13	Wisconsin Alumni Research Foundation	Anticorps à domaine unique et variants de ceux-ci ciblant la protéine d'activation des fibroblastes
US20250109187A1 (en)	2023-09-28	2025-04-03	Novavax, Inc.	ANTI-SARS-CoV-2 SPIKE (S) ANTIBODIES AND THEIR USE IN TREATING COVID-19
EP4703468A1 (fr)	2024-08-29	2026-03-04	Sartorius Albumedix Limited	Procédés et utilisations
WO2026058155A1 (fr)	2024-09-11	2026-03-19	Novartis Ag	Anticorps ciblant il-31
WO2026074121A1 (fr)	2024-10-02	2026-04-09	Sartorius Albumedix Limited	Formulations d'albumine et leurs utilisations

Family Cites Families (702)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5625041A (en) *	1990-09-12	1997-04-29	Delta Biotechnology Limited	Purification of proteins
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
DE2449885C3 (de) *	1974-10-21	1980-04-30	Biotest-Serum-Institut Gmbh, 6000 Frankfurt	Verfahren zur Herstellung von chemisch modifizierten haltbaren Hämoglobinpräparaten sowie das nach diesem Verfahren hergestellte modifizierte Hämoglobinpräparat
US4002531A (en)	1976-01-22	1977-01-11	Pierce Chemical Company	Modifying enzymes with polyethylene glycol and product produced thereby
US4264731A (en) *	1977-05-27	1981-04-28	The Regents Of The University Of California	DNA Joining method
US4440859A (en) *	1977-05-27	1984-04-03	The Regents Of The University Of California	Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4363877B1 (en)	1977-09-23	1998-05-26	Univ California	Recombinant dna transfer vectors
US4283489A (en)	1977-09-23	1981-08-11	The Regents Of The University Of California	Purification of nucleotide sequences suitable for expression in bacteria
US4407948A (en)	1977-09-23	1983-10-04	The Regents Of The University Of California	Purification of nucleotide sequences suitable for expression in bacteria
US4366246A (en)	1977-11-08	1982-12-28	Genentech, Inc.	Method for microbial polypeptide expression
US4263428A (en)	1978-03-24	1981-04-21	The Regents Of The University Of California	Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4652525A (en) *	1978-04-19	1987-03-24	The Regents Of The University Of California	Recombinant bacterial plasmids containing the coding sequences of insulin genes
US4447538A (en) *	1978-04-19	1984-05-08	Regents Of The University Of California	Microorganism containing gene for human chorionic somatomammotropin
US5514567A (en) *	1979-01-30	1996-05-07	Juridical Foundation, Japanese Foundation For Cancer Research	DNA and recombinant plasmid
US5326859A (en)	1979-10-30	1994-07-05	Juridical Foundation, Japanese Foundation For Cancer Research	DNA and recombinant plasmid
US4342832A (en)	1979-07-05	1982-08-03	Genentech, Inc.	Method of constructing a replicable cloning vehicle having quasi-synthetic genes
AU538665B2 (en)	1979-10-30	1984-08-23	Juridical Foundation, Japanese Foundation For Cancer Research	Human interferon dna
US4444887A (en)	1979-12-10	1984-04-24	Sloan-Kettering Institute	Process for making human antibody producing B-lymphocytes
ES8308534A1 (es)	1980-01-08	1983-09-01	Biogen Nv	Un metodo de producir un polipeptido que exhibe actividad inmunologica o biologica del interferon de leucocitos humanos.
US4530901A (en)	1980-01-08	1985-07-23	Biogen N.V.	Recombinant DNA molecules and their use in producing human interferon-like polypeptides
EP0041313B1 (fr)	1980-04-03	1990-09-12	Biogen, Inc.	Séquences d'ADN, molécules d'ADN recombinant et procédé pour la production de l'interféron de fibroblaste humain
DE3023787A1 (de)	1980-06-25	1982-01-21	Studiengesellschaft Kohle mbH, 4330 Mülheim	Verfahren zur erhoehung der inkorporation und der expression von genetischem material in die kerne von intakten zellen mit hilfe von liposomen
US6610830B1 (en)	1980-07-01	2003-08-26	Hoffman-La Roche Inc.	Microbial production of mature human leukocyte interferons
GR81946B (fr)	1980-09-25	1984-12-12	Genentech Inc
US4456748A (en)	1981-02-23	1984-06-26	Genentech, Inc.	Hybrid human leukocyte interferons
DE3169595D1 (en)	1980-11-10	1985-05-02	Gersonde Klaus	Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
DE3273787D1 (en)	1981-02-04	1986-11-20	Japan Found Cancer	Human interferon-beta gene
IE52535B1 (en)	1981-02-16	1987-12-09	Ici Plc	Continuous release pharmaceutical compositions
NZ199722A (en)	1981-02-25	1985-12-13	Genentech Inc	Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
JPS57149228A (en)	1981-03-11	1982-09-14	Ajinomoto Co Inc	Novel erythropoietin and its preparation
US4873191A (en)	1981-06-12	1989-10-10	Ohio University	Genetic transformation of zygotes
US4792602A (en)	1981-06-19	1988-12-20	Cornell Research Foundation, Inc.	Adaptors, and synthesis and cloning of proinsulin genes
CA1204682A (fr)	1981-06-19	1986-05-20	Saran A. Narang	Adapteurs, synthese et clonage des genes proinsuliniques
US4714681A (en)	1981-07-01	1987-12-22	The Board Of Reagents, The University Of Texas System Cancer Center	Quadroma cells and trioma cells and methods for the production of same
US4474893A (en)	1981-07-01	1984-10-02	The University of Texas System Cancer Center	Recombinant monoclonal antibodies
US4485045A (en)	1981-07-06	1984-11-27	Research Corporation	Synthetic phosphatidyl cholines useful in forming liposomes
IL66614A (en)	1981-08-28	1985-09-29	Genentech Inc	Method of constructing a dna sequence encoding a polypeptide,microbial production of human serum albumin,and pharmaceutical compositions comprising it
AU561343B2 (en)	1981-10-19	1987-05-07	Genentech Inc.	Human immune interferon by recombinant dna
EP0079739A3 (fr)	1981-11-12	1984-08-08	The Upjohn Company	Nucléotides basés sur l'albumine, leur réplication et utilisation, et plasmides à utiliser à cet effet
EP0091527A3 (fr)	1981-12-14	1984-07-25	The President And Fellows Of Harvard College	Séquences d'ADN, molécules d'ADN recombinant et procédé de préparation de polypeptides du genre de sérumalbumine humaine
JPS58107298A (ja)	1981-12-21	1983-06-25	Yoshitsuka Seiki:Kk	粉末成形プレスにおけるシエ−カ−カムの位相調整装置
JPS58118008A (ja)	1982-01-06	1983-07-13	Nec Corp	デ−タ処理装置
WO1983002461A1 (fr)	1982-01-19	1983-07-21	Cetus Corp	Interferons hybrides de classes multiples
DE3374837D1 (en)	1982-02-17	1988-01-21	Ciba Geigy Ag	Lipids in the aqueous phase
US4450103A (en) *	1982-03-01	1984-05-22	Cetus Corporation	Process for recovering human IFN-β from a transformed microorganism
US4775622A (en)	1982-03-08	1988-10-04	Genentech, Inc.	Expression, processing and secretion of heterologous protein by yeast
US4670393A (en) *	1982-03-22	1987-06-02	Genentech, Inc.	DNA vectors encoding a novel human growth hormone-variant protein
CA1341562C (fr)	1982-03-31	2007-11-27	Tadatsugu Taniguchi	Gene codant pour un polypeptide ayant une activite interleukine 2, adn recombinant portant ledit gene, lignees cellulaires possedant ledit adn recombinant et procede pour la preparation d'interleukine 2 en utilisant lesdites cellules
DE3377363D1 (en)	1982-03-31	1988-08-18	Ajinomoto Kk	Gene coding for interleukin-2 polypeptide, recombinant dna carrying said gene, cell lines possessing the recombinant dna,and method for producing interleukin-2 using said cells
US5824330A (en)	1982-04-20	1998-10-20	Sloan-Kettering Institute For Cancer Research	Highly purified interleukin-2 and method
US4778879A (en)	1982-04-20	1988-10-18	Sloan-Kettering Institute For Cancer Research	Highly purified human interleukin 2 and method
US4925919A (en) *	1984-04-25	1990-05-15	Roland Mertelsmann	Purified interleukin 2
US4499188A (en) *	1982-05-05	1985-02-12	Cetus Corporation	Bacterial production of heterologous polypeptides under the control of a repressible promoter-operator
US6936694B1 (en)	1982-05-06	2005-08-30	Intermune, Inc.	Manufacture and expression of large structural genes
DE3218121A1 (de)	1982-05-14	1983-11-17	Leskovar, Peter, Dr.-Ing., 8000 München	Arzneimittel zur tumorbehandlung
EP0102324A3 (fr)	1982-07-29	1984-11-07	Ciba-Geigy Ag	Lipides et composés tensio-actifs en phase aqueuse
US4716111A (en)	1982-08-11	1987-12-29	Trustees Of Boston University	Process for producing human antibodies
JPS5945835U (ja)	1982-09-16	1984-03-27	株式会社東芝	回路しや断器の消弧装置
US4490289A (en)	1982-09-16	1984-12-25	Hoffmann-La Roche Inc.	Homogeneous human interleukin 2
US4462940A (en) *	1982-09-23	1984-07-31	Cetus Corporation	Process for the recovery of human β-interferon-like polypeptides
US4992271A (en)	1982-09-23	1991-02-12	Cetus Corporation	Formulation for lipophilic IL-2 proteins
IE56026B1 (en)	1982-10-19	1991-03-27	Cetus Corp	Cysteine-depleted muteins of biologically active proteins
US4588585A (en)	1982-10-19	1986-05-13	Cetus Corporation	Human recombinant cysteine depleted interferon-β muteins
US4966843A (en) *	1982-11-01	1990-10-30	Cetus Corporation	Expression of interferon genes in Chinese hamster ovary cells
US4741900A (en)	1982-11-16	1988-05-03	Cytogen Corporation	Antibody-metal ion complexes
EP0116201B1 (fr)	1983-01-12	1992-04-22	Chiron Corporation	Expression sécrétoire en eukaryotes
US4840934A (en) *	1983-01-25	1989-06-20	Eleanor Roosevelt Institute For Cancer Research, Inc.	Therapeutic method using T cell growth factor
NZ207394A (en)	1983-03-08	1987-03-06	Commw Serum Lab Commission	Detecting or determining sequence of amino acids
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4914026A (en) *	1983-04-07	1990-04-03	Chiron Corporation	Alpha factor leader sequence directed secretion of insulin
US5015575A (en) *	1983-04-07	1991-05-14	Chiron Corporation	Hybrid DNA synthesis of insulin
DK172738B1 (da)	1983-04-07	1999-06-21	Chiron Corp	Fremgangsmåde til at udtrykke modent insulin og DNA-struktur til anvendelse ved fremgangsmåden
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4518584A (en)	1983-04-15	1985-05-21	Cetus Corporation	Human recombinant interleukin-2 muteins
JPS60501140A (ja)	1983-04-22	1985-07-25	アムジエン	酵母による外因性ポリペプチドの分泌
NZ207926A (en)	1983-04-25	1988-04-29	Genentech Inc	Use of yeast #a#-factor to assist in expression of proteins heterologus to yeast
US5010003A (en) *	1983-04-25	1991-04-23	Genentech, Inc.	Use of yeast homologous signals to secrete heterologous proteins
CA1196863A (fr) *	1983-06-08	1985-11-19	Mattheus F.A. Goosen	Composes d'insuline injectable a liberation lente
US4544545A (en)	1983-06-20	1985-10-01	Trustees University Of Massachusetts	Liposomes containing modified cholesterol for organ targeting
US4576813A (en)	1983-07-05	1986-03-18	Monsanto Company	Heat recovery from concentrated sulfuric acid
HUT35524A (en)	1983-08-02	1985-07-29	Hoechst Ag	Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
JPS6087792A (ja)	1983-09-23	1985-05-17	ジェネックス・コーポレイション	雑種制御領域
DE3483949D1 (de)	1983-09-26	1991-02-21	Udo Dr Med Ehrenfeld	Mittel und erzeugnis fuer die diagnose und therapie von tumoren sowie zur behandlung von schwaechen der zelligen und humoralen immunabwehr.
US4518564A (en) *	1983-10-03	1985-05-21	Jeneric Industries, Inc.	Gallium and silver free, palladium based dental alloys for porcelain-fused-to-metal restorations
DE3474511D1 (en)	1983-11-01	1988-11-17	Terumo Corp	Pharmaceutical composition containing urokinase
JPS60115528A (ja)	1983-11-28	1985-06-22	Takeda Chem Ind Ltd	ヒトインタ―ロイキン―２蛋白質を含有する抗腫瘍用または免疫機能低下疾患治療用組成物
GB8334102D0 (en)	1983-12-21	1984-02-01	Searle & Co	Interferons with cysteine pattern
US4703008A (en)	1983-12-13	1987-10-27	Kiren-Amgen, Inc.	DNA sequences encoding erythropoietin
NZ210501A (en) *	1983-12-13	1991-08-27	Kirin Amgen Inc	Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US4855238A (en)	1983-12-16	1989-08-08	Genentech, Inc.	Recombinant gamma interferons having enhanced stability and methods therefor
GB8334261D0 (en)	1983-12-22	1984-02-01	Bass Plc	Fermentation processes
JPS60136596A (ja)	1983-12-26	1985-07-20	Suntory Ltd	ペプチド及びこれを有効成分とする利尿剤
IT1185503B (it)	1984-01-11	1987-11-12	Univ New York	Cloni di odna di eritropietina umana
US4908433A (en) *	1984-04-25	1990-03-13	Sloan-Kettering Institute For Cancer Research	Uses of interleukin-2
US4908434A (en) *	1984-04-25	1990-03-13	Sloan-Kettering Institute For Cancer Research	Process for preparing purified interleukin-2
CA1213537A (fr)	1984-05-01	1986-11-04	Canadian Patents And Development Limited - Societe Canadienne Des Brevets Et D'exploitation Limitee	Methode d'expression de polypeptides
FR2564106B1 (fr) *	1984-05-09	1988-04-22	Transgene Sa	Vecteurs d'expression du facteur ix, cellules transformees par ces vecteurs et procede de preparation du facteur ix.
DK58285D0 (da)	1984-05-30	1985-02-08	Novo Industri As	Peptider samt fremstilling og anvendelse deraf
EP0172619A1 (fr)	1984-06-20	1986-02-26	Takeda Chemical Industries, Ltd.	Transformateur et son utilisation
US4736866B1 (en)	1984-06-22	1988-04-12		Transgenic non-human mammals
US5908763A (en)	1984-07-06	1999-06-01	Novartis Corporation	DNA encoding GM-CSF and a method of producing GM-CSF protein
JPS61227526A (ja)	1984-07-25	1986-10-09	Chugai Pharmaceut Co Ltd	新規なコロニー刺激因子
JPS6147500A (ja)	1984-08-15	1986-03-07	Res Dev Corp Of Japan	キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (fr)	1984-08-27	1987-11-25	The Board Of Trustees Of The Leland Stanford Junior University	Récepteurs chimériques par liaison et expression de l'ADN
US5807715A (en)	1984-08-27	1998-09-15	The Board Of Trustees Of The Leland Stanford Junior University	Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4734491A (en)	1984-08-31	1988-03-29	University Patents, Inc.	DNA sequences encoding hybrid lymphoblastoid-leukocyte human interferons
US4716217A (en)	1984-08-31	1987-12-29	University Patents, Inc.	Hybrid lymphoblastoid-leukocyte human interferons
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
US4959314A (en)	1984-11-09	1990-09-25	Cetus Corporation	Cysteine-depleted muteins of biologically active proteins
IL77081A (en)	1984-12-04	1999-10-28	Genetics Inst	Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin
US5049386A (en)	1985-01-07	1991-09-17	Syntex (U.S.A.) Inc.	N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4946787A (en)	1985-01-07	1990-08-07	Syntex (U.S.A.) Inc.	N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en)	1985-01-07	1990-01-30	Syntex (U.S.A.) Inc.	N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4677195A (en)	1985-01-11	1987-06-30	Genetics Institute, Inc.	Method for the purification of erythropoietin and erythropoietin compositions
US4970300A (en)	1985-02-01	1990-11-13	New York University	Modified factor VIII
GB8504099D0 (en)	1985-02-18	1985-03-20	Wellcome Found	Physiologically active substances
DK129385A (da)	1985-03-22	1986-09-23	Novo Industri As	Peptider og fremstilling deraf
FR2579224B1 (fr) *	1985-03-25	1987-05-22	Genetica	Procede de preparation microbiologique de la serum-albumine humaine
CA1260858A (fr)	1985-03-28	1989-09-26	Lawrence S. Cousens	Expression a l'aide de genes fusionnes pour l'obtention de proteines
US4751180A (en)	1985-03-28	1988-06-14	Chiron Corporation	Expression using fused genes providing for protein product
EP0216846B2 (fr)	1985-04-01	1995-04-26	Celltech Limited	Lignee cellulaire de myelomes transformee et procede d'expression d'un gene codant un polypeptide eucaryotique employant cette lignee
GR860984B (en)	1985-04-17	1986-08-18	Zymogenetics Inc	Expression of factor vii and ix activities in mammalian cells
GB8510219D0 (en)	1985-04-22	1985-05-30	Bass Plc	Isolation of fermentation products
JPS6229985A (ja)	1985-06-17	1987-02-07	ジエネツクス・コ−ポレ−シヨン	クロ−ン化プレプロ−ヒト血清アルブミン遺伝子およびヒト血清アルブミン遺伝子、それらの遺伝子を含むプラスミド、プラスミドにより形質転換された微生物、およびその微生物を用いたプレプロ−ヒト血清アルブミン遺伝子の製造方法
US4980286A (en)	1985-07-05	1990-12-25	Whitehead Institute For Biomedical Research	In vivo introduction and expression of foreign genetic material in epithelial cells
US4810643A (en)	1985-08-23	1989-03-07	Kirin- Amgen Inc.	Production of pluripotent granulocyte colony-stimulating factor
US5102872A (en) *	1985-09-20	1992-04-07	Cetus Corporation	Controlled-release formulations of interleukin-2
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
JPH0618778B2 (ja)	1985-10-04	1994-03-16	中外製薬株式会社	白血球減少症治療剤
JPS6296086A (ja)	1985-10-21	1987-05-02	Agency Of Ind Science & Technol	複合プラスミド
US5139941A (en)	1985-10-31	1992-08-18	University Of Florida Research Foundation, Inc.	AAV transduction vectors
DE3689123T2 (de)	1985-11-01	1994-03-03	Xoma Corp	Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
CA1295563C (fr)	1985-11-01	1992-02-11	Robert T. Garvin	Production de proteines actives contenant des residus de cystine
US5576195A (en)	1985-11-01	1996-11-19	Xoma Corporation	Vectors with pectate lyase signal sequence
CA1295566C (fr)	1987-07-21	1992-02-11	Robert T. Garvin	Caracterisation et structure de genes pour protease a et protease b de streptomyces griseus
US5641663A (en) *	1985-11-06	1997-06-24	Cangene Corporation	Expression system for the secretion of bioactive human granulocyte macrophage colony stimulating factor (GM-CSF) and other heterologous proteins from steptomyces
JPH0780930B2 (ja)	1985-12-26	1995-08-30	三井石油化学工業株式会社	α−オレフインの重合方法
JPH0645551B2 (ja)	1986-01-07	1994-06-15	塩野義製薬株式会社	インタ−ロイキン−２組成物
EP0230980B2 (fr)	1986-01-22	1996-03-20	Chugai Seiyaku Kabushiki Kaisha	Composé pharmaceutique promouvant le rétablissement de la capacité hémopoiétique
ES2036530T3 (es)	1986-01-22	1993-06-01	Chugai Seiyaku Kabushiki Kaisha	Utilizacion de un factor estimulante de las colonias granulociticas humano para preparar una composicion farmaceutica para el tratamiento de la leucemia mielogena.
GB8601597D0 (en)	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
FR2594846B1 (fr) *	1986-02-21	1989-10-20	Genetica	Procede de preparation de la serum albumine humaine mature
EP0237019A3 (fr)	1986-03-14	1988-03-09	Toray Industries, Inc.	Interféron conjugué et sa préparation à partir d'un gène recombinant
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
IT1203758B (it)	1986-03-27	1989-02-23	Univ Roma	Vettori di clonazione e di espressione di geni eterologhi in lieviti e lieviti trasformati con tali vettori
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
DK179286D0 (da)	1986-04-18	1986-04-18	Nordisk Gentofte	Insulinpraeparat
US4765980A (en) *	1986-04-28	1988-08-23	International Minerals & Chemical Corp.	Stabilized porcine growth hormone
US4859609A (en)	1986-04-30	1989-08-22	Genentech, Inc.	Novel receptors for efficient determination of ligands and their antagonists or agonists
US5028422A (en) *	1986-05-27	1991-07-02	Schering Corporation	Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
US5985599A (en)	1986-05-29	1999-11-16	The Austin Research Institute	FC receptor for immunoglobulin
IT1204400B (it) *	1986-06-20	1989-03-01	Sclavo Spa	Composizioni farmaceutiche contenente una calcitonina
GB8615701D0 (en)	1986-06-27	1986-08-06	Delta Biotechnology Ltd	Stable gene integration vector
IT1196484B (it)	1986-07-11	1988-11-16	Sclavo Spa	Vettore ad espressione e secrezione in lieviti,utile per la preparazione di proteine eterologhe
GR871067B (en)	1986-07-18	1987-11-19	Chugai Pharmaceutical Co Ltd	Process for producing stable pharmaceutical preparation containing granulocyte colony stimulating factor
US4857467A (en)	1986-07-23	1989-08-15	Phillips Petroleum Company	Carbon and energy source markers for transformation of strains of the genes Pichia
US4801575A (en) *	1986-07-30	1989-01-31	The Regents Of The University Of California	Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US5002764A (en) *	1986-08-12	1991-03-26	Schering Corporation	Treatment of actinic keratoses with alpha2 interferon
GB8620926D0 (en) *	1986-08-29	1986-10-08	Delta Biotechnology Ltd	Yeast promoter
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US4929442A (en) *	1986-09-26	1990-05-29	Exovir, Inc.	Compositions suitable for human topical application including a growth factor and/or related materials
US5508031A (en) *	1986-11-21	1996-04-16	Cetus Oncology Corporation	Method for treating biological damage using a free-radial scavenger and interleukin-2
AU624789B2 (en)	1987-02-19	1992-06-25	Amgen, Inc.	Purified platelet-derived growth factor and methods for purification thereof
US4835260A (en) *	1987-03-20	1989-05-30	Genetics Institute, Inc.	Erythropoietin composition
JP2873012B2 (ja) *	1987-04-09	1999-03-24	デルタバイオテクノロジーリミテッド	酵母ベクター
DE3855504T2 (de)	1987-04-22	1997-01-23	Chiron Corp	Rekombinante Herstellung von A-Ketten-Polypeptiden von PDGF
US5258498A (en)	1987-05-21	1993-11-02	Creative Biomolecules, Inc.	Polypeptide linkers for production of biosynthetic proteins
US5489425A (en)	1987-06-24	1996-02-06	The Dow Chemical Company	Functionalized polyamine chelants
US4994560A (en)	1987-06-24	1991-02-19	The Dow Chemical Company	Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies
GB8717430D0 (en)	1987-07-23	1987-08-26	Celltech Ltd	Recombinant dna product
AR247761A1 (es)	1987-07-28	1995-03-31	Gist Brocades Nv	Metodo para producir un polipeptido en una celula hospedante de kluyveromyces, dicha celula hospedante transformada y secuencia a adn empleada
JPH0622784Y2 (ja)	1987-08-04	1994-06-15	東洋シヤッター株式会社	オ−バ−ドア用可動中柱の高さ調整装置
JP2627899B2 (ja)	1987-08-19	1997-07-09	株式会社ビタミン研究所	遺伝子封入リポソームの製法
SE459586B (sv)	1987-09-14	1989-07-17	Mta Szegedi Biolog Koezponti	Strukturgen som kodar foer autentiskt humant serum albumin och foerfarande foer dess framstaellning
PT88641B (pt)	1987-10-02	1993-04-30	Genentech Inc	Metodo para a preparacao de uma variante de adesao
US5336603A (en) *	1987-10-02	1994-08-09	Genentech, Inc.	CD4 adheson variants
GB8725529D0 (en) *	1987-10-30	1987-12-02	Delta Biotechnology Ltd	Polypeptides
JPH0811074B2 (ja)	1987-10-30	1996-02-07	財団法人化学及血清療法研究所	プレアルブミンをコードする遺伝子を組込んだ組換えプラスミドおよびこれを用いたプレアルブミンの製法
GB8726953D0 (en)	1987-11-18	1987-12-23	Delta Biotechnology Ltd	Yeast expression system
JP2791418B2 (ja) *	1987-12-02	1998-08-27	株式会社ミドリ十字	異種蛋白質の製造方法、組換えｄｎａ、形質転換体
US5282856A (en)	1987-12-22	1994-02-01	Ledergerber Walter J	Implantable prosthetic device
PT89484B (pt)	1988-01-22	1994-03-31	Gen Hospital Corp	Genes clonados codificadores de proteinas de fusao ig-cd4 e sua utilizacao
JPH01240191A (ja) *	1988-02-16	1989-09-25	Green Cross Corp:The	酵母で機能する新規シグナルペプチドおよびこれを用いた異種蛋白質の分泌発現
JPH01215289A (ja)	1988-02-22	1989-08-29	Toa Nenryo Kogyo Kk	遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
US5066489A (en)	1988-03-28	1991-11-19	Cetus Corporation	Combination therapy of IL-2 and DTIC for the treatment of melanoma
US4999339A (en) *	1988-03-28	1991-03-12	Cetus Corporation	Combination therapy of IL-2 and DTIC for the treatment of melanoma
US5061488A (en)	1988-04-15	1991-10-29	The United States Of America As Represented Department Of Health & Human Services	Flavone-8-acetic acid and interleukin-2 for cancer therapy
US5763394A (en) *	1988-04-15	1998-06-09	Genentech, Inc.	Human growth hormone aqueous formulation
US5981485A (en)	1997-07-14	1999-11-09	Genentech, Inc.	Human growth hormone aqueous formulation
US5096885A (en) *	1988-04-15	1992-03-17	Genentech, Inc.	Human growth hormone formulation
US5096707A (en) *	1988-04-15	1992-03-17	The United States Of America As Represented By The Department Of Health And Human Services	Flavone-8-acetic acid and interleukin-2 in a method of treating certain cancers
GB8809129D0 (en)	1988-04-18	1988-05-18	Celltech Ltd	Recombinant dna methods vectors and host cells
IL89992A0 (en)	1988-04-25	1989-12-15	Phillips Petroleum Co	Expression of human serum albumin in methylotrophic yeasts
IL89989A0 (en)	1988-04-25	1989-12-15	Phillips Petroleum Co	Expression of human interleukin-2 in methylotrophic yeasts
US5126129A (en) *	1988-05-23	1992-06-30	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services	Cancer therapy using interleukin-2 and flavone compounds
DE58906966D1 (de)	1988-06-23	1994-03-24	Hoechst Ag	Mini-Proinsulin, seine Herstellung und Verwendung.
ZA894792B (en)	1988-06-24	1991-04-24	Dow Chemical Co	Macrocyclic bifunctional chelants,complexes thereof and their antibody conjugates
US5756065A (en)	1988-06-24	1998-05-26	The Dow Chemical Company	Macrocyclic tetraazacyclododecane conjugates and their use as diagnostic and therapeutic agents
CA1341373C (fr)	1988-06-24	2002-07-02	Roberta C. Cheng	Agents chelateurs bifonctionnels macrocycliques, leurs complexes et leurs conjugues d'anticorps
US5274119A (en)	1988-07-01	1993-12-28	The Dow Chemical Company	Vicinal diols
EP0387319B1 (fr) *	1988-07-23	1996-03-06	Delta Biotechnology Limited	Sequences conductrices secretoires
US4925648A (en)	1988-07-29	1990-05-15	Immunomedics, Inc.	Detection and treatment of infectious and inflammatory lesions
FR2649991B2 (fr)	1988-08-05	1994-03-04	Rhone Poulenc Sante	Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
FR2635115B1 (fr)	1988-08-05	1992-04-03	Rhone Poulenc Sante	Procede de preparation de la serum albumine humaine a partir d'une levure
AU4216689A (en)	1988-08-11	1990-03-05	California Biotechnology, Inc.	Method for stabilizing heterologous protein expression and vectors for use therein
US5601819A (en)	1988-08-11	1997-02-11	The General Hospital Corporation	Bispecific antibodies for selective immune regulation and for selective immune cell binding
EP0436597B1 (fr)	1988-09-02	1997-04-02	Protein Engineering Corporation	Production et selection de proteines de liaison diversifiees de recombinaison
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
US5260202A (en)	1988-09-07	1993-11-09	Delta Biotechnology Limited	Fermentation method
JPH02227079A (ja)	1988-10-06	1990-09-10	Tonen Corp	ヒト血清アルブミン断片
US5349052A (en)	1988-10-20	1994-09-20	Royal Free Hospital School Of Medicine	Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
US5298243A (en)	1988-10-20	1994-03-29	Denki Kagaku Kogyo Kabushiki Kaisha	Colony stimulating factor-gelatin conjugate
JPH02117384A (ja)	1988-10-26	1990-05-01	Tonen Corp	酵母宿主によるヒト血清アルブミンａの製造
US5759802A (en)	1988-10-26	1998-06-02	Tonen Corporation	Production of human serum alubumin A
EP0397834B1 (fr)	1988-10-28	2000-02-02	Genentech, Inc.	Procede d'identification de domaines actifs et de residus d'acides amines dans des polypeptides et des vaiantes d'hormones
US5342604A (en)	1988-10-31	1994-08-30	The Dow Chemical Company	Complexes possessing ortho ligating functionality
US5696239A (en)	1988-10-31	1997-12-09	The Dow Chemical Company	Conjugates possessing ortho ligating functionality and complexes thereof
US5256410A (en)	1988-12-01	1993-10-26	Schering Corporation	Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon
US4975271A (en)	1988-12-19	1990-12-04	Vipont Pharmaceutical, Inc.	Muscosal delivery systems for treatment of periodontal disease
WO1990006952A1 (fr)	1988-12-22	1990-06-28	Kirin-Amgen, Inc.	Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5198346A (en)	1989-01-06	1993-03-30	Protein Engineering Corp.	Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en)	1989-01-06	1992-03-17	Protein Engineering Corporation	Generation and selection of novel dna-binding proteins and polypeptides
DK105489D0 (da) *	1989-03-03	1989-03-03	Novo Nordisk As	Polypeptid
US5116964A (en) *	1989-02-23	1992-05-26	Genentech, Inc.	Hybrid immunoglobulins
US5705363A (en) *	1989-03-02	1998-01-06	The Women's Research Institute	Recombinant production of human interferon τ polypeptides and nucleic acids
ATE193541T1 (de)	1989-03-20	2000-06-15	Gen Hospital Corp	Insulinotropes hormon
CA2489769A1 (fr)	1989-03-21	1990-10-04	Philip L. Felgner	Expression des sequences polynocleotides exogenes chez un vertebre
US5703055A (en)	1989-03-21	1997-12-30	Wisconsin Alumni Research Foundation	Generation of antibodies through lipid mediated DNA delivery
US5693622A (en)	1989-03-21	1997-12-02	Vical Incorporated	Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5231020A (en)	1989-03-30	1993-07-27	Dna Plant Technology Corporation	Genetic engineering of novel plant phenotypes
US5328470A (en)	1989-03-31	1994-07-12	The Regents Of The University Of Michigan	Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
EP0392300B1 (fr) *	1989-04-11	1992-08-26	BOEHRINGER INGELHEIM INTERNATIONAL GmbH	Utilisation d'au moins une cytokine pour l'obtention d'un médicament pour le traitement systémique des lésions prénéoplastiques
FI901810A7 (fi)	1989-04-13	1990-10-14	Vascular Laboratory Inc	Puhtaan pro-urokinaasin plasminogeeniaktivaattorikompleksi, joka on sidottu ihmisen seerumialbumiiniin disulfidisillan välityksellä
US5324844A (en)	1989-04-19	1994-06-28	Enzon, Inc.	Active carbonates of polyalkylene oxides for modification of polypeptides
EP0394827A1 (fr)	1989-04-26	1990-10-31	F. Hoffmann-La Roche Ag	Polypeptides chimériques de CD4-immunoglobuline
GB8909916D0 (en) *	1989-04-29	1989-06-14	Delta Biotechnology Ltd	Polypeptides
US5766883A (en) *	1989-04-29	1998-06-16	Delta Biotechnology Limited	Polypeptides
ATE92107T1 (de)	1989-04-29	1993-08-15	Delta Biotechnology Ltd	N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
US5332671A (en)	1989-05-12	1994-07-26	Genetech, Inc.	Production of vascular endothelial cell growth factor and DNA encoding same
DE69031120T2 (de)	1989-05-19	1998-01-15	Genentech, Inc., South San Francisco, Calif.	Her2 extrazellulare domäne
DE69024261T2 (de)	1989-05-24	1996-07-18	Merck & Co Inc	Reinigung und Charakterisierung eines von einem Glioma abstammenden Wachstumsfaktors
US5808003A (en)	1989-05-26	1998-09-15	Perimmune Holdings, Inc.	Polyaminocarboxylate chelators
WO1990015142A1 (fr) *	1989-06-09	1990-12-13	Gropep Pty. Ltd.	Proteines de fusion pour hormones de croissance
JPH0327320A (ja)	1989-06-26	1991-02-05	Ajinomoto Co Inc	ヒトｂ細胞分化因子医薬組成物
ES2096590T3 (es)	1989-06-29	1997-03-16	Medarex Inc	Reactivos biespecificos para la terapia del sida.
US5413923A (en)	1989-07-25	1995-05-09	Cell Genesys, Inc.	Homologous recombination for universal donor cells and chimeric mammalian hosts
DE3924746A1 (de) *	1989-07-26	1991-01-31	Behringwerke Ag	Erythropoietin (epo)-peptide und dagegen gerichtete antikoerper
FR2650598B1 (fr)	1989-08-03	1994-06-03	Rhone Poulenc Sante	Derives de l'albumine a fonction therapeutique
CU22222A1 (es)	1989-08-03	1995-01-31	Cigb	Procedimiento para la expresion de proteinas heterologicas producidas de forma fusionada en escherichia coli, su uso, vectores de expresion y cepas recombinantes
GB8927480D0 (en)	1989-12-05	1990-02-07	Delta Biotechnology Ltd	Mutant fungal strain detection and new promoter
US5073627A (en) *	1989-08-22	1991-12-17	Immunex Corporation	Fusion proteins comprising GM-CSF and IL-3
DE69007975T2 (de)	1989-08-22	1994-07-21	Immunex Corp	Fusionsprotein bestehend aus gm-csf und il-3.
US5436146A (en)	1989-09-07	1995-07-25	The Trustees Of Princeton University	Helper-free stocks of recombinant adeno-associated virus vectors
US6063373A (en) *	1989-09-19	2000-05-16	Maxim Pharmaceuticals, Inc.	Enhanced activation of NK cells using an NK cell activator and a hydrogen peroxide scavenger or inhibitor
CA1340994C (fr)	1989-09-21	2000-05-16	Rudolf Edgar Dr. Falk	Traitement de maladies et d'etats pathologiques
IE66494B1 (en)	1989-09-26	1996-01-10	Immunex Corp	Granulocyte-colony stimulating factor receptors
WO1991005052A1 (fr)	1989-09-28	1991-04-18	Leningradsky Gosudarstvenny Universitet	Procede d'obtention d'un polypeptide presentant une activite d'interleukine-2 humaine, secrete par des cellules de levure, saccharomyces cerevisiae
AU638762B2 (en)	1989-10-05	1993-07-08	Optein Inc	Cell-free synthesis and isolation of novel genes and polypeptides
FR2653020B1 (fr)	1989-10-17	1993-03-26	Roussel Uclaf	Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour la preparation de compositions pharmaceutiques destinees au traitement des leucemies.
US5667986A (en)	1989-10-18	1997-09-16	Delta Biotechnology Limited	Yeast promoter for expressing heterologous polypeptides
GB8924021D0 (en)	1989-10-25	1989-12-13	Celltech Ltd	Recombinant dna method and vectors for the use therein
US5676954A (en)	1989-11-03	1997-10-14	Vanderbilt University	Method of in vivo delivery of functioning foreign genes
EP0452457B1 (fr)	1989-11-03	1997-08-20	Vanderbilt University	Procede d'administration in vivo de genes etrangers fonctionnels
US5173408A (en)	1989-11-13	1992-12-22	Lange Louis George Iii	Mammalian pancreatic cholesterol esterase
US5580560A (en) *	1989-11-13	1996-12-03	Novo Nordisk A/S	Modified factor VII/VIIa
DK608589D0 (da)	1989-12-01	1989-12-01	Holm Arne	Kemisk fremgangsmaade
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
JPH03201987A (ja) *	1989-12-29	1991-09-03	Tonen Corp	ヒト血清アルブミン断片
US5116944A (en)	1989-12-29	1992-05-26	Neorx Corporation	Conjugates having improved characteristics for in vivo administration
US5780225A (en)	1990-01-12	1998-07-14	Stratagene	Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
AU7247191A (en)	1990-01-11	1991-08-05	Molecular Affinities Corporation	Production of antibodies using gene libraries
US6075181A (en)	1990-01-12	2000-06-13	Abgenix, Inc.	Human antibodies derived from immunized xenomice
WO1996033735A1 (fr)	1995-04-27	1996-10-31	Abgenix, Inc.	Anticorps humains derives d'une xenosouris immunisee
DE69120146T2 (de)	1990-01-12	1996-12-12	Cell Genesys Inc	Erzeugung xenogener antikörper
US5545618A (en)	1990-01-24	1996-08-13	Buckley; Douglas I.	GLP-1 analogs useful for diabetes treatment
ATE164852T1 (de)	1990-01-24	1998-04-15	Douglas I Buckley	Glp-1-analoga verwendbar in der diabetesbehandlung
DE69117545T2 (de) *	1990-01-25	1996-10-31	Univ Washington	Faktor X-LACI-Hybridprotein
JPH04211375A (ja)	1990-02-05	1992-08-03	Ajinomoto Co Inc	合成遺伝子及びそれを用いたヒト血清アルブミンの製造法
US5747334A (en)	1990-02-15	1998-05-05	The University Of North Carolina At Chapel Hill	Random peptide library
US5208018A (en) *	1990-03-19	1993-05-04	Brigham And Women's Hospital	Treatment of cachexia with interleukin 2
FR2660863B1 (fr) *	1990-04-17	1994-01-21	Roussel Uclaf	Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour preparer une composition pharmaceutique destinee au traitement de cancers primitifs de la plevre.
US5264618A (en)	1990-04-19	1993-11-23	Vical, Inc.	Cationic lipids for intracellular delivery of biologically active molecules
US5427908A (en)	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
WO1991018088A1 (fr)	1990-05-23	1991-11-28	The United States Of America, Represented By The Secretary, United States Department Of Commerce	Vecteurs eucaryotiques a base de virus adeno-associes (aav)
GB9013017D0 (en)	1990-06-11	1990-08-01	Mars Uk Ltd	Compounds
US5766897A (en) *	1990-06-21	1998-06-16	Incyte Pharmaceuticals, Inc.	Cysteine-pegylated proteins
HUT65846A (en)	1990-07-10	1994-07-28	Boehringer Ingelheim Int	Method for preparation of o-glycosylated alpha-interferons and medicinal drugs containing it
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
US5225341A (en)	1990-07-19	1993-07-06	The Regents Of The University Of California	Biologically safe plant transformation system using a ds transposon
US5202239A (en) *	1990-08-07	1993-04-13	Scios Nova Inc.	Expression of recombinant polypeptides with improved purification
US5071872A (en)	1990-08-14	1991-12-10	The Ohio State University Research Foundation	Method for improving interleukin-2 activity using aci-reductone compounds
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de)	1990-08-29	1997-09-15	Genpharm Int	Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en)	1990-08-29	1998-09-29	Genpharm International Inc.	Transgenic non-human animals for producing heterologous antibodies
US5391183A (en) *	1990-09-21	1995-02-21	Datascope Investment Corp	Device and method sealing puncture wounds
IT1242149B (it)	1990-09-27	1994-02-16	Consiglio Nazionale Ricerche	Sequenza di nucleotidi codificante per una proteina umana con proprieta' regolative dell'angiogenesi
US5698426A (en)	1990-09-28	1997-12-16	Ixsys, Incorporated	Surface expression libraries of heteromeric receptors
DK0553244T4 (da)	1990-10-05	2005-08-01	Celldex Therapeutics Inc	Målrettet immunostimulering med bispecifikke reagenser
JPH07108232B2 (ja)	1990-10-09	1995-11-22	エム・ディ・リサーチ株式会社	ペプチド又は蛋白質の製造方法
JPH0638771Y2 (ja)	1990-10-26	1994-10-12	株式会社カンセイ	エアバック制御装置
WO1992008802A1 (fr)	1990-10-29	1992-05-29	Cetus Oncology Corporation	Anticorps bispecifiques, methodes de production et utilisation desdits anticorps
US5173414A (en)	1990-10-30	1992-12-22	Applied Immune Sciences, Inc.	Production of recombinant adeno-associated virus vectors
FR2668368B1 (fr)	1990-10-30	1995-03-10	Roussel Uclaf	Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour preparer une composition pharmaceutique destinee au traitement des tumeurs malignes epitheliales.
JPH0638771A (ja)	1990-10-31	1994-02-15	Tonen Corp	ヒトプロテインジスルフィドイソメラーゼ遺伝子の発現方法および該遺伝子との共発現によるポリペプチドの製造方法
US5353535A (en)	1990-11-05	1994-10-11	Plumly George W	Floor type advertising apparatus
US5830452A (en)	1990-11-20	1998-11-03	Chiron Corporation	Method for enhancing the anti-tumor therapeutic index of interleukin-2
AU656353B2 (en)	1990-11-29	1995-02-02	Institut National De La Recherche Agronomique (Inra)	New variants derived from interferons of type I, production process thereof and their applications
CA2095633C (fr)	1990-12-03	2003-02-04	Lisa J. Garrard	Methode d'enrichissement de proteines variantes aux proprietes liantes alterees
US5272080A (en) *	1991-02-19	1993-12-21	Pharmavene, Inc.	Production of butyrylcholinesterase
US5833982A (en)	1991-02-28	1998-11-10	Zymogenetics, Inc.	Modified factor VII
US5272070A (en) *	1991-03-08	1993-12-21	Board Of Regents, The University Of Texas System	Method for the preparation of cell lines producing Man3 GlcNac 2 asparagine-linked gylcans and cell lines produced thereby
CA2062659A1 (fr)	1991-03-12	1992-09-13	Yasutaka Igari	Composition a liberation prolongee d'erythropoietine
US5811396A (en)	1991-03-14	1998-09-22	The United States Of America As Represented By The Department Of Health And Human Services	TRK tyrosine kinase receptor is the physiological receptor for nerve growth factor
EP0506477B1 (fr)	1991-03-28	1999-06-23	Merck & Co. Inc.	Sous-unité C du facteur de croissance de cellules vasculaires endotheliales
US5374617A (en)	1992-05-13	1994-12-20	Oklahoma Medical Research Foundation	Treatment of bleeding with modified tissue factor in combination with FVIIa
ATE414768T1 (de)	1991-04-10	2008-12-15	Scripps Research Inst	Bibliotheken heterodimerer rezeptoren mittels phagemiden
EP0509841A3 (en)	1991-04-18	1993-08-18	Tonen Corporation	Co-expression system of protein disulfide isomerase gene and useful polypeptide gene and process for producing the polypeptide using its system
CA2058820C (fr)	1991-04-25	2003-07-15	Kotikanyad Sreekrishna	Cassettes d'expression et vecteurs pour la secretion de serum albumine humaine dans des cellules pichia pastoris
CA2108451A1 (fr)	1991-04-26	1992-10-27	Beverley J. Randle	Nouveaux anticorps et methodes d'utilisation
US5330901A (en)	1991-04-26	1994-07-19	Research Corporation Technologies, Inc.	Expression of human serum albumin in Pichia pastoris
US5646012A (en) *	1991-04-30	1997-07-08	Rhone-Poulenc Rorer S.A.	Yeast promoter and use thereof
FR2676070B1 (fr)	1991-04-30	1994-09-30	Rhone Poulenc Rorer Sa	Promoteur de levure et son utilisation.
EP0519596B1 (fr)	1991-05-17	2005-02-23	Merck & Co. Inc.	Procédé pour réduire l'immunogénicité des domaines variables d'anticorps
IL101943A0 (en)	1991-05-24	1992-12-30	Genentech Inc	Structure,production and use of heregulin
US5304473A (en) *	1991-06-11	1994-04-19	Eli Lilly And Company	A-C-B proinsulin, method of manufacturing and using same, and intermediates in insulin production
WO1992022324A1 (fr)	1991-06-14	1992-12-23	Xoma Corporation	Fragments d'anticorps produits par des microbes et leurs conjugues
FR2677996B1 (fr)	1991-06-21	1993-08-27	Rhone Poulenc Rorer Sa	Vecteurs de clonage et/ou d'expression preparation et utilisation.
US5851795A (en) *	1991-06-27	1998-12-22	Bristol-Myers Squibb Company	Soluble CTLA4 molecules and uses thereof
US5844095A (en)	1991-06-27	1998-12-01	Bristol-Myers Squibb Company	CTLA4 Ig fusion proteins
AU2147192A (en)	1991-06-28	1993-01-25	Genentech Inc.	Method of stimulating immune response using growth hormone
US5223408A (en) *	1991-07-11	1993-06-29	Genentech, Inc.	Method for making variant secreted proteins with altered properties
JPH05292972A (ja)	1991-07-29	1993-11-09	Tonen Corp	改良された酵母発現系
EP0597010A4 (en)	1991-07-31	1996-12-27	Rhone Poulenc Rorer Int	Transgenic protein production.
US5723719A (en)	1991-08-08	1998-03-03	Health Research Inc.	Transgenic mouse as model for diseases involving dopaminergic dysfunction
DE4126968A1 (de)	1991-08-14	1993-02-18	Detlev Prof Dr Med Ganten	Transgene ratten, die in ihrem genom mindestens ein menschliches gen enthalten, das an der blutdruckregulation beteiligt ist
US5565332A (en)	1991-09-23	1996-10-15	Medical Research Council	Production of chimeric antibodies - a combinatorial approach
US5641670A (en)	1991-11-05	1997-06-24	Transkaryotic Therapies, Inc.	Protein production and protein delivery
US6270989B1 (en)	1991-11-05	2001-08-07	Transkaryotic Therapies, Inc.	Protein production and delivery
PT101031B (pt) *	1991-11-05	2002-07-31	Transkaryotic Therapies Inc	Processo para o fornecimento de proteinas por terapia genetica
EP0611306B1 (fr) *	1991-11-08	1998-07-08	Somatogen, Inc.	Hemoglobines utilisees comme agents administrateurs de medicaments
US5786883A (en) *	1991-11-12	1998-07-28	Pilkington Barnes Hind, Inc.	Annular mask contact lenses
PT1024191E (pt)	1991-12-02	2008-12-22	Medical Res Council	Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5540923A (en) *	1991-12-06	1996-07-30	Landsforeningen Til Kraeftens Bekaemplse	Interferon proteins
US6348327B1 (en) *	1991-12-06	2002-02-19	Genentech, Inc.	Non-endocrine animal host cells capable of expressing variant proinsulin and processing the same to form active, mature insulin and methods of culturing such cells
US5428139A (en)	1991-12-10	1995-06-27	The Dow Chemical Company	Bicyclopolyazamacrocyclophosphonic acid complexes for use as radiopharmaceuticals
AU671093B2 (en)	1992-01-07	1996-08-15	Elan Pharmaceuticals, Inc.	Transgenic animal models for alzheimer's disease
GB9200417D0 (en)	1992-01-09	1992-02-26	Bagshawe Kenneth D	Cytotoxic drug therapy
FR2686620B1 (fr) *	1992-01-27	1995-06-23	Rhone Poulenc Rorer Sa	Serum-albumine humaine, preparation et utilisation.
FR2686900B1 (fr) *	1992-01-31	1995-07-21	Rhone Poulenc Rorer Sa	Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
FR2686901A1 (fr)	1992-01-31	1993-08-06	Rhone Poulenc Rorer Sa	Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
FR2686899B1 (fr) *	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
CA2372813A1 (fr)	1992-02-06	1993-08-19	L.L. Houston	Proteine fixatrice biosynthetique pour marqueur du cancer
PT627940E (pt)	1992-03-05	2003-07-31	Univ Texas	Utilizacao de imunoconjugados para o diagnostico e/ou terapia de tumores vascularizados
US5230886A (en)	1992-03-18	1993-07-27	Trustees Of Boston University	Tumor cell suppression
DK36392D0 (da) *	1992-03-19	1992-03-19	Novo Nordisk As	Anvendelse af kemisk forbindelse
DK36492D0 (da)	1992-03-19	1992-03-19	Novo Nordisk As	Praeparat
USRE37302E1 (en)	1992-03-19	2001-07-31	Novo Nordisk A/S	Peptide
US5733743A (en)	1992-03-24	1998-03-31	Cambridge Antibody Technology Limited	Methods for producing members of specific binding pairs
US5573905A (en)	1992-03-30	1996-11-12	The Scripps Research Institute	Encoded combinatorial chemical libraries
US5460954A (en)	1992-04-01	1995-10-24	Cheil Foods & Chemicals, Inc.	Production of human proinsulin using a novel vector system
US5229109A (en)	1992-04-14	1993-07-20	Board Of Regents, The University Of Texas System	Low toxicity interleukin-2 analogues for use in immunotherapy
DK0598877T3 (da)	1992-06-09	2000-02-21	Hoppe Ag	Falle og dørlås
EP0969016A2 (fr)	1992-06-15	2000-01-05	Scios Inc.	Derivés d'insulinotropine et de peptide analogue au glucagon
US5686268A (en) *	1992-06-19	1997-11-11	Pfizer Inc.	Fused proteins
US5505931A (en)	1993-03-04	1996-04-09	The Dow Chemical Company	Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
JP3269504B2 (ja)	1992-07-08	2002-03-25	三菱ウェルファーマ株式会社	ヒト血清アルブミンの製造方法
FR2694294B1 (fr)	1992-07-30	1994-09-09	Rhone Poulenc Rorer Sa	Promoteur de levure et son utilisateur.
DK0955062T3 (da)	1992-07-31	2007-09-17	Genentech Inc	Vandig formulering indeholdende humant væksthormon
US5602307A (en)	1992-08-12	1997-02-11	Baylor College Of Medicine	Non-human animal having predefined allele of a cellular adhesion gene
DE4244915C2 (de) *	1992-08-14	1998-12-03	Widmar Prof Dr Tanner	DNA-Moleküle codierend Proteine, die an der O-Glykosylierung von Proteinen beteiligt sind
US5639641A (en)	1992-09-09	1997-06-17	Immunogen Inc.	Resurfacing of rodent antibodies
US5728553A (en) *	1992-09-23	1998-03-17	Delta Biotechnology Limited	High purity albumin and method of producing
US5731490A (en)	1992-09-29	1998-03-24	The Ontario Cancer Institute	Mutant mouse lacking the expression of interferon regulatory factor 1 (IRF-1)
AU5171293A (en)	1992-10-14	1994-05-09	Regents Of The University Of Colorado, The	Ion-pairing of drugs for improved efficacy and delivery
FR2697752B1 (fr) *	1992-11-10	1995-04-14	Rhone Poulenc Rorer Sa	Compositions antitumorales contenant des dérivés du taxane.
TW402639B (en)	1992-12-03	2000-08-21	Transkaryotic Therapies Inc	Protein production and protein delivery
US5478745A (en)	1992-12-04	1995-12-26	University Of Pittsburgh	Recombinant viral vector system
US5441050A (en)	1992-12-18	1995-08-15	Neoprobe Corporation	Radiation responsive surgical instrument
US6221958B1 (en) *	1993-01-06	2001-04-24	Societe De Conseils De Recherches Et D'applications Scientifiques, Sas	Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5489743A (en)	1993-01-19	1996-02-06	Amgen Inc.	Transgenic animal models for thrombocytopenia
US5593972A (en)	1993-01-26	1997-01-14	The Wistar Institute	Genetic immunization
FR2701953B1 (fr)	1993-02-22	1995-05-24	Centre Nat Rech Scient	Protéine de fusion multi-VIP et procédé de préparation de VIP recombinant.
US5441734A (en) *	1993-02-25	1995-08-15	Schering Corporation	Metal-interferon-alpha crystals
US5780021A (en)	1993-03-05	1998-07-14	Georgetown University	Method for treating type 1 diabetes using α-interferon and/or β-i
US5869445A (en)	1993-03-17	1999-02-09	University Of Washington	Methods for eliciting or enhancing reactivity to HER-2/neu protein
US6284727B1 (en)	1993-04-07	2001-09-04	Scios, Inc.	Prolonged delivery of peptides
HU225496B1 (en)	1993-04-07	2007-01-29	Scios Inc	Pharmaceutical compositions of prolonged delivery, containing peptides
WO1994024160A2 (fr)	1993-04-21	1994-10-27	Brigham And Women's Hospital	Erythropoïetines-muteines a activite renforcee
GB9308581D0 (en)	1993-04-26	1993-06-09	Univ Manitoba	A method for induction of antigen-specific suppression of immune-response
EP0699075B1 (fr) *	1993-05-21	2001-12-12	Zymogenetics, Inc.	FACTEUR VII MODIFIE pour l'inhibition de la resténose vasculaire et du dépôt des plaquettes
JP3626187B2 (ja)	1993-06-07	2005-03-02	バイカルインコーポレイテッド	遺伝子治療に適するプラスミド
US5621039A (en) *	1993-06-08	1997-04-15	Hallahan; Terrence W.	Factor IX- polymeric conjugates
DK82893D0 (da) *	1993-07-08	1993-07-08	Novo Nordisk As	Peptid
US5512459A (en)	1993-07-20	1996-04-30	Bionebraska, Inc.	Enzymatic method for modification or recombinant polypeptides
KR100340091B1 (ko)	1993-08-09	2002-09-27	베르찌 이스트반	킬러세포개재세포용해를위한암세포감작용약학적제제
CN1057534C (zh)	1993-08-17	2000-10-18	柯瑞英-艾格公司	促红细胞生成素类似物
GB9317618D0 (en)	1993-08-24	1993-10-06	Royal Free Hosp School Med	Polymer modifications
WO1995005848A1 (fr)	1993-08-24	1995-03-02	Novo Nordisk A/S	Peptide-1 du type glucagon a action prolongee
US5521086A (en) *	1993-09-16	1996-05-28	Cephalon, Inc.	Secretion sequence for the production of a heterologous protein in yeast
US5643575A (en)	1993-10-27	1997-07-01	Enzon, Inc.	Non-antigenic branched polymer conjugates
US5459031A (en)	1993-11-05	1995-10-17	Amgen Inc.	Methods for controlling sialic acid derivatives in recombinant glycoproteins
WO1995015982A2 (fr)	1993-12-08	1995-06-15	Genzyme Corporation	Procede de generation d'anticorps specifiques
US5705483A (en)	1993-12-09	1998-01-06	Eli Lilly And Company	Glucagon-like insulinotropic peptides, compositions and methods
CA2137206A1 (fr)	1993-12-09	1995-06-10	John A. Galloway	Peptites insulinotropiques agissant comme le glucagon, compositions et methodes
WO1995016708A1 (fr)	1993-12-17	1995-06-22	Novo Nordisk A/S	Composes du type pro-insuline
DK144093D0 (fr)	1993-12-23	1993-12-23	Novo Nordisk As
DE69534347T2 (de)	1994-01-31	2006-05-24	Trustees Of Boston University, Boston	Bibliotheken aus Polyklonalen Antikörpern
US5550214A (en)	1994-02-10	1996-08-27	Brigham And Women's Hospital	Isolated antigenic oncogene peptide fragments and uses
US5837458A (en)	1994-02-17	1998-11-17	Maxygen, Inc.	Methods and compositions for cellular and metabolic engineering
US5834252A (en)	1995-04-18	1998-11-10	Glaxo Group Limited	End-complementary polymerase reaction
US5605793A (en)	1994-02-17	1997-02-25	Affymax Technologies N.V.	Methods for in vitro recombination
US5932780A (en)	1994-02-28	1999-08-03	Yissum Research Development Company Of Hebrew University Of Jerusalem	Transgenic non-human animal assay system for anti-cholinesterase substances
GB9404270D0 (en)	1994-03-05	1994-04-20	Delta Biotechnology Ltd	Yeast strains and modified albumins
US6608182B1 (en)	1994-03-08	2003-08-19	Human Genome Sciences, Inc.	Human vascular endothelial growth factor 2
US5652352A (en)	1994-03-31	1997-07-29	Amgen Inc.	Afamin: a human serum albumin-like gene
US5629286A (en) *	1994-03-31	1997-05-13	Brewitt; Barbara	Homeopathic dilutions of growth factors
US5646113A (en)	1994-04-07	1997-07-08	Genentech, Inc.	Treatment of partial growth hormone insensitivity syndrome
FR2719593B1 (fr)	1994-05-06	1996-05-31	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur préparation et composition pharmaceutique les contenant.
GB9409496D0 (en)	1994-05-12	1994-06-29	London Health Ass	Method for improving glycaemic control in diabetes
GB9411356D0 (en)	1994-06-07	1994-07-27	Delta Biotechnology Ltd	Yeast strains
US5516637A (en)	1994-06-10	1996-05-14	Dade International Inc.	Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5985660A (en)	1994-06-15	1999-11-16	Systemix, Inc.	Method of identifying biological response modifiers involved in dendritic and/or lymphoid progenitor cell proliferation and/or differentiation
US5639642A (en)	1994-06-16	1997-06-17	Novo Nordisk A/S	Synthetic leader peptide sequences
US5623054A (en)	1994-06-23	1997-04-22	The General Hospital Corporation	Crucifer AFT proteins and uses thereof
EP0769963A4 (fr)	1994-07-27	1999-07-28	Commw Scient Ind Res Org	Vaccins a base de polyepitopes
JPH0853500A (ja)	1994-08-11	1996-02-27	Asahi Glass Co Ltd	融合タンパク質および該タンパク質をコードする遺伝子
JPH0851982A (ja)	1994-08-11	1996-02-27	Asahi Glass Co Ltd	ヒト血清アルブミンをコードする改変された遺伝子
JPH0859509A (ja)	1994-08-16	1996-03-05	Teijin Ltd	サイトメガロウイルス抗原血症治療剤およびサイトメガロウイルス感染症治療剤
US5574008A (en)	1994-08-30	1996-11-12	Eli Lilly And Company	Biologically active fragments of glucagon-like insulinotropic peptide
US6071923A (en) *	1994-09-16	2000-06-06	Bar-Ilan University	Retinoyloxy aryl-substituted alkylene butyrates useful for the treatment of cancer and other proliferative diseases
US5512549A (en) *	1994-10-18	1996-04-30	Eli Lilly And Company	Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
FR2726471B1 (fr) *	1994-11-07	1997-01-31	Pf Medicament	Procede pour ameliorer l'immunogenicite d'un compose immunogene ou d'un haptene et application a la preparation de vaccins
FR2726576B1 (fr)	1994-11-07	1997-01-31	Pf Medicament	Production de peptides analogues de peptides hydrophobes, peptide recombinant, sequence d'adn correspondante
JP4046349B2 (ja)	1994-11-07	2008-02-13	ヒューマンジノームサイエンシーズ，インコーポレイテッド	腫瘍壊死因子−γ
AT403167B (de)	1994-11-14	1997-11-25	Immuno Ag	Selektion und expression von fremdproteinen mittels eines selektions-amplifikations-systems
US5695750A (en)	1994-11-25	1997-12-09	The United States Of America As Represented By The Secretary Of The Army	Compositions for use to deactivate organophosphates
AU4415796A (en)	1994-12-07	1996-06-26	Bionebraska, Inc.	Production of c-terminal amidated peptides from recombinant protein constructs
EP0796335A1 (fr)	1994-12-07	1997-09-24	Bionebraska, Inc.	Production de peptides au moyen de proteines de fusion de recombinaison
DE69534265T2 (de) *	1994-12-12	2006-05-04	Beth Israel Deaconess Medical Center, Inc., Boston	Chimäre zytokine und ihre verwendung
US20010006943A1 (en)	1994-12-23	2001-07-05	Ejvind Jensen	Protracted GLP-1 compositions
ATE234625T1 (de)	1994-12-23	2003-04-15	Novo Nordisk As	Glp-1 zusammensetzungen mit verlängerter wirkdauer
US5583415A (en)	1994-12-27	1996-12-10	Motorola, Inc.	Apparatus for simulating high battery temperature for rechargeble battery systems
US5652224A (en)	1995-02-24	1997-07-29	The Trustees Of The University Of Pennsylvania	Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism
US5928939A (en)	1995-03-01	1999-07-27	Ludwig Institute For Cancer Research	Vascular endothelial growth factor-b and dna coding therefor
US5837281A (en) *	1995-03-17	1998-11-17	Takeda Chemical Industries, Ltd.	Stabilized interface for iontophoresis
JP2758154B2 (ja)	1995-04-06	1998-05-28	エフ・ホフマン−ラロシユアーゲー	インターフェロンを含む液体製剤
US6184201B1 (en)	1995-04-14	2001-02-06	Nps Allelix Corp.	Intestinotrophic glucagon-like peptide-2 analogs
JPH11507205A (ja)	1995-04-27	1999-06-29	ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド	ヒト腫瘍壊死因子受容体
WO1996034096A1 (fr)	1995-04-28	1996-10-31	Abgenix, Inc.	Anticorps humains derives de xeno-souris immunisees
US5480640A (en)	1995-05-02	1996-01-02	Schering Corporation	Alpha interferon for treating prostate cancer
EP0741188A3 (fr)	1995-05-05	1999-07-14	Eli Lilly And Company	Insuline monocaténaire avec bioactivité élevée
AU3134695A (en)	1995-05-05	1996-11-21	Human Genome Sciences, Inc.	Human chemokine beta-8, chemokine beta-1 and macrophage infl ammatory protein-4
US5728915A (en)	1995-05-08	1998-03-17	Children's Hospital, Inc.	Transgenic mice which express simian SV 40 T-antigen under control of the retinoblastoma gene promoter
US5705151A (en)	1995-05-18	1998-01-06	National Jewish Center For Immunology & Respiratory Medicine	Gene therapy for T cell regulation
US6387365B1 (en) *	1995-05-19	2002-05-14	Schering Corporation	Combination therapy for chronic hepatitis C infection
US6001625A (en)	1995-05-19	1999-12-14	The United States Of America As Represented By The Secretary Of The Army	Site-directed mutagenesis of esterases
US5741815A (en)	1995-06-02	1998-04-21	Lai; Ching-San	Methods for in vivo reduction of nitric oxide levels and compositions useful therefor
US5804162A (en)	1995-06-07	1998-09-08	Alliance Pharmaceutical Corp.	Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients
US5728707A (en) *	1995-07-21	1998-03-17	Constantia Gruppe	Treatment and prevention of primary and metastatic neoplasms with salts of aminoimidazole carboxamide
US5811097A (en)	1995-07-25	1998-09-22	The Regents Of The University Of California	Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5840542A (en)	1995-07-28	1998-11-24	Mogam Biotechnology Research Institute	Method for manufacture of proinsulin with high export yield
DE19530865A1 (de)	1995-08-22	1997-02-27	Michael Dr Med Nauck	Wirkstoff sowie Mittel zur parenteralen Ernährung
JPH0995455A (ja)	1995-09-29	1997-04-08	Sumitomo Pharmaceut Co Ltd	腎機能改善剤
US5849322A (en)	1995-10-23	1998-12-15	Theratech, Inc.	Compositions and methods for buccal delivery of pharmaceutical agents
US5766620A (en)	1995-10-23	1998-06-16	Theratech, Inc.	Buccal delivery of glucagon-like insulinotropic peptides
US5702717A (en)	1995-10-25	1997-12-30	Macromed, Inc.	Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers
DE69632062T2 (de)	1995-11-02	2004-11-18	Schering Corp.	Kontinuierliche, niedrigdosierte zytokine-infusionstherapie
US6048964A (en)	1995-12-12	2000-04-11	Stryker Corporation	Compositions and therapeutic methods using morphogenic proteins and stimulatory factors
US6080409A (en)	1995-12-28	2000-06-27	Dendreon Corporation	Immunostimulatory method
GB9526733D0 (en) *	1995-12-30	1996-02-28	Delta Biotechnology Ltd	Fusion proteins
WO1997026321A2 (fr)	1996-01-19	1997-07-24	Board Of Regents, The University Of Texas System	Expression recombinee de proteines a partir de lignees cellulaires secretoires
US6087129A (en)	1996-01-19	2000-07-11	Betagene, Inc.	Recombinant expression of proteins from secretory cell lines
US6110707A (en)	1996-01-19	2000-08-29	Board Of Regents, The University Of Texas System	Recombinant expression of proteins from secretory cell lines
US6150337A (en)	1996-01-23	2000-11-21	Icn Pharmaceuticals, Inc.	Specific modulation of Th1/Th2 cytokine expression by Ribavirin in activated T-lymphocytes
US5767097A (en) *	1996-01-23	1998-06-16	Icn Pharmaceuticals, Inc.	Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
JP2978435B2 (ja)	1996-01-24	1999-11-15	チッソ株式会社	アクリロキシプロピルシランの製造方法
US5616724A (en)	1996-02-21	1997-04-01	Cephalon, Inc.	Fused pyrrolo[2,3-c]carbazole-6-ones
DE19639601A1 (de)	1996-02-28	1997-09-04	Bayer Ag	Parapockenviren, die Fremd-DNA enthalten, ihre Herstellung und ihre Verwendung in Impfstoffen
US6045788A (en) *	1996-02-28	2000-04-04	Cornell Research Foundation, Inc.	Method of stimulation of immune response with low doses of IL-2
DE69740176D1 (de)	1996-03-01	2011-05-26	Novo Nordisk As	Appetithemmendes Peptid, Zusammensetzung und Verwendung
US5912229A (en) *	1996-03-01	1999-06-15	Novo Nordisk Als	Use of a pharmaceutical composition comprising an appetite-suppressing peptide
JP3794748B2 (ja) *	1996-03-04	2006-07-12	第一アスビオファーマ株式会社	メタノール代謝系を有する微生物の培養法
WO1997033904A1 (fr)	1996-03-12	1997-09-18	Human Genome Sciences, Inc.	Recepteurs contenant un domaine de mort cellulaire
ATE241695T1 (de)	1996-03-13	2003-06-15	Delta Biotechnology Ltd	Gärungs-steuerungssysteme
WO1997033998A1 (fr)	1996-03-14	1997-09-18	The Immune Response Corporation	Apport cible de genes codant l'interferon
AU5711196A (en)	1996-03-14	1997-10-01	Human Genome Sciences, Inc.	Apoptosis inducing molecule i
WO1997034997A1 (fr) *	1996-03-21	1997-09-25	Human Genome Sciences, Inc.	Facteur i, ii et iii de liaison de steroides specifique a l'endometre humain
CA2248868A1 (fr)	1996-03-22	1997-09-25	Human Genome Sciences, Inc.	Molecule ii inductrice d'apoptose
US6204022B1 (en) *	1996-04-12	2001-03-20	Pepgen Corporation And University Of Florida	Low-toxicity human interferon-alpha analogs
WO1997039132A1 (fr)	1996-04-16	1997-10-23	University Of Miami	Preparations stabilisees de troponines humaines et modifications de ces troponines, procedes diagnostiques de dosage et trousses de dosage
US6497878B1 (en) *	1996-04-23	2002-12-24	Chugai Seiyaku Kabushiki Kaisha	Treatment of cerebral disorders by inhibition of IL-8 binding to receptor
US5919815A (en)	1996-05-22	1999-07-06	Neuromedica, Inc.	Taxane compounds and compositions
ES2151277T3 (es) *	1996-05-22	2000-12-16	Protarga Inc	Composiciones que comprenden conjugados de acido cis-docosahexaenoico y taxotere.
US6300065B1 (en)	1996-05-31	2001-10-09	Board Of Trustees Of The University Of Illinois	Yeast cell surface display of proteins and uses thereof
EP0917566B1 (fr) *	1996-06-11	2004-09-22	Roche Diagnostics GmbH	Proteases recombinees de coagulation sanguine
US6110891A (en)	1996-06-21	2000-08-29	Alizyme Therapeutics Ltd.	Lectin compositions and uses thereof
GB2318352A (en)	1996-06-25	1998-04-22	Dejan Markovic	Polypeptides mimicking the activity of human erythropoietin
GB9613858D0 (en)	1996-07-02	1996-09-04	Cortecs Ltd	Hydrophobic preparations
US5932547A (en)	1996-07-03	1999-08-03	Alza Corporation	Non-aqueous polar aprotic peptide formulations
US6110703A (en)	1996-07-05	2000-08-29	Novo Nordisk A/S	Method for the production of polypeptides
WO1998002543A1 (fr)	1996-07-15	1998-01-22	Chugai Research Institute For Molecular Medicine, Inc.	Nouveaux facteurs analogues au vegf
AR008077A1 (es)	1996-07-26	1999-12-09	Talarico Salinas Laura Beatriz	Un polipeptido de fusion o una sal del mismo, su uso, un proceso para prepararlos, una composicion farmaceutica que los comprende, y un vector.
WO1998005782A1 (fr)	1996-08-02	1998-02-12	Zymogenetics, Inc.	Polypeptides homologues de l'insuline, specifiques des testicules
US6190533B1 (en)	1996-08-15	2001-02-20	Exxon Chemical Patents Inc.	Integrated hydrotreating steam cracking process for the production of olefins
ATE412740T1 (de)	1996-08-16	2008-11-15	Human Genome Sciences Inc	Menschliches alpha-endokin
ES2308787T3 (es)	1996-08-16	2008-12-01	Schering Corporation	Antigenos de superficie de celular de mamiferos; reactivos relacionados.
EP1283268A3 (fr)	1996-08-23	2004-01-02	Ludwig Institute For Cancer Research	Facteur recombinant de croissance de cellules vascularies endothéliales D (VEGF-D)
US6006753A (en)	1996-08-30	1999-12-28	Eli Lilly And Company	Use of GLP-1 or analogs to abolish catabolic changes after surgery
US6458924B2 (en)	1996-08-30	2002-10-01	Novo Nordisk A/S	Derivatives of GLP-1 analogs
US6277819B1 (en)	1996-08-30	2001-08-21	Eli Lilly And Company	Use of GLP-1 or analogs in treatment of myocardial infarction
US5922761A (en)	1996-09-06	1999-07-13	Medinox, Inc.	Methods for in vivo reduction of iron levels and compositions useful therefor
AU4199597A (en)	1996-09-09	1998-04-02	Novo Nordisk A/S	A cdna and peptide with relation to cancer and weight loss
US20020052309A1 (en)	1996-09-11	2002-05-02	Athanasius A. Anagnostou	Method of treating endothelial injury
AU7364696A (en) *	1996-09-18	1998-04-14	Human Genome Sciences, Inc.	Human tumor necrosis factor receptor-like genes
US6225290B1 (en)	1996-09-19	2001-05-01	The Regents Of The University Of California	Systemic gene therapy by intestinal cell transformation
US5994112A (en)	1996-10-09	1999-11-30	Incyte Pharmaceuticals, Inc.	Human protein tyrosine kinase
US5916771A (en)	1996-10-11	1999-06-29	Abgenix, Inc.	Production of a multimeric protein by cell fusion method
US5955508A (en) *	1996-10-15	1999-09-21	Loyola University Of Chicago	Method for the enhancement of lymphocyte activity against opportunistic microbial pathogens
KR20060079258A (ko)	1996-10-18	2006-07-05	제넨테크, 인크.	항-ＥｒｂＢ２ 항체
AU4988697A (en)	1996-10-24	1998-05-15	Vion Pharmaceuticals, Inc.	Monophosphate prodrugs of beta-l-fd4c and beta-l-fddc as potent antiviral agents
PT939804E (pt)	1996-10-25	2005-11-30	Human Genome Sciences Inc	Neutroquina alfa
JPH10134761A (ja)	1996-10-30	1998-05-22	Ebara Corp	イオン注入装置及びイオン注入方法
US5908830A (en) *	1996-10-31	1999-06-01	Merck & Co., Inc.	Combination therapy for the treatment of diabetes and obesity
EP1306092A3 (fr)	1996-11-05	2003-05-07	Eli Lilly & Company	Utilisation d'analogues et de derivés de GLP-1 administrés de facon périphérique aux fins de la régulation de l'obésité
UA65549C2 (uk)	1996-11-05	2004-04-15	Елі Ліллі Енд Компані	Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
GB9623205D0 (en) *	1996-11-07	1997-01-08	Eurand Int	Novel pharmaceutical compositions
DE69732572T2 (de)	1996-11-12	2005-12-29	Novo Nordisk A/S	Verwendung von glp-1 peptiden
CA2722378C (fr)	1996-12-03	2015-02-03	Amgen Fremont Inc.	Anticorps humains qui se lient au tnf.alpha.
US6130248A (en)	1996-12-30	2000-10-10	Bar-Ilan University	Tricarboxylic acid-containing oxyalkyl esters and uses thereof
US5833994A (en)	1997-01-08	1998-11-10	Paracelsian, Inc.	Use of the AH receptor and AH receptor ligands to treat or prevent cytopathicity of viral infection
JP2001505060A (ja)	1997-01-14	2001-04-17	ヒューマンジノームサイエンシーズ，インコーポレイテッド	腫瘍壊死因子受容体５
EP0954589A1 (fr)	1997-01-24	1999-11-10	Novo Nordisk A/S	Nouvelles sequences-guides synthetiques de peptides
PT1012274E (pt)	1997-01-28	2007-08-14	Craig A Rosen	Receptor 4 contendo um domínio de morte (dm4; receptor de morte 4), membro da super-família do ftn e ligação a liart (ap02)
WO1998032466A1 (fr)	1997-01-29	1998-07-30	Polymasc Pharmaceuticals Plc	Procede de p.e.g.ylation
EP0981635A1 (fr)	1997-02-13	2000-03-01	Applied Phytologics, Inc.	Production de proteines matures dans des plantes
GB2324529A (en)	1997-02-21	1998-10-28	Merck & Co Inc	A combinatorial library based on a tetrapeptide substituted with aminomethylcoumarin for characterizing proteases
US7026447B2 (en)	1997-10-09	2006-04-11	Human Genome Sciences, Inc.	53 human secreted proteins
WO1999019339A1 (fr) *	1997-10-09	1999-04-22	Human Genome Sciences, Inc.	53 proteines secretees humaines
US5939455A (en)	1997-03-11	1999-08-17	Beacon Laboratories, Inc.	Therapeutic augmentation of oxyalkylene diesters and butyric acid derivatives
US6110955A (en)	1997-03-11	2000-08-29	Beacon Laboratories, Inc.	Metabolically stabilized oxyalkylene esters and uses thereof
US6030961A (en) *	1997-03-11	2000-02-29	Bar-Ilan Research & Development Co., Ltd.	Oxyalkylene phosphate compounds and uses thereof
US6124495A (en)	1997-03-11	2000-09-26	Beacon Laboratories, Inc.	Unsaturated oxyalkylene esters and uses thereof
US6110970A (en)	1997-03-11	2000-08-29	Beacon Laboratories, Inc.	Nitrogen-containing oxyalkylene esters and uses thereof
US5846774A (en)	1997-03-21	1998-12-08	Bionebraska, Inc.	Chlorella virus promoters
US5981488A (en)	1997-03-31	1999-11-09	Eli Lillly And Company	Glucagon-like peptide-1 analogs
BRPI9809391B8 (pt)	1997-04-14	2021-05-25	Amgen Res Munich Gmbh	processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica
MY118835A (en) *	1997-04-18	2005-01-31	Ipsen Pharma Biotech	Sustained release compositions and the process for their preparation
US6235883B1 (en)	1997-05-05	2001-05-22	Abgenix, Inc.	Human monoclonal antibodies to epidermal growth factor receptor
US6140368A (en)	1997-05-05	2000-10-31	The Regents Of The University Of California	Naphthols useful in antiviral methods
CA2292790A1 (fr)	1997-05-30	1998-12-03	Human Genome Sciences, Inc.	Recepteur tr10 du facteur de necrose tumorale humain
US6071743A (en)	1997-06-02	2000-06-06	Subsidiary No. 3, Inc.	Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
CA2295991A1 (fr)	1997-06-11	1998-12-17	Human Genome Sciences, Inc.	Recepteur humain tr9 du facteur de necrose tumorale
GB9713412D0 (en)	1997-06-26	1997-08-27	Delta Biotechnology Ltd	Improved protein expression strains
US5858719A (en)	1997-07-17	1999-01-12	Incyte Pharmaceuticals, Inc.	Polynucleotides encoding human ATP binding-cassette transport protein and methods of use
ES2208798T3 (es)	1997-09-01	2004-06-16	Aventis Pharma Deutschland Gmbh	Eritropoyetina humana recombinante con un perfil de glicosilacion ventajoso.
HUP9701554D0 (en)	1997-09-18	1997-11-28	Human Oltoanyagtermeloe Gyogys	Pharmaceutical composition containing plazma proteins
US6172046B1 (en) *	1997-09-21	2001-01-09	Schering Corporation	Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
US6472373B1 (en)	1997-09-21	2002-10-29	Schering Corporation	Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
ES2186660T3 (es)	1997-09-21	2003-05-16	Schering Corp	Terapia de combinacion para erradicar hcv-rna detectable en pacientes con infeccion por hepatitis c cronica.
EP1426058A3 (fr)	1997-09-23	2004-07-28	Dr. Rentschler Biotechnologie GmbH	Formulations liquides d'interféron bèta
US6201072B1 (en) *	1997-10-03	2001-03-13	Macromed, Inc.	Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6004573A (en)	1997-10-03	1999-12-21	Macromed, Inc.	Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6117949A (en)	1998-10-01	2000-09-12	Macromed, Inc.	Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
CA2309541C (fr)	1997-11-03	2011-01-11	Human Genome Sciences, Inc.	Vegi, un inhibiteur de l'angiogenese et de la croissance tumorale
WO1999028346A1 (fr)	1997-12-03	1999-06-10	Roche Diagnostics Gmbh	Erythropoietine a activite specifique marquee
EP1049486A4 (fr)	1997-12-05	2006-01-04	Lilly Co Eli	Formulations de glp-1
ES2590912T3 (es)	1997-12-08	2016-11-24	Merck Patent Gmbh	Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario
AU738804B2 (en) *	1997-12-08	2001-09-27	Bristol-Myers Squibb Company	Novel salts of metformin and method
US6380357B2 (en)	1997-12-16	2002-04-30	Eli Lilly And Company	Glucagon-like peptide-1 crystals
KR100253916B1 (ko)	1997-12-29	2000-05-01	김충환	사람 인슐린 전구체의 제조방법
US5951996A (en)	1998-02-04	1999-09-14	Czeizler Zaharia; Veronica L.	Treatment of chronic diffuse GI bleeding with erythropoietin
US6221378B1 (en) *	1998-02-10	2001-04-24	Generex Pharmaceuticals Incorporated	Mixed micellar delivery system and method of preparation
US6017545A (en) *	1998-02-10	2000-01-25	Modi; Pankaj	Mixed micellar delivery system and method of preparation
EP1054594B1 (fr)	1998-02-13	2007-07-04	Amylin Pharmaceuticals, Inc.	Effets inotropiques et diuretiques de l'exendine et du glp-1
WO1999043706A1 (fr)	1998-02-27	1999-09-02	Novo Nordisk A/S	Derives d'analogues de glp-1
WO1999047160A1 (fr)	1998-03-13	1999-09-23	Novo Nordisk A/S	Solutions peptidiques aqueuses stabilisees
WO1999047161A1 (fr)	1998-03-19	1999-09-23	Bionebraska, Inc.	Regulation de l'appetit chez les humains par un compose se liant a un recepteur de peptide de type glucagon
DE19813802A1 (de)	1998-03-27	1999-11-11	Retro Tech Gmbh	Anti-virale Wirkung von Propolis durch Inhibition viraler Nukleinsäure Polymerasen
GB9806631D0 (en)	1998-03-28	1998-05-27	Safeglass Europ Limited	Safetyglass
AU3047299A (en)	1998-04-13	1999-11-01	Modex Therapeutiques, S.A.	Methods of delivering glp-1
CA2270320A1 (fr)	1998-04-28	1999-10-28	Patricia Lee Brubaker	Nouvelle composition microsphere
US6251868B1 (en)	1998-04-30	2001-06-26	Teijin Limited	Method for treating a human immunodeficiency virus infection
CN1119352C (zh)	1998-05-15	2003-08-27	中国科学院上海生物化学研究所	人血清白蛋白在毕赤酵母中的表达与纯化
AU766597B2 (en)	1998-05-15	2003-10-16	Schering Corporation	Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having chronic hepatitis C infection
US5970300A (en) *	1998-06-01	1999-10-19	Xerox Corporation	Apparatus for applying scents to paper in a printer/copier
SE9802080D0 (sv)	1998-06-11	1998-06-11	Hellstroem	Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
MXPA00012286A (es)	1998-06-12	2002-10-17	Bionebraska Inc	Peptide-1 similar a glucagon mejora la respuesta celular beta a glucosa en sujetos con tolerancia danada de glucosa.
DE69933216T2 (de) *	1998-06-15	2007-09-20	GTC Biotherapeutics, Inc., Framingham	Erythropoietin-analog-menschliches serum-albumin fusionsprotein
CN1105727C (zh)	1998-06-17	2003-04-16	上海海济医药生物工程有限公司	重组人血清白蛋白的生产方法
CA2335617C (fr)	1998-06-24	2009-12-15	Novirio Pharmaceuticals Limited	3'-azido-2',3'-dideoxyuridine (cs-87) utilise en combinaison avec d'autres medicaments anti-vih pour la fabrication d'un medicament destine a traiter le vih
IL140341A0 (en)	1998-06-30	2002-02-10	Novo Nordisk As	Seeding crystals for preparation of peptides or proteins
AU8508398A (en)	1998-07-15	2000-02-07	Wisconsin Alumni Research Foundation	Treatment of diabetes with synthetic beta cells
ATE251465T1 (de)	1998-07-31	2003-10-15	Novo Nordisk As	In-vitro stimulation von beta zellen vermehrung
GB9817084D0 (en)	1998-08-06	1998-10-07	Wood Christopher B	A method for promoting extra-heptic production of proteins for the correction of hypoalbuminaemia,anaemia,thrombocytopenia and/or coagulation disorders
DE69941510D1 (de)	1998-08-10	2009-11-19	Us Gov Nat Inst Health	Differenzierung von nicht-insulin in insulin-produzierende zellen durch glp-1 und exendin-4 und dessen verwendung
US6346543B1 (en) *	1998-08-17	2002-02-12	Aventis Pharma S.A.	Use of a taxoid to treat abnormal cell proliferation in the brain
BR9913284A (pt)	1998-08-28	2001-05-15	Lilly Co Eli	Métodos para administrar peptìdeos insulinotrópicos
MY155270A (en)	1998-09-24	2015-09-30	Lilly Co Eli	Use of glp-1 or analogs in treatment of stroke
US6193997B1 (en) *	1998-09-27	2001-02-27	Generex Pharmaceuticals Inc.	Proteinic drug delivery system using membrane mimetics
US6290987B1 (en)	1998-09-27	2001-09-18	Generex Pharmaceuticals, Inc.	Mixed liposome pharmaceutical formulation with amphiphiles and phospholipids
US6429197B1 (en)	1998-10-08	2002-08-06	Bionebraska, Inc.	Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain
US6284725B1 (en)	1998-10-08	2001-09-04	Bionebraska, Inc.	Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
CA2345382A1 (fr)	1998-10-16	2000-04-27	Immunex Corporation	Inhibiteurs de l'activation et du recrutement plaquettaires
AU774989B2 (en)	1998-10-23	2004-07-15	Amgen, Inc.	Methods and compositions for the prevention and treatment of anemia
ATE365210T1 (de)	1998-10-30	2007-07-15	Novozymes As	Glykosylierte proteine mit reduzierter allergenität
EP1135493A2 (fr)	1998-11-30	2001-09-26	Eli Lilly And Company	Composes erythropoietiques
US6048891A (en) *	1998-12-17	2000-04-11	Loma Linda University Medical Center	Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of natriuretic disease
US6271200B1 (en)	1998-12-21	2001-08-07	Generex Pharmaceuticals Inc.	Proteinic drug delivery system using aerosolized membrane-mimetic amphiphiles
US6294153B1 (en)	1998-12-21	2001-09-25	Generex Pharmaceuticals, Inc.	Aerosol pharmaceutical formulation for pulmonary and nasal delivery
US6312665B1 (en)	1998-12-21	2001-11-06	Generex Pharmaceuticals Incorporated	Aerosol formulations for buccal and pulmonary application
DE69928006T2 (de)	1998-12-22	2006-07-13	Eli Lilly And Co., Indianapolis	Lagerstabile flüssige zusammensetzungen von glucagon-ähnlichem peptid-1
US20030009013A1 (en) *	1998-12-30	2003-01-09	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
GB9902000D0 (en)	1999-01-30	1999-03-17	Delta Biotechnology Ltd	Process
EP1175440A1 (fr)	1999-04-09	2002-01-30	Human Genome Sciences, Inc.	48 proteines secretees humaines
JP2002542183A (ja)	1999-04-16	2002-12-10	ノボノルディスクアクティーゼルスカブ	成形可能な乾燥した医薬製剤
US6287588B1 (en)	1999-04-29	2001-09-11	Macromed, Inc.	Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
DE19921537A1 (de)	1999-05-11	2000-11-23	Dieter Hoersch	Verfahren zur Induzierung von Zellwachstum durch Verwendung geeigneter Mittel
US6348192B1 (en) *	1999-05-11	2002-02-19	Bayer Corporation	Interleukin-2 mutein expressed from mammalian cells
US6514500B1 (en) *	1999-10-15	2003-02-04	Conjuchem, Inc.	Long lasting synthetic glucagon like peptide {GLP-!}
BR0010750A (pt)	1999-05-17	2002-02-26	Conjuchem Inc	Peptìdeos insulinotrópicos de longa duração
RU2262510C9 (ru)	1999-05-19	2006-04-20	Лексиген Фармасьютикэлс Корп.	Слитый белок, обладающий биологической активностью интерферона-альфа, димерный слитый белок, фармацевтическая композиция, их содержащая, молекула днк (варианты) и способ адресования интерферона-альфа в ткани печени
US6344180B1 (en)	1999-06-15	2002-02-05	Bionebraska, Inc.	GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes
EP1849475A1 (fr)	1999-06-21	2007-10-31	Eli Lilly & Company	Utilisation synergique des thiazolidinediones avec peptide-1 comme glucagon et agonistes correspondants pour traiter les diabètes non dépendants de l'insuline
JO2291B1 (en)	1999-07-02	2005-09-12	اف . هوفمان لاروش ايه جي	Erythropoietin derivatives
US20020048571A1 (en)	1999-07-19	2002-04-25	Jeno Gyuris	Chimeric polypeptides of serum albumin and uses related thereto
CA2376641A1 (fr)	1999-07-19	2001-01-25	Aaron Morris	Polypeptides chimeres d'albumine serique et utilisations associees
EP1203005A4 (fr)	1999-08-17	2004-11-24	Human Genome Sciences Inc	25 proteines secretees humaines
US7144574B2 (en) *	1999-08-27	2006-12-05	Maxygen Aps	Interferon β variants and conjugates
TWI302149B (en)	1999-09-22	2008-10-21	Bristol Myers Squibb Co	Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
PH12000002657B1 (en)	1999-10-12	2006-02-21	Bristol Myers Squibb Co	C-aryl glucoside SGLT2 inhibitors
BR0014945A (pt)	1999-10-21	2004-08-31	Monsanto Co	Modificação pós-traducional de proteìnas recombinantes produzidas em plantas
AU1226901A (en)	1999-10-22	2001-05-08	Amgen, Inc.	Biodegradable microparticles with novel erythropoietin stimulating protein
ATE381343T1 (de)	1999-11-03	2008-01-15	Novo Nordisk As	Verwendung eines wachstumshormons oder eines wachstumshormon-sekretion fördernden mittels zur appetit-unterdrückung bzw. sättigungsinduktion
CA2324801A1 (fr)	1999-11-10	2001-05-10	Andrew Gordon Swick	Utilisation d'inhibiteurs de secretion d'apo b et/ou de mtp et d'agents contre l'obesite
US6569832B1 (en) *	1999-11-12	2003-05-27	Novo Nordisk A/S	Inhibition of beta cell degeneration
CA2391080A1 (fr)	1999-11-12	2001-05-25	Merck Patent Gesellschaft Mit Beschraenkter Haftung	Formes d'erythropoietine dotees de proprietes ameliorees
CA2392615A1 (fr)	1999-12-06	2001-06-07	The General Hospital Corporation	Cellules souches pancreatiques et leur utilisation en transplantation
US20020025306A1 (en)	2000-01-07	2002-02-28	Baetge Edward E.	Methods of increasing the glucose responsiveness of pancreatic ss-cells
EP1125579A3 (fr)	2000-01-18	2003-01-02	Pfizer Products Inc.	Utilisations de composés modulant la liaison entre l'AGRP et les récepteurs à la mélanocortine
MXPA02007231A (es)	2000-01-27	2002-12-09	Lilly Co Eli	Proceso para solubilizar los compuestos de peptido 1 similares a glucagon.
AU2001228327A1 (en)	2000-01-31	2001-08-14	Novo-Nordisk A/S	Crystallisation of a glp-1 analogue
CN1487836A (zh)	2000-03-14	2004-04-07	埃米林药品公司	胰高糖素样肽1(7-36)对胃窦幽门十二指肠能动性的影响
US6946134B1 (en)	2000-04-12	2005-09-20	Human Genome Sciences, Inc.	Albumin fusion proteins
EP2213743A1 (fr)	2000-04-12	2010-08-04	Human Genome Sciences, Inc.	Protéines de fusion d'albumine
US20050100991A1 (en)	2001-04-12	2005-05-12	Human Genome Sciences, Inc.	Albumin fusion proteins
PT1274728E (pt)	2000-04-21	2008-06-20	Amgen Inc	Métodos e composições para a prevenção e tratamento de anemia
IL142707A0 (en)	2000-04-27	2002-03-10	Pfizer Prod Inc	Methods of treating obesity using a neurotensin receptor ligand
ME00673B (fr) *	2000-05-15	2011-12-20	Hoffmann La Roche	Nouvelle composition pharmaceutique
US20020061838A1 (en)	2000-05-17	2002-05-23	Barton Holmquist	Peptide pharmaceutical formulations
JP4716641B2 (ja)	2000-06-16	2011-07-06	イーライリリーアンドカンパニー	グルカゴン様ペプチド−１類似体
EP1970072A1 (fr)	2000-09-18	2008-09-17	Sanos Bioscience A/S	Utilisation de peptides GLP-2 pour le traitement d'hyperparathyroïdie
US7101561B2 (en) *	2000-12-01	2006-09-05	Innogenetics N.V.	Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
AU2002221222A1 (en)	2000-12-04	2002-06-18	Biovitrum Ab	Novel method and use
IL155812A0 (en)	2000-12-07	2003-12-23	Lilly Co Eli	Glp-1 fusion proteins
AU3938402A (en)	2000-12-13	2002-06-24	Lilly Co Eli	Chronic treatment regimen using glucagon-like insulinotropic peptides
AU2002228608A1 (en)	2000-12-13	2002-06-24	Eli Lilly And Company	Amidated glucagon-like peptide-1
US7070973B2 (en)	2000-12-26	2006-07-04	Board Of Regents Of The University Of Nebraska	Butyrylcholinesterase variants and methods of use
WO2002066062A2 (fr)	2001-02-01	2002-08-29	Drucker Daniel J	Renforcement de l'activite de glp-2
KR100399337B1 (ko)	2001-02-07	2003-09-26	드림바이오젠 주식회사	단백질의 무세포 번역후수식법
EP1949908A1 (fr)	2001-03-07	2008-07-30	Novo Nordisk A/S	Utilisation combinée de dérivés d'analogues GLP-1 et ligands PPAR
US20020169128A1 (en)	2001-04-09	2002-11-14	Geroge Sigounas	Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
US20060084794A1 (en)	2001-04-12	2006-04-20	Human Genome Sciences, Inc.	Albumin fusion proteins
US20050244931A1 (en)	2001-04-12	2005-11-03	Human Genome Sciences, Inc.	Albumin fusion proteins
US20050054051A1 (en) *	2001-04-12	2005-03-10	Human Genome Sciences, Inc.	Albumin fusion proteins
WO2002085406A1 (fr)	2001-04-24	2002-10-31	Restoragen, Inc.	Procedes et compositions pour le traitement d'etats lies a la resistance a l'insuline
WO2002097038A2 (fr)	2001-05-25	2002-12-05	Human Genome Sciences, Inc.	Proteines hybrides beta-1 de chimiokine
AU2002308706A1 (en)	2001-06-01	2002-12-16	Eli Lilly And Company	Glp-1 formulations with protracted time action
EP1397124B1 (fr)	2001-06-20	2006-11-29	Merck Sante	Utilisation d'agents antidiabetiques pour fabriquer un medicament ayant un effet cicatrisant
WO2003002136A2 (fr)	2001-06-28	2003-01-09	Novo Nordisk A/S	Formulation stable de glp-1 modifie
ATE408414T1 (de)	2001-07-31	2008-10-15	Us Gov Health & Human Serv	Glp 1 exendin 4 peptidanaloga und deren verwendungen
EP1572885A2 (fr)	2001-08-08	2005-09-14	Genzyme Corporation	Procede pour traiter le diabete et d'autres troubles lies a la glycemie
EP1423136A4 (fr)	2001-08-10	2007-07-25	Epix Pharm Inc	Conjugues de polypeptides ayant des demi-vies de circulation accrues
AU2002322403A1 (en)	2001-08-23	2003-03-10	Eli Lilly And Company	Glucagon-like peptide-1 analogs
AU2002332041A1 (en)	2001-10-05	2003-04-22	Human Genome Sciences, Inc.	Albumin fusion proteins
ES2411007T3 (es) *	2001-10-10	2013-07-04	Novo Nordisk A/S	Remodelación y glicoconjugación de péptidos
US20080167238A1 (en)	2001-12-21	2008-07-10	Human Genome Sciences, Inc.	Albumin Fusion Proteins
US20080194481A1 (en)	2001-12-21	2008-08-14	Human Genome Sciences, Inc.	Albumin Fusion Proteins
WO2003059934A2 (fr)	2001-12-21	2003-07-24	Human Genome Sciences, Inc.	Proteines de fusion d'albumine
AU2002364586A1 (en)	2001-12-21	2003-07-30	Delta Biotechnology Limited	Albumin fusion proteins
WO2005003296A2 (fr)	2003-01-22	2005-01-13	Human Genome Sciences, Inc.	Proteines hybrides d'albumine
WO2003054182A2 (fr)	2001-12-21	2003-07-03	Nexia Biotechnologies, Inc.	Production de butyrylcholinesterases par des mammiferes transgeniques
KR101271635B1 (ko) *	2001-12-21	2013-06-12	휴먼 게놈 사이언시즈, 인코포레이티드	알부민 융합 단백질
AU2003210806A1 (en)	2002-03-05	2003-09-22	Eli Lilly And Company	Heterologous g-csf fusion proteins
DE60336555D1 (de) *	2002-06-21	2011-05-12	Novo Nordisk Healthcare Ag	Pegylierte glykoformen von faktor vii
CN1241946C (zh) *	2002-07-01	2006-02-15	美国福源集团	对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白
US6913890B2 (en) *	2002-12-18	2005-07-05	Palo Alto Research Center Incorporated	Process for preparing albumin protein conjugated oligonucleotide probes
AU2004216476B2 (en) *	2003-02-27	2009-01-08	Takeda Pharmaceutical Company Limited	Method for the validatable inactivation of pathogens in a biological fluid by irradiation
DK1641823T3 (da)	2003-06-12	2011-12-12	Lilly Co Eli	GLP-1-analog fusionsproteiner
HUE027902T2 (en)	2004-02-09	2016-11-28	Human Genome Sciences Inc Corp Service Company	Albumin fusion proteins
US20060051859A1 (en) *	2004-09-09	2006-03-09	Yan Fu	Long acting human interferon analogs
US7436410B2 (en) *	2005-04-01	2008-10-14	Seiko Epson Corporation	System and method for programming a controller
WO2007021494A2 (fr)	2005-08-12	2007-02-22	Human Genome Sciences, Inc.	Proteines de fusion avec l'albumine
US7438904B1 (en)	2005-10-04	2008-10-21	University Of Kentucky Research Foundation	High-activity mutants of butyrylcholinesterase for cocaine hydrolysis and method of generating the same
US8008257B2 (en)	2005-10-20	2011-08-30	University Of Ottawa Heart Institute	ANF fusion proteins
EP1816201A1 (fr) *	2006-02-06	2007-08-08	CSL Behring GmbH	Facteur de coagulation VIIa modifié ayant une stabilité 'half-life' améliorée
WO2007146038A2 (fr)	2006-06-07	2007-12-21	Human Genome Sciences, Inc.	Protéines de fusion d'albumine
US9486507B2 (en) *	2011-06-10	2016-11-08	Biogen Ma Inc.	Pro-coagulant compounds and methods of use thereof

2001
- 2001-04-12 EP EP10075164A patent/EP2213743A1/fr not_active Withdrawn
- 2001-04-12 ES ES10075011.6T patent/ES2529300T3/es not_active Expired - Lifetime
- 2001-04-12 EP EP01932546A patent/EP1274719A4/fr not_active Ceased
- 2001-04-12 EP EP01937179A patent/EP1276856A4/fr not_active Withdrawn
- 2001-04-12 JP JP2001575607A patent/JP2004506407A/ja active Pending
- 2001-04-12 EP EP06015131A patent/EP1803730A1/fr not_active Withdrawn
- 2001-04-12 AU AU2001259066A patent/AU2001259066A1/en not_active Abandoned
- 2001-04-12 AU AU2001264563A patent/AU2001264563A1/en not_active Abandoned
- 2001-04-12 EP EP10075388A patent/EP2311872A1/fr not_active Withdrawn
- 2001-04-12 EP EP10075499A patent/EP2357008A1/fr not_active Withdrawn
- 2001-04-12 EP EP10075010.8A patent/EP2236152B1/fr not_active Expired - Lifetime
- 2001-04-12 EP EP01934875A patent/EP1278767A4/fr not_active Withdrawn
- 2001-04-12 JP JP2001577463A patent/JP2003530852A/ja active Pending
- 2001-04-12 EP EP06076852A patent/EP1832599A3/fr not_active Ceased
- 2001-04-12 EP EP01944114A patent/EP1276756A4/fr not_active Withdrawn
- 2001-04-12 WO PCT/US2001/011850 patent/WO2001079442A2/fr not_active Ceased
- 2001-04-12 AU AU2001259063A patent/AU2001259063A1/en not_active Abandoned
- 2001-04-12 WO PCT/US2001/011988 patent/WO2001077137A1/fr not_active Ceased
- 2001-04-12 JP JP2001577426A patent/JP2003531590A/ja active Pending
- 2001-04-12 DK DK10075010.8T patent/DK2236152T3/da active
- 2001-04-12 AU AU2001274809A patent/AU2001274809A1/en not_active Abandoned
- 2001-04-12 ES ES10075010.8T patent/ES2484966T3/es not_active Expired - Lifetime
- 2001-04-12 WO PCT/US2001/012008 patent/WO2001079258A1/fr not_active Ceased
- 2001-04-12 US US09/832,929 patent/US6926898B2/en not_active Expired - Lifetime
- 2001-04-12 CA CA2405557A patent/CA2405557C/fr not_active Expired - Lifetime
- 2001-04-12 EP EP01941457A patent/EP1278544A4/fr not_active Ceased
- 2001-04-12 WO PCT/US2001/012009 patent/WO2001079271A1/fr not_active Ceased
- 2001-04-12 CA CA002405525A patent/CA2405525A1/fr not_active Abandoned
- 2001-04-12 EP EP10075064A patent/EP2206720A1/fr not_active Withdrawn
- 2001-04-12 WO PCT/US2001/012013 patent/WO2001079444A2/fr not_active Ceased
- 2001-04-12 WO PCT/US2001/011991 patent/WO2001079480A1/fr not_active Ceased
- 2001-04-12 CA CA002405912A patent/CA2405912A1/fr not_active Abandoned
- 2001-04-12 CA CA2747325A patent/CA2747325A1/fr not_active Abandoned
- 2001-04-12 EP EP01932549A patent/EP1274720A4/fr not_active Ceased
- 2001-04-12 US US09/832,501 patent/US20030199043A1/en not_active Abandoned
- 2001-04-12 WO PCT/US2001/011924 patent/WO2001079443A2/fr not_active Ceased
- 2001-04-12 EP EP10075387A patent/EP2267026A1/fr not_active Withdrawn
- 2001-04-12 EP EP10075011.6A patent/EP2216409B1/fr not_active Expired - Lifetime
- 2001-04-12 EP EP01938994A patent/EP1276849A4/fr not_active Withdrawn
- 2001-04-12 JP JP2001577427A patent/JP2003530846A/ja active Pending
- 2001-04-12 JP JP2001576866A patent/JP2003530839A/ja active Pending
- 2001-04-12 US US09/833,041 patent/US6994857B2/en not_active Expired - Lifetime
- 2001-04-12 US US09/833,118 patent/US6905688B2/en not_active Expired - Lifetime
- 2001-04-12 JP JP2001576855A patent/JP2003530838A/ja active Pending
- 2001-04-12 AU AU2001266557A patent/AU2001266557A1/en not_active Abandoned
- 2001-04-12 JP JP2001577428A patent/JP2003530847A/ja active Pending
- 2001-04-12 CA CA002405709A patent/CA2405709A1/fr not_active Abandoned
- 2001-04-12 AU AU2001262942A patent/AU2001262942A1/en not_active Abandoned
- 2001-04-12 EP EP10075316A patent/EP2275557A1/fr not_active Withdrawn
- 2001-04-12 EP EP08075909A patent/EP2067488A1/fr not_active Withdrawn
- 2001-04-12 EP EP08075327A patent/EP1983055A1/fr not_active Withdrawn
- 2001-04-12 AU AU2001261024A patent/AU2001261024A1/en not_active Abandoned
- 2001-04-12 US US09/833,117 patent/US20030171267A1/en not_active Abandoned
- 2001-04-12 DK DK10075011.6T patent/DK2216409T3/en active
- 2001-04-12 EP EP10075375A patent/EP2298355A3/fr not_active Withdrawn
- 2001-04-12 US US09/833,245 patent/US20040010134A1/en not_active Abandoned
- 2001-04-12 CA CA002405701A patent/CA2405701A1/fr not_active Withdrawn
- 2001-04-12 EP EP10075391A patent/EP2295456A1/fr not_active Ceased
- 2001-04-12 CA CA002405550A patent/CA2405550A1/fr not_active Abandoned
- 2001-04-12 CA CA002405563A patent/CA2405563A1/fr not_active Abandoned
2005
- 2005-03-14 US US11/078,663 patent/US7507414B2/en not_active Expired - Lifetime
- 2005-03-14 US US11/078,914 patent/US7482013B2/en not_active Expired - Lifetime
2007
- 2007-10-29 US US11/927,607 patent/US20080269126A1/en not_active Abandoned
- 2007-10-29 US US11/927,617 patent/US20080269128A1/en not_active Abandoned
- 2007-10-29 US US11/927,555 patent/US20090285816A9/en not_active Abandoned
- 2007-10-29 US US11/927,602 patent/US10080785B2/en not_active Expired - Lifetime
- 2007-10-29 US US11/927,593 patent/US20080261877A1/en not_active Abandoned
- 2007-10-29 US US11/927,610 patent/US20080269127A1/en not_active Abandoned
- 2007-10-29 US US11/927,600 patent/US9821039B2/en not_active Expired - Fee Related
- 2007-10-29 US US11/927,583 patent/US20120141415A1/en not_active Abandoned
- 2007-10-30 US US11/929,677 patent/US7785599B2/en not_active Expired - Fee Related
2009
- 2009-02-04 US US12/365,878 patent/US20110280830A9/en not_active Abandoned
2011
- 2011-05-16 JP JP2011109620A patent/JP2011217750A/ja active Pending
- 2011-08-18 US US13/212,879 patent/US20120252732A1/en not_active Abandoned
2012
- 2012-05-04 US US13/464,248 patent/US8946156B2/en not_active Expired - Fee Related
2013
- 2013-04-02 US US13/855,434 patent/US9775888B2/en not_active Expired - Fee Related
- 2013-04-02 US US13/855,454 patent/US9849162B2/en not_active Expired - Fee Related
- 2013-10-17 JP JP2013216509A patent/JP2014057589A/ja active Pending
2016
- 2016-11-04 BE BE2016C059C patent/BE2016C059I2/nl unknown
- 2016-11-04 FR FR16C0043C patent/FR16C0043I2/fr active Active
2017
- 2017-12-21 US US15/850,371 patent/US20180200346A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US9849162B2 (en)	2017-12-26
US6926898B2 (en)	2005-08-09
AU2001274809A1 (en)	2001-10-30
US20080269128A1 (en)	2008-10-30
WO2001079443A3 (fr)	2002-02-21
US20180200346A1 (en)	2018-07-19
EP1278544A2 (fr)	2003-01-29
EP2236152A1 (fr)	2010-10-06
EP2216409B1 (fr)	2014-12-03
EP1803730A1 (fr)	2007-07-04
US10080785B2 (en)	2018-09-25
EP1276756A4 (fr)	2004-06-09
JP2014057589A (ja)	2014-04-03
CA2405912A1 (fr)	2001-10-18
WO2001079442A2 (fr)	2001-10-25
EP1278767A1 (fr)	2003-01-29
EP2298355A3 (fr)	2011-06-29
AU2001266557A1 (en)	2001-10-23
DK2216409T3 (en)	2015-01-05
EP1274720A4 (fr)	2004-08-18
EP2298355A2 (fr)	2011-03-23
FR16C0043I1 (fr)	2016-12-09
US20050266533A1 (en)	2005-12-01
US20120252732A1 (en)	2012-10-04
DK2236152T3 (da)	2014-07-07
EP1274720A1 (fr)	2003-01-15
JP2003531590A (ja)	2003-10-28
JP2004506407A (ja)	2004-03-04
JP2003530852A (ja)	2003-10-21
US20140004095A1 (en)	2014-01-02
US6905688B2 (en)	2005-06-14
JP2003530839A (ja)	2003-10-21
EP2213743A1 (fr)	2010-08-04
US20080269126A1 (en)	2008-10-30
US20080269127A1 (en)	2008-10-30
AU2001259063A1 (en)	2001-10-30
US20050266532A1 (en)	2005-12-01
EP2067488A1 (fr)	2009-06-10
US9775888B2 (en)	2017-10-03
US8946156B2 (en)	2015-02-03
EP1274719A4 (fr)	2004-05-19
AU2001259066A1 (en)	2001-10-30
US20040171123A1 (en)	2004-09-02
US20110280830A9 (en)	2011-11-17
WO2001077137A1 (fr)	2001-10-18
AU2001261024A1 (en)	2001-10-30
CA2405550A1 (fr)	2001-10-25
EP2216409A1 (fr)	2010-08-11
CA2747325A1 (fr)	2001-10-25
US7785599B2 (en)	2010-08-31
WO2001079444A2 (fr)	2001-10-25
JP2003530838A (ja)	2003-10-21
US20140010798A1 (en)	2014-01-09
EP1278767A4 (fr)	2003-11-12
US20130266553A1 (en)	2013-10-10
EP2275557A1 (fr)	2011-01-19
WO2001079444A3 (fr)	2002-05-23
US7482013B2 (en)	2009-01-27
CA2405709A1 (fr)	2001-10-25
AU2001262942A1 (en)	2001-10-30
FR16C0043I2 (fr)	2020-04-10
CA2405563A1 (fr)	2001-10-25
EP2357008A1 (fr)	2011-08-17
AU2001264563A1 (en)	2001-10-30
WO2001079271A9 (fr)	2002-02-28
WO2001079442A3 (fr)	2002-06-06
US20080269125A1 (en)	2008-10-30
CA2405557A1 (fr)	2001-10-25
JP2003530847A (ja)	2003-10-21
WO2001079480A1 (fr)	2001-10-25
EP2206720A1 (fr)	2010-07-14
EP1832599A3 (fr)	2007-11-21
WO2001079443A2 (fr)	2001-10-25
EP1276849A4 (fr)	2004-06-09
US20090285816A9 (en)	2009-11-19
US20080131399A1 (en)	2008-06-05
US9821039B2 (en)	2017-11-21
ES2529300T3 (es)	2015-02-18
US20070287173A9 (en)	2007-12-13
CA2405525A1 (fr)	2001-10-25
US20030219875A1 (en)	2003-11-27
WO2001079480A9 (fr)	2003-09-18
EP1276856A1 (fr)	2003-01-22
EP2236152B1 (fr)	2014-06-04
EP1276856A4 (fr)	2004-06-09
WO2001079258A9 (fr)	2002-02-28
EP1276849A2 (fr)	2003-01-22
EP2311872A1 (fr)	2011-04-20
WO2001077137A9 (fr)	2002-05-02
US6994857B2 (en)	2006-02-07
US20080267962A1 (en)	2008-10-30
US20100189686A1 (en)	2010-07-29
WO2001079271A1 (fr)	2001-10-25
US7507414B2 (en)	2009-03-24
ES2484966T3 (es)	2014-08-12
EP2295456A1 (fr)	2011-03-16
EP1276756A1 (fr)	2003-01-22
EP1983055A1 (fr)	2008-10-22
US20040010134A1 (en)	2004-01-15
US20120141415A1 (en)	2012-06-07
US20030199043A1 (en)	2003-10-23
US20030171267A1 (en)	2003-09-11
JP2003530846A (ja)	2003-10-21
US20120141449A1 (en)	2012-06-07
WO2001079258A1 (fr)	2001-10-25
US20080261877A1 (en)	2008-10-23
EP1274719A2 (fr)	2003-01-15
EP1278544A4 (fr)	2004-08-18
EP1832599A2 (fr)	2007-09-12
CA2405557C (fr)	2013-09-24
EP2267026A1 (fr)	2010-12-29
JP2011217750A (ja)	2011-11-04
US20030125247A1 (en)	2003-07-03
CA2405701A1 (fr)	2001-10-25

Publication	Publication Date	Title
BE2016C059I2 (fr)	2020-08-20
BE2014C019I2 (fr)	2021-01-29
BE2010C009I2 (fr)	2020-01-30
BE2009C057I2 (fr)	2021-01-28
JP2000347946A5 (fr)	2007-05-17
BRPI0110940B8 (fr)	2021-05-25
JP2003514716A5 (fr)	2007-12-27
BE2010C040I2 (fr)	2020-01-30
AU2000236813A8 (fr)	2001-11-15
JP2001308306A5 (fr)	2007-06-07
JP2002195162A5 (fr)	2007-02-08
BR0112866A2 (fr)	2009-12-08
JP2002104386A5 (fr)	2007-11-01
JP2001309113A5 (fr)	2006-02-09
IN192825B (fr)	2004-05-22
IN191958B (fr)	2004-01-24
BRPI0000763B8 (fr)	2021-06-22
AU2000270757A8 (fr)	2002-04-18
AU2000274567A8 (fr)	2002-05-02
CN3144928S (fr)	2000-04-05
AU2000266391A8 (fr)	2002-05-23
CN3143841S (fr)	2000-03-29
CN3143422S (fr)	2000-03-29
CN3146242S (fr)	2000-04-19
CN3141860S (fr)	2000-03-15